COVID-19
Vaccine Updates

Number 50, 19th May 2022

Table of Contents

Introduction

This document summarises the vaccine efficacy and effectiveness, the vaccine specifications, the vaccine development pipeline and the timeline for World Health Organization (WHO) review of the various COVID-19 vaccines in late phase development. This document is updated weekly.

- Vaccine efficacy refers to the performance of a vaccine in a controlled clinical trial (study) situation
- Vaccine effectiveness refers to the performance of a vaccine in a population under real-world conditions

Key messages

- COVID-19 vaccine efficacy results from different trials cannot be directly compared against each other. They must be interpreted in the context of study designs (including case definitions, clinical endpoints, access to testing), target populations, and COVID-19 epidemiologic conditions (the variants circulating at the time of the study). All efficacy studies were conducted prior to Omicron predominance and most prior to Delta.
- All COVID-19 vaccines in late phase development report high vaccine efficacy against severe COVID-19 and favourable safety profiles
- Most vaccines have low effectiveness against Omicron infection but maintain moderate to high effectiveness against severe disease, especially post booster.

- The Pfizer/BioNTech vaccine has been authorised in children aged ≥5 years by the US FDA, EU EMA, Australian TGA and Health Canada; and in those ≥12 years by the UK MHRA and NZ Medsafe. The EMA, MHRA and TGA have authorised the Moderna vaccine in those ≥12 years.
- WHO SAGE recommends that boosters should be administered 4-6 months after the primary series in high-priority groups, including older adults and health workers.1 ATAGI has recommended that immunocompromised persons in Australia receive a third dose as part of the primary series and booster doses of Pfizer/BioNTech be offered to all adults irrespective of the primary COVID-19 vaccine given.2,3 Boosters are recommended for all adults ≥18 years of age in Australia, Canada, the US and UK, plus second boosters for the elderly and vulnerable groups.4,5
- Mixed vaccine schedules (i.e. delivering different types of vaccine for the first and second dose) generally provide good protection against infection and severe disease
- Seven intranasal vaccines are in development (6 live-attenuated viruses or virus-vectored vaccines; 1 protein subunit.6 These may be beneficial in preventing transmission
- A very rare clotting disorder with low platelets (Thrombosis with Thrombocytopaenia Syndrome – TTS) has been associated with the AstraZeneca and Johnson & Johnson vaccines.7–9 The majority of cases fully recover with adequate treatment. The risk following the first dose of AstraZeneca vaccine has been estimated by the EMA as 1 in 100,000 and by the Australian Technical Advisory Group on Immunisation (ATAGI) as 1 in 50,000.10,11 Risk of TTS is much lower following the second dose of AstraZeneca vaccine: estimate in the UK is 1 in 1.5 million second doses.12
- The risk of TTS following the first dose of Johnson & Johnson vaccine has been estimated as 1 in 319,000 in the USA13
- The risk of myocarditis/pericarditis is increased following the second dose of Pfizer/BioNTech and Moderna vaccines, particularly in younger males, occurring in >1 in 20,000 males under 25 years of age.14 Highest rate in males 16-17 years of age following Pfizer/BioNTech vaccine but no clear difference in risk between Moderna and Pfizer/BioNTech.15 There is a small increase in risk of myocarditis in females <30 and males >50 years of age. Data from Ontario, Canada, and the UK suggest higher rates following Moderna than Pfizer/BioNTech vaccine. ATAGI in Australia continue to review the data.
- Appropriate communication on the benefit-risk profile of COVID-19 vaccines remains crucial to maintain confidence in immunisation programmes and to avoid vaccine hesitancy. suggest higher rates following Moderna than Pfizer/BioNTech vaccine. ATAGI in Australia continue to review the data.

New updates

Key updates include *(also highlighted in yellow text in the document)*:

- Effectiveness of a fourth dose of Moderna or Pfizer/BioNTech against infection and severe outcomes with Omicron prior among long-term care residents in Ontario, Canada (Page 8,35,41):
  - ≥7 days after vaccination versus a third dose received ≥84 days
    - Any infection: 40% (34-45)
    - Symptomatic infection: 63% (51-71)
    - Hospitalisation or death: 54% (31-70)
  - Among persons aged ≥60 years in Israel (Page 8,35,41):
    - Any infection: 45% (44-47)
    - Symptomatic infection: 55% (53-58)
    - Hospitalisation: 68% (59-74)
    - Death: 74% (50-90)
- Rate ratio for any infection with Omicron following a fourth dose of Pfizer/BioNTech compared with three doses among participants who were 60 years or older in Israel (Page 9)
  - Week 2: 1.5 (1.5 to 1/6)
  - Week 3: 2.1 (2.0 to 2.1)
  - Week 4: 2.0 (1.9 to 2.1)
  - Week 5: 1.7 (1.6 to 1.7)
  - Week 6: 1.5 (1.4 to 1.6)
  - Week 7: 1.2 (1.2 to 1.3)
  - Week 8: 1.1 (1.0 to 1.2)
- Effectiveness of two or three doses of Pfizer/BioNTech or Moderna against infection with Omicron
  - 14-30 days among individuals aged 12-59 years in Denmark. (Page 7,35):
    Symptomatic infection
    - 2 doses: 39.8% (38.4-41.2)
    - 3 doses: 55.2% (54.7-55.6)

    Hospitalisation
    - 2 doses: 62.4.9% (46.3-73.6)
    - 3 doses: 89.8% (87.9-91.3)

    Emergency department admission
    - 2 doses: 31% (16-43)
    - 3 doses: 55% (28-71)
  - Among individuals >60 years in USA (Page 7,34).
    - <3 months: 85% (80-89)
    - ≥3 months: 55% (28-71)
- Effectiveness of two doses of inactivated virus vaccines (Sinovac, Sinopharm or BioKangtai) against mechanical ventilation with Delta in China:
  - 100% among age groups 18-59 and ≥ 60 years. [256]
  - 40-59 years. (Page 35)
    - Infection: 59% (16-81.6)
    - Moderate disease: 70% (29.6-89.3)
    - Severe disease: 100%
- Effectiveness of third doses of Sinovac, Pfizer/BioNTech and AstraZeneca vaccines against infection and severe outcomes among > 16 years old due to Omicron following two dose Sinovac primary series in Chile (Page 7, 13,34,35,36)
  - Sinovac
    - Symptomatic infection: 78.8% (76.8-80.6)
    - Hospitalisation: 86.3% (83.7-88.5)
    - Death: 86.7% (80.5-91.0)
  - Pfizer/BioNTech
    - Symptomatic infection: 96.5% (96.2-96.7)
    - Hospitalisation: 96.1% (95.3- 96.9)
    - Death: 96.8% (93.9-98.3)
  - AstraZeneca
    - Symptomatic infection: 93.2 (92.9-93.6)
    - Hospitalisation: 97.7% (97.3- 98)
    - Death: 98.1% (97.3-98.6)
- A study in Israel reported that the third dose of Pfizer/BioNTech against Omicron did not show signs of waning over a period of seven months with rates of severe disease among individuals who are aged 60 years or older[257].

- A retrospective cohort study in Sweden with older frail individuals with specific comorbidities > 65 years found during the first 2 months of follow-up in one dose of vaccine (AstraZeneca, Pfizer-BioNTech or Moderna) in those previously infected (hybrid immunity) was associated with a 58% lower risk of reinfection compared with natural immunity: aHR 0·42 (0·38-0·47), which reduced to 45% (0·55 [0·39–0·76]; p<0·001) after 2 months[2]. Outcomes of this study were documented SARS-CoV-2 infection from March 20,2020 until October 4,2021.

- Effectiveness of two doses of Pfizer/BioNTech/Moderna/AstraZeneca or one dose of Johnson & Johnson among individuals over 12 years in Italy[1]
    - Symptomatic infection over nine months
        - Pfizer/BioNTech/Moderna: 46·2% (31·7-57·7)
        - AstraZeneca/Johnsons & Johnson: 83·2% (70·3-90·5)

- Effectiveness of two doses of Pfizer/BioNTech with Omicron variant among children and adolescents (Page 11)

    - Symptomatic infection after 2 months
        - Children (5-11): 28.9% (24.5-33.1)
        - Adolescents (12-15): 16.6% (8.1%-24.3%)

    - Symptomatic infection among 12-17 years old in Scotland
        - 14-27 days: 78.3% (75.3-80.9).
        - >98 days: 31.3 (4.8-50.5)

    - Hospitalisation in Brazil
        - 75.4% (57.3-85.9) in 14 days

- Effectiveness of three doses of Pfizer/BioNTech or Moderna against Omicron infection among ≥ 12 years-old
    - Infected with SARS-CoV2 variant (non-Omicron)
        - 83% (81-84)

    - Non--infected individuals
        - 73% (72-73)[258]

- Effectiveness of booster dose of Pfizer/BioNTech against Omicron variant among adolescents aged 12-15years(Page 11)
    - Symptomatic infection after 2-6.5 weeks
        - 71.1% (65.5-75.7)

- The reporting rate for MIS-C was 1.0 case per million individuals aged 12-20 years who received one or two doses of Pfizer/BioNTech, and was similar regardless of timing of previous SARS-CoV-2 infection, in USA during delta period[4]

- In the Phase 3 COVE trial, Bivalent Moderna booster vaccine (50µg or 100µg; targeting the ancestral and Beta variants) given to individuals >18 years of age who previously received 2 doses of Moderna had a clinically acceptable and comparable safety and reactogenicity profile to standard Moderna vaccine[3]

- In the COV-BOOST trial, the safety, reactogenicity and immunogenicity of the fourth dose of either Pfizer/BioNTech or Moderna against the Omicron variant among > 60 years old SARS-CoV-2 anti spike protein IgG concentration, ELU/ml at Day 14 after fourth dose:

    - Four doses of Pfizer/BioNTech: 35 116(31868-38696)
    - Three doses of Pfizer/BioNTech and half dose of Moderna: 46 053(42 311-50 126)
    - Two doses of AstraZeneca and two dose of Pfizer/BioNTech: 34 582(32 335-36 985)
    - Two doses of AstraZeneca with one dose of Pfizer/BioNTech and Moderna: 47 167(43 536-51102)

- Paediatric COVID-19 Vaccine Safety Summary has been added (Page 22)

COVID-19 Vaccine Specifications

	ASTRAZENECA	GAMALEYA	JOHNSON & JOHNSON	MODERNA	NOVAVAX	PFIZER/ BIONTECH	SINOVAC	SINOPHARM	BHARAT BIOTECH	CLOVER
VACCINE TYPE	Viral vector (chimpanzee adenovirus ChAdOx1)	Viral vector (recombinant adenovirus types 5 and 26)	Viral vector (recombinant adenovirus type 26)	mRNA	Protein subunit	mRNA	Inactivated virus	Inactivated virus	Inactivated virus	Protein
Available Through COVAX	✓	-	✓	-	✓	✓	-	-	-	-
Doses Required	2 doses 4-12 weeks apart	2 doses 3 weeks apart	1 dose or 2 doses with 2-6 month interval also recommended	2 doses 4 weeks apart*	2 doses 3 weeks apart	2 doses 3-4 weeks apart*	2 doses 2-4 weeks apart*	2 doses 3-4 weeks apart*	2 doses 3 weeks apart	2 doses 3 weeks apart
Third dose/ boosters	As part of primary series for those with immunocomp.	-	-	As part of primary series for those with immunocomp. USA: at least 6 months after primary series in at-risk groups and ≥65 years	As part of primary series for those with immunocomp.	As part of primary series for those with immunocomp. USA: at least 6 months after primary series in at-risk groups and ≥65 years	As part of primary series for ≥60 years	As part of primary series for ≥60 years	-	-
Shipping, Storage & Presentation	Normal cold chain requirements (2-8°C); 10-dose vials	-18.5°C (liquid form); 2-8°C (dry form)	Shipped at -20°C; 2-8°C for up to 3 months; 5-dose vials	-25°C to -15°C; 10-dose vials	2-8°C; 10-dose vials	-80°C to -60°C; 2-8°C for up to 1 month; 6-dose vials	2-8°C; Single-dose vials	2-8°C; Single-dose vials/ pre-filled syringes	2-8°C; 10-dose or 20-dose vials	2-8°C
Approval by a Stringent Regulatory Authority (SRA)	WHO EUL, EMA, TGA, MHRA	Under review by WHO SAGE	WHO EUL, EMA, FDA, MHRA	WHO EUL, EMA, FDA, TGA	WHO EUL, EMA, TGA	WHO EUL, EMA, FDA, TGA, MHRA	WHO EUL	WHO EUL	WHO EUL	-

WHO EUL:	WHO Emergency Use Listing
EMA:	European Medicines Agency
FDA:	Food and Drug Administration (US)
TGA:	Therapeutic Goods Administration (Australia)
MHRA:	Medicines and Healthcare Products Regulatory Agency (UK)

Vaccine Efficacy/Effectiveness Against Omicron at-a-glance

Detailed summary of vaccine efficacy/effectiveness against other variants available in Appendix 4.
At-a-glance summary of one and two-dose efficacy/effectiveness against Delta available in Appendix 5; and of booster efficacy/effectiveness against Delta in Appendix 6.
Detailed summary of booster efficacy/effectiveness against Delta available in Appendix 7.

VACCINE	VACCINE EFFECTIVENESS (AFTER 2 DOSES) UNLESS OTHERWISE STATED		
	ANY INFECTION	SYMPTOMATIC INFECTION	HOSPITALISATION AND DEATH
AstraZeneca	-	No protective effect beyond 15 weeks[5] -39-50%[6,7]	55-83%[6,8] 3-6 months: 76%[8] ≥6 months: 25-39%[6,8]
Johnson & Johnson	Strong antibody response[9]	-	Booster: Hospitalisation: 85% (54-95)[10]
Moderna	30-37%[11,12] Single dose: 20%[12] Booster: 64%[12]	45%[13] ≥7 months: 0-2%[13,14] Booster: 47-55%[13,15] Booster ≥6 weeks: 39%[13] Booster >6 months: 61%[14] Single dose: 0%[13]	77-97%[8,13] ≥6 months: 64-86%[8,13,14] Booster: Hospitalisation: 83-98%[6,8,14] Booster: Hospitalisation ≥2 months: 93%[8] Efficacy: Fourth dose compared to three doses: Any infection: 11% (-43-44); Symptomatic infection: 31% (-18-60)[16]
Pfizer/BioNTech	55%[11] Booster: 55%[11]	-18-88%[5,7,13,16–18] ≥15 weeks: 34-37%[5] >6 months: 0%[13] Booster: 49-86%[5,7,13–15] Booster ≥12 weeks: 38%[13] Booster: >6 months: 0%[14] Single dose: 26-34%[5,13]	Hospitalisation: 70-93%[9,14,18,1820,21] Hospitalisation >6 months: 68-81%[8,13,14,18,19,21] Booster: Hospitalisation: 77-96%[6,8,13–15,19] Booster: Hospitalisation ≥2 months: 75-92%[6,8] Booster: Hospitalisation >3 months 33.3% (0.9-55)[18] Second booster compared to single booster ≥60 years: 78% (72-83)[22]
Sinovac		Booster: 78.8% (76.8-80.6)[23]	Booster: Hospitalisation: 86.3% (83.7-88.5)[23] Booster: Death: 86.7% (80.5-91.0)[23]

Vaccine Efficacy/Effectiveness of Fourth Dose against Omicron at-a-glance

Detailed summary of vaccine efficacy/effectiveness against other variants available in Appendix 4.

VACCINE	VACCINE EFFECTIVENESS UNLESS OTHERWISE STATED		
	ANY INFECTION	SYMPTOMATIC INFECTION	HOSPITALISATION AND DEATH
Johnson & Johnson		-	Booster: Hospitalisation: 85% (54-95)[10]
Moderna	Efficacy: Fourth dose compared to third dose: 11% (-43-44)[16]	Efficacy: Fourth dose compared to third dose: 31% (-18-60)[16]	
Pfizer/BioNTech	Efficacy: Fourth dose compared to third dose: 30% (-9-55)[16] Fourth dose compared to third dose: 40-45%[24,25]	Efficacy: Fourth dose compared to third dose: 43% (7-65)[16] Fourth dose compared to third dose: 51-74[24,25]	Second booster compared to single booster ≥60 years: 78% (72-83)[22] Hospitalisation and death: Fourth dose compared to third dose: 50-90%[24,25]

Graphs of Vaccine Effectiveness Against Omicron in Adults

Each line represents data from an individual study; note the scale changes on the x axis.
Although VE against symptomatic infection declines after 2 or 3 doses of any vaccine, VE against severe disease/hospitalisation is still moderately high after 2 doses and even higher after a third dose, irrespective of which vaccine was given as a primary series.



References: [5,6,13]



References: [67,86]



References: [6]



References: [6,8,13,19]



References: [6,8,13,19,20]



References: [6,8]

Vaccine Efficacy/Effectiveness in High-Risk Groups at-a-glance

Detailed summary available in Appendix 8.

VACCINE	VACCINE EFFICACY/EFFECTIVENESS			
	DIABETES	OBESITY	AT RISK FOR SEVERE COVID-19	ELDERLY*
AstraZeneca	-	-	Efficacy against symptomatic infection: 76%[26] Effectiveness of single dose against: Symptomatic infection: 60%[27] Effectiveness against: Symptomatic infection: 80%[27] Hospitalisation: 63%[28]	Efficacy against infection: 85%[26] Effectiveness of single dose against: Symptomatic infection: 53-61%[27,29] Hospitalisation: 80%[30] Death: 83%[31] Effectiveness against: Symptomatic infection: 39-81%[27,32–36] Hospitalisation: 37-94%[32,33,35–37] Death: 65-94%[31,35,36,38]
Bharat Biotech	-	-	Efficacy against infection: 66%[39]	Efficacy against symptomatic infection: 68%[39]
Gamaleya	-	-	-	Symptomatic infection: 92%[40]
Johnson & Johnson	Efficacy: 23%[41]	Efficacy: 66%[41]	Efficacy: 59%[41]	Efficacy 66%[41]
Moderna	-	-	Efficacy against symptomatic infection: 84-91%[42] Effectiveness against hospitalisation: 84% (80-87)[43]	Efficacy against symptomatic infection: 86%[42] Effectiveness against infection: pre-Omicron: 75-97%[12,44,45]; Omicron: 57%[12]
Novavax			Efficacy against infection: 91%[46]	
Pfizer/BioNTech	Effectiveness against infection: 82%[47] 89%[48]	Effectiveness against infection: 90%[48]	Efficacy against symptomatic infection: 95%[49] Effectiveness of single dose against symptomatic infection: 56%[27] Effectiveness against: Infection: 71-90%[48,50] Symptomatic infection: 89%[27] Hospitalisation: 72-81%[50]	Efficacy against symptomatic infection: 95-100%[49,51] Effectiveness of single dose against: Infection: 76%[29] Symptomatic infection: 40-80%[27,36,52] Hospitalisation: 71-91%[30,36,37] Death: 77-92%[31,36] Effectiveness against: Infection: 70-89%[47,48,50,53] Smptomatic infection: 61-93%[27,32,34,52] Hospitalisation: 43-93%[32,37,53] Death: 87-98%[31,38]
Sinopharm	-	81%[54]	-	Effectiveness against symptomatic infection 91%[54]
Sinovac	-	Infection: 75%[54]	Infection: 49%[54]	Infection: 28%[35] Hospitalisation: 32%[35] Death: 34%[35]

*Estimates in those ≥60 years to ≥90 years

Vaccine Efficacy/Effectiveness in Children

Most studies conducted during Delta predominance.

VACCINE	VACCINE EFFICACY, EFFECTIVENESS AND OTHER OUTCOMES		COUNTRIES VACCINATING CHILDREN BY AGE GROUP
	<12 years	12-18 years	
Moderna	Well tolerated and produced strong antibody response in 6-11 year olds in USA (Moderna press release)[55]	Efficacy: Symptomatic infection in USA, 12-15 years: 96%[56]	≥12 years: Authorised by EMA, MHRA, TGA ≥12 years: France, Italy, Japan, Australia, Canada, Guinea, Philippines ≥3 years: Colombia
Novavax	7-12 years trial underway in India	Study in 12-18 years has started recruitment	-
Pfizer/BioNTech	5-11 years: Antibody response and safety profile for reactogenicity similar to 16-25 year-olds[57] Efficacy: Symptomatic infection in 5-11 year olds in USA during Delta predominance: 90.9% (68.3-98.3)[58] <5 years: Evaluation of a 3 dose schedule underway due to low immunogenicity of 2 doses[59] UK JCVI: estimated impact of single dose in 5-11 years with underlying health conditions: Prevented per million first doses: 105 PICU admissions; 1265 hospital admissions; 16 PIMS-TS cases[60] Effectiveness: Hospitalisation in USA in the week beginning 20 December 2021: 5-11 years: 76%[61] USA: Hospitalisation due to Delta or Omicron: 5-11 years: 2 doses 14-67 days: 74% (-35-95)[62] USA: Effectiveness: Hospitalisation: 5-11 years: Omicron: 68% (42-82)[63] Effectiveness: Symptomatic infection in USA against Omicron variant: 2 doses 2 month: 5-11: 28.9%[64]	Efficacy: Symptomatic infection in USA, 12-15 years: 100%[65]; Up to 4 months after second dose: 100% (87.5-100)[66] Efficacy: Symptomatic infection in Israel, 12-15 years: 100%[67] Effectiveness in Israel 12-18 years: Any infection: 90% (88-92); Symptomatic infection: 93% (88-97)[68] Effectiveness against hospitalisation in USA: 12-18 years: 93% (83-97)[69] Effectiveness: Symptomatic infection 12-15 years: Single dose 2 weeks: 75.4% (73.9-76.9); Single dose 8-9 weeks: 46.8% (14.9-66.7); 16-17 years: Single dose 2 weeks: 75.9% (74.3-77.4); Single dose 8-9 weeks: 34.3 (30.7 to 37.7); 2 doses 2-9 weeks: 94.6% (92.8-95.9); Hospitalisation: 16-17 years: Single dose: 84.5% (64.6-93.2)[70] USA: Effectiveness: MIS-C: 91% (78-97)[71] USA: Effectiveness: 2 doses: Hospitalisation: 94% (90-96); ICU admission: 98% (93-99); Single dose: Hospitalisation: 97% (86-100)[72] Effectiveness: Hospitalisation in USA in the week beginning 20 December 2021: 12-17 years: 81%[61] UK: Effectiveness: Symptomatic infection: Delta: 12-15 years: Single dose: 14-20 days: 74.5% (73.2-75.6); 70-83 days: 45.9% (41.2-50.1); Two doses: 7-13 days: 93.2% (81.5-97.5); 16-17 years: Single dose: 14-20 days: 75.9% (74.3-77.3); 84-101 days: 29.3% (25.9-32.6); Two doses: 14-34 days: 96.1% (95.2-96.8); ≥10 weeks: 83.7% (72.0-90.5) Omicron: 12-15 years: Single dose: 14-20 days: 49.6% (43.9-54.8); 70-83 days: 16.1% (12.1-20.0); Two doses: 7-13 days: 83.1% (78.2-86.9); 16-17 years: Single dose: 21-27 days: 52.7% (43.3-60.5); ≥15 weeks: 12.5% (6.9-17.8); Two doses: 7-13 days: 76.1% (73.4-78.6); ≥10 weeks: 22.6% (14.5-29.9)[73] USA: Hospitalisation due to Delta or Omicron: 12-15 years: 2 doses: 14-149 days: 92% (79-97); ≥150 days: 73% (43-88); 16-17 years: 2 doses: 14-149 days: 94% (87-97); ≥150 days: 88% (72-95)[62] France: Effectiveness: MIS-C: Delta (>95% Pfizer/BioNTech in the study and <5% Moderna): 91% (79-96)[74] USA: Effectiveness: Hospitalisation: Delta: 2-22 weeks: 93% (89-95); 23-44 weeks: 92% (80-97); Omicron: 2-22 weeks: 43% (-1-68); 23-44 weeks: 38% (-3-62)[63] Effectiveness: Symptomatic infection with Omicron in USA: Two doses during month 2: 12-15: 16.6%[64] Effectiveness: Symptomatic infection against Omicron in Norway: 23% (3-40%) in 63 days[75]. Effectiveness: Symptomatic infection with Omicron in Brazil: Two doses:75.4%(57.3-85.9) in 14 days[76] Effectiveness: Hospitalisation with Omicron in Scotland: Two doses: 31.3 (4.8-50.5)[76] >98 days[76]	≥5 years: Authorised by FDA, EMA, TGA ≥5 years: USA, Israel, Canada, Oman, Saudi Arabia, Bahrain, UAE, Costa Rica, UK ≥12 years: Authorised by EMA, MHRA TGA, Medsafe ≥12 years: USA, Canada, UK Israel, France, Spain, Italy, Netherlands, Germany, South Africa, Singapore, Japan, Australia, Estonia, Denmark, Greece, Ireland, Lithuania, Sweden, Finland, Norway, Switzerland, Jordan, Morocco, Egypt, Guinea, Namibia, South Korea, Philippines, Brazil 12-15 years single dose: South Africa 12-17 years single dose: Hong Kong ≥3 years: Colombia
Sinovac	Phase I/II studies complete in 3-17 year olds in China[77]; Phase 3 studies underway in Chile, Kenya, Malaysia, the Philippines, and South Africa	-	≥12 years: Indonesia ≥6 years: Chile, El Salvador, Ecuador Indonesia ≥3 years: China, Colombia, Hong Kong
Sinopharm	Phase I/II studies in 3-17 year olds in China		≥12 years: Morocco ≥3 years: China, UAE, Venezuela, Argentina, Bahrain
AstraZeneca	Trials suspended when evidence emerged of the higher risk of TTS in younger adults compared to older adults		≥3 years: Colombia
Bharat Biotech	Phase 2/3 trial in 2-18 year olds		-

Maternal Vaccination

VACCINE	VACCINE EFFICACY/EFFECTIVENESS IN PREGNANT WOMEN	OTHER OUTCOMES
AstraZeneca	-	In four clinical trials in the UK, Brazil and South Africa, fertility was unaffected by vaccination and there was no increased risk of miscarriage and no instances of stillbirth in women vaccinated before pregnancy[78]
Moderna	-	Following maternal vaccination with mRNA vaccines, 100% of neonates (n=36) had protective antibodies at birth[79] Comparison in USA of 35,691 participants who received an mRNA vaccine in pregnancy and nonpregnant women (v-safe registry and VAERS): Injection-site pain more frequent in pregnancy; headache, myalgia, chills, and fever less frequent. Adverse pregnancy and neonatal outcomes similar in pregnant women to studies conducted before the Covid-19 pandemic[80] Durability of anti-spike antibodies in infants after maternal Pfizer or Moderna: 98% of infants had antibodies at 2 months of age; higher antibody levels than in infants of those previously infected; 57% of infants of vaccinated mothers had antibodies at 6 months of age compared to 8% of infants of infected mothers[81] Pooled effectiveness of maternal vaccination with two doses of Pfizer or Moderna against hospitalisation in infants <6 months of age: Overall: 61% (31-78); During first 20 weeks of pregnancy: 32% (-43-68); From 21 weeks to 14 days before delivery: 80% (55-91)[82]
Novavax	-	-
Pfizer/BioNTech	Effectiveness in Israel: Any infection: 96% (89-100); Symptomatic infection: 97% (91-100); Hospitalisation: 89% (43-100)[83] Effectiveness in Israel: Any infection: 78% (57-89)[84]	Following maternal vaccination with mRNA vaccines, 100% of neonates (n=36) had protective antibodies at birth[79] NIH-funded MOMI-VAX study will assess antibody responses in 750 pregnant women and 250 women vaccinated with any US-licensed vaccine within 2 months of birth, and their infants[85] Comparison in USA of 35,691 participants who received an mRNA vaccine in pregnancy and nonpregnant women (v-safe registry and VAERS): Injection-site pain more frequent in pregnancy; headache, myalgia, chills, and fever less frequent. Adverse pregnancy and neonatal outcomes similar in pregnant women to studies conducted before the Covid-19 pandemic[80] Durability of anti-spike antibodies in infants after maternal Pfizer or Moderna: 98% of infants had antibodies at 2 months of age; higher antibody levels than in infants of those previously infected; 57% of infants of vaccinated mothers had antibodies at 6 months of age compared to 8% of infants of infected mothers[81] Infants of vaccinated and unvaccinated mothers in Israel: No difference in preterm birth, congenital anomalies, hospitalisation, or death[86] Pooled effectiveness of maternal vaccination with two doses of Pfizer or Moderna against hospitalisation in infants <6 months of age: Overall: 61% (31-78); During first 20 weeks of pregnancy: 32% (-43-68); From 21 weeks to 14 days before delivery: 80% (55-91)[82]
Sinopharm	-	-
Sinovac	-	-

Mixed Dose Vaccine Safety and Immune Responses

Mixed vaccine schedules (i.e. delivering different types of vaccine for the first and second dose) could be particularly useful to facilitate better protection against variants of concern and enable vaccination programs to continue if a particular vaccine is unavailable.

SCHEDULE	SAFETY	IMMUNE RESPONSES OR EFFECTIVENESS	COUNTRIES USING SCHEDULE
AZ-PF	Spain: Similar side effects to those receiving 2 doses of the same vaccine; no safety concerns (not peer reviewed)[87] UK: Greater systemic side effects (mild-moderate symptoms) following the booster dose than with 2 doses of the same vaccine; no safety concerns[88] Germany: greater reactogenicity with first dose of AstraZeneca than with the Pfizer/BioNTech booster[89] Increased reactogenicity (54.4%; 49.4-59.5) vs AstraZeneca-AstraZeneca (33.5%; 28.0-39.2)[90] Total adverse event reporting in Korea: 0.28% (vs AZ-AZ: 0.22%; and PF-PF: 0.31%)	Spain: ≥8 week dose interval: Stronger immune response following Pfizer/BioNTech than after 2 doses of AstraZeneca vaccine (not peer reviewed)[87] Spain: 8-12 week dose interval: robust antibody response[91] UK: 4 week dose interval: stronger antibody and cellular response than after 2 doses of AstraZeneca vaccine[92] Germany: 9-12 week dose interval: Significantly stronger immune response following Pfizer/BioNTech booster than AstraZeneca, and slightly stronger than after 2 doses of Pfizer/BioNTech (not peer reviewed)[93] Germany: 4-fold greater immune response than 2 doses of AstraZeneca[94] South Korea: 6-fold greater neutralising antibody response than 2 doses of AstraZeneca Germany: Higher neutralising antibody response against wild-type, Alpha, Beta, Gamma and Delta variants than AZ-AZ[95]	Canada, Denmark, Finland, France, Germany, Sweden, Norway, Spain and South Korea[96]
PF-AZ	UK: Greater systemic side effects (mild-moderate symptoms) following the booster dose than with 2 doses of the same vaccine; no safety concerns[88] Greater reactogenicity with first of homologous and heterologous prime-boost immunisation with BNT162b2 and ChAdOx1-nCoV19: a prospective cohort study increased reactogenicity (55.2%; 46.1-64.1) vs Pfizer/BioNTech-Pfizer/BioNTech (33.3%; 23.4-44.5)[90]	UK: 4 week dose interval: weaker antibody response than after 2 doses of Pfizer/BioNTech vaccine (but stronger than after 2 doses of AstraZeneca vaccine)[92]	-
AZ-mRNA (PF or MO)	-	Effectiveness in Canada: Infection: 90% (89-91); 87% (85-89); Hospitalisation: 99% (98-100); 98% (95-99)[33]	
Primary series of PF, J&J or MO followed by PF, J&J or MO booster	Reactogenicity for all combinations similar to primary series[9]	Homologous boosters increased neutralising antibody titres 4.2 to 20-fold; Heterologous boosters increased neutralising antibody titres 6 to 76-fold[9]	-
AZ, MO and PF	-	Canada: Trial underway mixing and matching all three vaccines with study arms assessing 4 week and 16 week dose intervals[97] Denmark: Vaccine effectiveness against infection: AZ-PF or AZ-MO: 88% (83-92)[98]	AstraZeneca followed by either Moderna or Pfizer/BioNTech: Denmark, Finland, France, Germany, Sweden, Norway and Spain[96]
Sinovac primary series	-	Chile: Symptomatic infection: Sinovac booster: 78.8% (76.8-80.6); PF booster: 96.5% (96.2-96.7); AZ booster: 93.2% (92.9-93.6); Hospitalisation: Sinovac: 86.3% (83.7-88.5); PF: 96·1% (95.3-96.9); AZ: 97.7 (97.3-98.0); Death: Sinovac: 86.7% (80.5-91.0); PF: 96.8% (93.9-98.3); AZ: 98.1% (97.3-98.6)[99] Chile: Symptomatic infection with Omicron: PF booster: 96.5% (96.2-96.7); AZ booster: 93.2 (92.9-93.6)[99,100]	Sinovac-AZ: Thailand

COVID-19 Vaccine Efficacy

All studies conducted prior to Omicron predominance and most prior to Delta. Efficacy is dependent on variants circulating at the time of the study so it is difficult to directly compare efficacy between vaccines.

VACCINE	VACCINE EFFICACY			
	SYMPTOMATIC INFECTION	MODERATE-SEVERE	SEVERE	HOSPITALISATION/DEATH
AstraZeneca	UK: 66.7% (57.4-74.0)[101] USA, Chile, Peru: 76%[26] (not peer-reviewed) Single dose in UK (22-90 days post-vaccination): 76.0% (59.3 to 85.9)[101] Efficacy with different interval between doses in UK: 12+ weeks: 82.4% (2.7-91.7) <6 weeks: 54.9% (32.7-69.7)[101]	-	Severe/critical and hospitalisation in USA, Chile, Peru: 100%[26] (not peer-reviewed) UK: 100% (15 cases in the placebo group)[101]	Hospitalisation in UK: 100% (9 cases in placebo group)[101]
Bharat Biotech	India: 77.8% (65.2-86.4)[39]	-	India: 93.4% (57.1-99.8)[39]	-
Clover	Philippines, Colombia, Brazil, South Africa and Belgium: Overall: 67.2% (54.3-76.8); Delta: 78.7% (57.3-90.4)[102]	Philippines, Colombia, Brazil, South Africa and Belgium: Overall: 83.7% (55.9-95.4); Delta: 81.7% (35.9-96.6)[102]		Hospitalisation in Philippines, Colombia, Brazil, South Africa and Belgium: 100% (42.7-100)[102]
Gamaleya	Russia: 91.6% (85.6–95.2)[40] Single dose (Sputnik Light) in Argentina: 78.6%[103]	Moderate-severe: 100% (20 cases in the placebo group)[40]	-	-
Johnson & Johnson	USA: 93.2% (91.0-94.8)[104] USA, Brazil, Peru, South Africa: 55.9% (51.0-60.5)[105]	Moderate to severe/critical: All sites: 66.1% (55.0-74.8) USA: 72.0% (58.2-81.7) Latin America: 61.0% (46.9-71.8) South Africa: 64.0% (41.2-78.7)[41,106] South Africa: 67-71%[107]	85.4% (54.2-96.9)[106] USA: 98.2% (92.8-99.6)[104] USA, Brazil, Peru, South Africa: 73.3% (63.9-80.5)[105]	100% (5 deaths in placebo group)[106] Death in South Africa: 96%[107] USA, Brazil, Peru, South Africa: Death: 84.5% (47.3-97.1)[105]
Moderna	USA: 94.1% (89.3-96.8)[42] USA: >90%[108] Efficacy in USA: 12-17 years: Symptomatic: 92.7% (67.8-99.2) Infection: 69.8% (49.9-82.1) Asymptomatic infection: 59.5% (28.4-77.3)[109]	-	USA: 100% (30 cases in placebo group)[42] US: >95%[108]	USA: 100% (1 death in placebo group)[42]
Novavax	UK: 89.7% (80.2-94.6)[110] US and Mexico: 90.4% (82.9-94.6)[46]	US and Mexico: 100% (87.0-100)[46]	-	-
Pfizer/BioNTech	Argentina, Brazil, Germany, South Africa, Turkey and the USA: 94.6% (89.9–97.3)[49] Infection over 6 months: 91.3% (89.0-93.2)[51] Single dose: 100%	-	Argentina, Brazil, Germany, South Africa, Turkey and the USA: 88.9% (20.1–99.7)[49] Severe disease: 96.7% (80.3-99.9)[51]	-
Sinopharm	UAE, Bahrain, Egypt and Jordan: 78.1% (64.9-86.3)[54]	-	-	Hospitalisation in UAE, Bahrain, Egypt and Jordan: 78.7% (26.0-93.9)[54]
Sinovac	Brazil: 50.7% (35.9-62.0) Chile: 67% (65-69) Indonesia: 65% (20-85)[54] Turkey: 83·5% (65·4-92·1)[111]	Requiring medical assistance in Brazil: 83.7% (58.0-93.7) Moderate-severe: 100% (56.4-100.0)[112]	-	Hospitalisation: Brazil: 100% (56-100) Chile: 85% (83-97) Turkey: 100% (20-100)[54]
CanSino Biologics	Pakistan, Mexico, Argentina, Russia and Chile: 57.5% (39.7-70.0)[113]	-	-	-

Vaccine Effectiveness of Primary Series Summary at-a-glance

Detailed summary available in Appendix 1.
At-a-glance summary of vaccine efficacy/effectiveness against asymptomatic infection available in Appendix 2 and details of vaccine efficacy/effectiveness against transmission available in Appendix 3.

VACCINE	ANY INFECTION	SYMPTOMATIC INFECTION	HOSPITALISATION/ SEVERE DISEASE	DEATH	EFFECTIVENESS 3 to <6 MONTHS	EFFECTIVENESS ≥6 MONTHS
AstraZeneca	45-73%[35,114–120] Single dose 30-67%[114,116,119,121]	-39-78%[5,7,27,33,34,36,117,122,123★] Single dose: 38-68%[27,29,123,124] Moderate-Severe: 82%; Single dose: 79%[119]	83-100%[8,28,33–36,43,117,122,123,125,126] Single dose: 49-94%[29,123,126,127]	90-100%[34–36,38,122]	Infection: 44-45%[5,36,123] Hospitalisation or death: 42-80%[8,36,123] Death: 85%[36]	Infection: 42-72%[5,120] Hospitalisation: 39%[8]
Bharat Biotech	-	50%[128]	-	-	-	-
Johnson & Johnson	50-88%[117,129–132]	54%[117]	71-91%[43,107,117,130,133]	-	-	Infection: 13%[134] Death: <65 years: 73%; ≥65 years: 52%[134]
Moderna	37-92%[11,44,45,117,131,135,136] Single dose: 20-72%[12,121]	45-95%[13,34,45,52,117,136,137] Single dose: 0-72%[13,31,52]	77-98%[8,12,13,34,43–45,117,133,135,136] Single dose: 69-96%[12,121]	98%[45]	85%[8]	Infection: 2-58%[13,14,134,136] Hospitalisation: 64-81%[8,13] Hospitalisation and death: 56-83%[14,136] Death: <65 years: 82%; ≥65 years: 76%[134]
Pfizer/BioNTech	55-95%[11,29,47,50,114,115,117,118,120,131,135,138–143] Single dose: 36-57%[114,116,121]	-18-97%[5,7,13,27,29,34,36,52,117,122,137,138,141,144–146★] Single dose: 26-61%[13,27,31,52,146]	74-99%[8,13,19,29,34,36,43,48,50,117,122,126,133,135,138,141,143,144,147,148] Single dose: 85-94%[126,127]	90-100%[34,36,38,48,50,122,138,141,147]	Infection: 47-65%[5,36,143] Hospitalisation: 87-92%[8,36] Death 92%[36]	Infection: 0-64%[5,13,14,120,134,146] Death: <65 years: 84%; ≥65 years: 70%[134] Hospitalisation: 68-81%[8,13,14,19]
Sinopharm	-	90%[54]	-	-	-	-
Sinovac	53-60%[35,147]	59[122]	73-91%[35,122,147]	74-95%[35,122,147]	-	-

Adverse Events Following Immunisation with WHO EUL Vaccines

Adverse events following immunisation (AEFIs) are any reactions occurring after immunisation. They can be either expected or unexpected. The vaccine may not actually cause the AEFI; it may occur coincidentally as millions of people are being vaccinated so some people may get sick after vaccination but this does not necessarily mean that it is due to the vaccine. Special investigations determine whether they are due to the vaccine. Adverse events of special interest (AESIs) are of scientific and medical concern that are found through active surveillance, that have the potential to be causally associated with a vaccine and that need to be carefully monitored and confirmed by further special studies.

For all injectable vaccines, appropriate medical treatment and supervision should always be readily available in case of an anaphylactic event following administration.

	ASTRAZENECA	MODERNA	PFIZER/BIONTECH	JOHNSON & JOHNSON	SINOPHARM	SINOVAC	CLOVER	BHARAT BIOTECH
Adverse events following immunisation (AEFIs)*	Very common (more than 1 in 10 people): headache, nausea, muscle pain, joint pain, injection site tenderness/ pain/ warmth/ itch, fatigue, malaise, fever, chills Common (between 1 in 10 and 1 in 100 people): injection site swelling/ redness[149]	Injection site pain (92%)/ swelling (15%)/ redness (10%), fatigue (70%), headache (65%), muscle pain (62%), joint pain (46%), fever (16%), chills (45%), nausea/vomiting (23%), axillary swelling/tenderness (20%)[150]	Very common: headache, muscle pain, joint pain, injection site pain/ swelling, fatigue, fever, chills; Common: nausea, injection site redness[149] Uncommon (between 1 in 100 and 1 in 1000 people): lymphadenopathy, insomnia, pain in extremity of vaccinated arm, malaise, injection site itch; Rare: (between 1 in 1000 and 1 in 10,000): acute peripheral facial paralysis[151]	Injection site pain/ redness/ swelling, headache, fatigue, muscle pain, nausea, fever[152]	Injection site pain (16%)/ itch (1%)/ swelling (2%)/ redness (1%), fever (4%), fatigue (3%), nausea (1%), headache (1%), diarrhoea (1%), muscle pain (<1%), itch (non-injection site) (1%)[153]	Fatigue (8.3%), fever (3.3%), diarrhoea (0.8%), nausea (1.7%), headache (2.5%), muscle pain (1.7%), injection site pain (10.0%)/ redness (0%)/ swelling (0%)[154]	Very common: Injection site pain, fatigue, headache Common: Injection site erythema, myalgia, arthralgia, loss of appetite, nausea, chills Uncommon: Injection site swelling, fever[102]	Common: Injection site pain/redness/ itching, headache, fever, malaise, fatigue, body ache
Adverse events of special interest (AESIs)	Thrombosis with thrombocytopaenia syndrome (TTS) (see page 13 for estimated risk); EMA PRAC: Guillain-Barre syndrome (GBS)[155] Australia: Guillain-Barre syndrome: 52 cases (10.4 per million doses)[156] Australia: Immune thrombocytopaenia (ITP)	Myopericarditis (most common in younger males) USA VAERS: myocarditis cases per million second doses: 18-24 year males 38.5, females: 5.3; 25-29 year males: 17.2, females: 5.7[157] ITP**[158]	Myopericarditis (most common in younger males) USA VAERS: myocarditis cases per million second doses: 12-15 year males: 39.9, females: 3.9; 16-17 year males: 69.1, females: 7.9; 18-24 year males: 36.8, females: 2.5; 25-29 year males 10.8, females: 1.2[157] >1 in 20,000 males under 25 years of age[159] Israel: 1 to 5 cases of myocarditis per 100,000 persons[160,161] ITP**[158]	TTS (see page 14 for estimated risk) USA: Guillain-Barre Syndrome: 100 preliminary reports of GBS following 12.5 million doses of vaccine administered (mostly males >50 years)[162]	-	-	-	-

*Details for AstraZeneca, Moderna, Pfizer/BioNTech and Johnson & Johnson from product information sheets in SRA countries, based on data from clinical trials; Sinopharm, Sinovac and Bharat Biotech details from published clinical trials
**The ITP cases are mostly without the thrombotic events characteristic of TTS

Serious Adverse Events

Caution is required when comparing safety profiles as definitions and reporting systems vary in trials and in particular phase IV studies. Risk of TTS in PICs available in Appendix 9.

VACCINE	VACCINE SAFETY
AstraZeneca	108 SAEs in 12,282 (0.9%) vaccine recipients and 127 in 11,962 (1.1%) placebo recipients; 7 deaths all considered unrelated to vaccination (2 vaccine, 5 placebo)[101] US Phase III study: No serious safety concerns involving 32,449 participants[26] (not peer-reviewed) EMA investigation: possible link between the AstraZeneca vaccine and Thrombosis with Thrombocytopaenia Syndrome (TTS) Blood clots affected the brain (central venous sinus thrombosis, CVST) and abdomen (splanchnic vein thrombosis) There have been reports of 169 cases of CVST and 53 cases of splanchnic vein thrombosis in ~34 million vaccinated people in Europe The EMA confirmed the overall benefits of the vaccine in preventing COVID-19 outweigh the risks of side effects[163] UK: Risk factors for death in patients with TTS following the AstraZeneca vaccine: baseline platelet count; and intracranial haemorrhage[164] TTS reported to occur in ~1 in 50,000 vaccinated adults in Australia[165] Several countries introduced age recommendations for the vaccine: >60 years in Germany and Australia; >55 years in France and Canada; >40 years in the UK[166–168] EMA has started a review of reports of capillary leak syndrome following 5 cases of this very rare disorder post vaccination[169] WHO GACVS reports Guillain Barre Syndrome (GBS) rates following adenovirus vector vaccines: EU/EEA: 4.4; AUS: 9.7; KOR: 0.4; PHL: <1[170] Guillain-Barre Syndrome in England: IRR 15-21 days: 2.90 (2.15-3.92); Scotland: IRR 1-28 days: 2.32 (1.08-5.02); following SARS-CoV-2 infection: IRR 1-28 days: 5.25 (3.00-9.18); Bell's Palsy in England: IRR 15-21 days: 1.29 (1.08-1.56); IRR 1-28 days: 1.07 (0.94-1.21)[171] Immune thrombocytopaenia (ITP) in Victoria, Australia: 8 cases per million doses (17 cases; 15 after second dose) (Expected background rate: 20-49 years: 1.9; ≥50 years: 4.1)[172]
Gamaleya	45 SAEs in 16,427 (0.3%) vaccine recipients and 23 in 5,435 (0.4%) placebo recipients; 4 deaths all considered unrelated to vaccination (3 vaccine, 1 placebo)[40]
Johnson & Johnson	83 SAEs in 21,895 (0.4%) vaccine recipients and 96 in 21,888 placebo recipients (0.4%); 19 deaths all considered unrelated to vaccination (3 vaccine, 16 placebo)[41] EMA investigation of 8 reports of TTS. Most cases occurred in women <60 years of age but specific risk factors have not been confirmed[173] USA: Cases of TTS per million doses: Overall: 3.1; Female: 5.2; Male: 1.5[157] Deaths: 5 (4 female, 1 male)Guillain-Barre Syndrome: 100 preliminary reports of GBS following 12.5 million doses of vaccine administered in USA (mostly males >50 years)[162] WHO GACVS reports Guillain Barre Syndrome (GBS) rates following adenovirus vector vaccines: USA: 7.8; KOR: 0.9; EU/EEA: AZ: 2.1[170]
Moderna	153 SAEs in 15,166 (1.0%) placebo recipients and 147 in 15,185 (1.0%) vaccine recipients; 5 deaths considered unrelated to vaccine (2 vaccine, 3 placebo)[42] Anaphylaxis reported in the US at a rate of 2.5 per million doses[174] No obvious safety signals among pregnant women who received mRNA COVID-19 vaccines in USA[80] USA: Myo/pericarditis reported in 40.6 males and 4.2 females aged 12-29 years per million second doses of mRNA vaccine; and 2.4 males and 1.0 females aged 30+[175] USA VAERS: myocarditis cases per million second doses: 18-24 year old males: 38.5, females: 5.3; 25-29 year old males: 17.2, females: 5.7[157] Ontario, Canada; Myo/pericarditis cases per million second doses in those aged 18-24 years: Males 198.6; Females 59.6[176] Overall rates in the UK per million second doses: Myocarditis: 28.3; Pericarditis: 17.2[177] EMA PRAC: French study: 57 extra cases of myocarditis per million 16-24-year-old males compared to unexposed; Nordic study: 190 extra cases of myocarditis per million 16-24-year-old males[178] Myo/pericarditis in Ontario, Canada: Rates in males 18-24 years 5.1 (1.9-15.5) times higher following Moderna second dose than Pfizer/BioNTech; Rates higher with shorter dose interval (i.e. ≤30 days)[179] Myocarditis excess cases in people <40 years in the UK: First dose: 8 (4-9) per million; Second dose: 15 (12-16)[180] Myo/pericarditis in Australia: 25 cases per million doses (18-33)[181] Australia: Myo/pericarditis following boosters: 4 cases[182]
Novavax	SAEs at low levels and similar between vaccine and placebo groups[183]
Pfizer/BioNTech	SAEs and deaths were low and comparable between vaccine and placebo groups (total 37,586 participants)[49] Anaphylaxis reported in the US at a rate of 4.7 per million doses[174] No obvious safety signals among pregnant women who received mRNA COVID-19 vaccines in USA[80] Brazil: SAEs: 5.4/100,000 doses USA: Myopericarditis reported in 40.6 males and 4.2 females aged 12-29 years per million second doses of mRNA vaccine; and 2.4 males and 1.0 females aged 30+[175] USA VAERS: myocarditis cases per million second doses: 12-15 year males: 39.9, females: 3.9; 16-17 year males: 69.1, females: 7.9; 18-24 year males: 36.8, females: 2.5; 25-29 year males 10.8, females: 1.2[157] Ontario, Canada; Myo/pericarditis cases per million second doses in those aged 18-24 years: Males 35.5; females 39.9[176] Overall rates in the UK per million second doses: Myocarditis7.4; Pericarditis 5.6[177] Israel: Myo/pericarditis: 106.9 (69.3-144.6) cases per million in those aged 16-29[184]; 137.3 (81.1-194.6) cases per million people aged 16-19[185] Haemorrhagic stroke in England: IRR 15-21 days: 1.38 (1.12-1.71) (not replicated in Scotland data)[171] Israel: Myo/pericarditis: 16-19 year old males: Second dose: 161 cases per million; Third dose: 52 cases per million[186] EMA PRAC: French study: 26 extra cases of myocarditis per million 12-29-year-old males compared to unexposed; Nordic study: 130 extra cases of myocarditis per million 12-29-year-old males[178] Hong Kong: Myo/pericarditis in 12-17 year-olds: After first dose: 34 (11-95) cases per million; Second dose: 212 (138-323); Males, first dose: 56 (24-125); Males, second dose: 373 (270-513)[187] Myo/pericarditis in Ontario, Canada: Rates higher with shorter dose interval (i.e. ≤30 days)[179] Myocarditis excess cases in people <40 years in the UK: First dose: 2 (1-3) per million; Second dose: 3 (2-4)[180] Myo/pericarditis in Australia: 16 cases per million doses (15-17)[181] USA: Myocarditis 5-11 years: 11 confirmed cases following ~8 million doses administered[188] Australia: Myo/pericarditis following boosters: 14 cases[182] France: MIS-C following vaccination in 12-17 year olds: 1.1 cases per million doses (post-SARS-CoV-2 MIS-C in the same age group in the same population was 113 per million doses)[189] USA: MIS-C following vaccination in 12-20 year olds: 21 cases (1 case per million persons vaccinated)[4] Israel: Myocarditis in 18-24 year old military recruits following a *third dose* of Pfizer/BioNTech: 64.3 (1.3-127.3) per million within 1 week of booster; 112.5 (29.2-195.9) per million within 2 weeks[190]
Sinovac	Brazil: SAEs: 79.7/100,000 doses Safety in Chile 6-11 years: Adverse events following 0.011% of doses administered (most common: vomiting, itching, injection site pain and erythema)[191]

Risk of Myo/Pericarditis in 12-17 Year Olds Following mRNA Vaccines

Estimated number of myo/pericarditis cases that potentially might occur in Pacific Island Countries if all 12-17 year olds received the Pfizer/BioNTech or Moderna vaccine, based on official country population estimates and incidence of myo/pericarditis (highest and lowest estimates) in other settings. The risk is reduced with an extended dose interval of ≥8 weeks between first and second doses. Nearly all myo/pericarditis cases related to mRNA vaccination are mild and managed conservatively.

COUNTRY	TOTAL POPULATION	ESTIMATED POPULATION AGED 12-17 YEARS*	POTENTIAL NUMBER OF MYO/PERICARDITIS CASES IF ALL 12-17 YEAR OLDS RECEIVED THE PFIZER/BIONTECH VACCINE**	POTENTIAL NUMBER OF MYO/PERICARDITIS CASES IF ALL 12-17 YEAR OLDS RECEIVED THE MODERNA VACCINE ***
American Samoa	55,519	7,217	0.3-1.5	0.1-1.4
Cook Islands	15,300	1,989	<1	<1
Federated States of Micronesia	102,300	13,299	0.5-2.8	0.3-2.6
Fiji	867,000	112,710	4.2-23.9	2.3-22.0
French Polynesia	275,918	35,869	1.3-7.6	0.7-7.0
Guam	159,358	20,717	0.8-4.4	0.4-4.1
Kiribati	113,400	14,742	0.6-3.1	0.3-2.9
Marshall Islands	54,900	7,137	0.3-1.5	0.1-1.4
Nauru	10,900	1,417	<1	<1
New Caledonia	271,407	35,283	1.3-7.5	0.7-6.9
Niue	1,611	209	<1	<1
Northern Mariana Islands	53,883	7,005	0.3-1.5	0.1-1.4
Palau	18,000	2,340	<1	<1
Papua New Guinea	7,744,700	1,006,811	37.7-213.4	20.8-196.8
Samoa	195,979	25,477	1.0-5.4	0.5-5.0
Solomon Islands	642,000	83,460	3.117.7	1.7-16.3
Tokelau	1,160	151	<1	<1
Tonga	99,419	12,924	0.5-2.7	0.3-2.5
Tuvalu	10,507	1,366	<1	<1
Vanuatu	272,173	35,382	1.3-7.5	0.7-6.9
Wallis and Futuna	11,558	1,503	<1	<1
All Pacific Island Countries	10,976,992	1,427,009	53.4-302.5	29.5-279.0

* Based on estimate of 13% of population aged 12-17 years
** Based on estimates of myo/pericarditis occurring in 212 per million second doses of Pfizer/BioNTech in 12-17 year olds in Hong Kong and 37.4 per million second doses in 16-17 year olds in USA (VAERS data)[157,187]
*** Based on estimates of myo/pericarditis occurring in 195.5 per million doses in 18-24 year olds in Canada (data not available for <18 years) and 20.7 per million second doses in 18-24 year olds in USA (VAERS data; not available for <18 years)[157,179]

Who Can be Vaccinated Based on WHO SAGE Recommendations?

WHO SAGE have made recommendations for use of AstraZeneca, Moderna, Pfizer/BioNTech, Johnson & Johnson, Sinopharm, Sinovac, Bharat Biotech and Novavax vaccines: https://www.who.int/groups/strategic-advisory-group-of-experts-on-immunization/covid-19-materialss

	ASTRAZENECA	MODERNA	PFIZER/BIONTECH	JOHNSON & JOHNSON	SINOPHARM	SINOVAC	BHARAT BIOTECH	NOVAVAX
Minumum Age	18 years	12 years	5 years	18 years	18 years	18 years	18 years	18 years
Maximum Age (SAGE WHO)	None	None	None	None	None	None	None	None
Pregnancy	Yes if high priority group & approved by health provider	Yes if high priority group & approved by health provider	Yes if high priority group & approved by health provider	Yes if high priority group & approved by health provider	Yes if high priority group & approved by health provider	Yes if high priority group & approved by health provider	Yes if the benefits outweigh the potential risks	Yes if the benefits outweigh the potential risks
Breastfeeding	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
People previously infected with SARS-CoV-2	May delay 6 months; Within 90 days if VOCs associated with reduced effectiveness are circulating (e.g. Beta)	May delay 6 months; Within 90 days if VOCs associated with reduced effectiveness are circulating (e.g. Beta)	May delay 6 months; Within 90 days if VOCs associated with reduced effectiveness are circulating (e.g. Beta)	May delay 6 months; <6 months may be advisable if VOCs with reduced neutralisation activity are circulating	May delay 6 months; <6 months may be advisable if VOCs associated with reduced effectiveness are circulating	May delay 6 months; <6 months may be advisable if VOCs associated with reduced effectiveness are circulating	May delay 6 months; <6 months may be advisable if VOCs associated with reduced effectiveness are circulating	May delay 6 months; <6 months may be advisable if VOCs associated with reduced effectiveness are circulating
Immunocompromised Including HIV	An additional dose at least 1 month, and within 3 months, after completing the primary series	An additional dose at least 1 month, and within 3 months, after completing the primary series	An additional dose at least 1 month, and within 3 months, after completing the primary series	An additional dose at least 1 month, and within 3 months, after completing the primary series	An additional dose at least 1 month, and within 3 months, after completing the primary series	An additional dose at least 1 month, and within 3 months, after completing the primary series	An additional dose at least 1 month, and within 3 months, after completing the primary series	An additional dose at least 1 month, and within 3 months, after completing the primary series
History of Anaphylaxis (Severe Allergy)	Yes (unless the allergy is to the vaccine or its components)	Yes (unless the allergy is to the vaccine or its components)	Yes (unless the allergy is to the vaccine or its components)	Yes (unless the allergy is to the vaccine or its components)	Yes (unless the allergy is to the vaccine or its components)	Yes (unless the allergy is to the vaccine or its components)	Yes (unless the allergy is to the vaccine or its components)	Yes (unless the allergy is to the vaccine or its components)

Vaccine Development Pipeline

WHO has recommended that vaccines adopted by countries have WHO SAGE EUL and/or Stringent Regulatory Approval. Last updated 11th April 2022.

VACCINE TYPE	NUMBER OF VACCINE CANDIDATES AT EACH PHASE OF DEVELOPMENT				
	PRE-CLINICAL	PHASE I/II	PHASE III	PHASE IV	IN USE*
RNA	26	16	3	2	2 (Pfizer/BioNTech, Moderna)
DNA	16	9	3	0	1 (Zydus Cadila Healthcare Limited)
Vector (non-replicating)	26	8	2	3	4 (CanSino, Gamaleya, Johnson & Johnson, AstraZeneca)
Vector (replicating)	18	7	0	0	0
Inactivated	5	11	7	3	11 (Sinopharm/BBIP; Sinopharm/WIBP; Sinovac; Bharat; Chumakov; Organisation of Defensive Innovation and Research; Research Instutute for Biological Safety Problems; Shenzhen Kangtai Biological Products; Shifa Pharmed; Erciyes University; Valneva/Dynavax)
Live-attenuated	2	1	0	0	0
Protein subunit	71	21	18	1	12 (Novavax; Vector institute; Anhui Zhifei Longcom Biopharmaceutical Chinese Academy of sciences; Center for Genetic Engineering and Biotechnology; Instituto Finlay de Vacunas [peptides 1 and 2]; Medigen Vaccine Biologics; Vaxine Pty Medytox CinnaGen Co; Biological E Ltd; Razi Vaccine and Serum Research Institute; National Vaccine and Serum Institute/Lanzhou Institute of Biological Products Co Ltd; Bagheiat-allah University of Medical Sciences)
Virus-like particle	22	4	2	0	1 (Medicago Inc)
Other/unknown	32	5	0	0	0

*Not all vaccines in use have SRA (as recognised by WHO) approval (see Vaccine specifications table and WHO SAGE Emergency Use Listing and prequalification timeline for approval status of vaccines).

Source: London School of Hygiene and Tropical Medicine
COVID-19 vaccine tracker.

WHO SAGE Emergency Use Listing and Prequalification Timeline

MANUFACTURER	NAME OF VACCINE	PLATFORM	STATUS OF ASSESSMENT	ANTICIPATED DECISION DATE
Pfizer/BioNTech	BNT162b2/COMIRNATY Tozinameran (INN)	mRNA	Final decision made	Authorised 31/12/20
AstraZeneca	AZD1222	Adenoviral vector	Final decision made	SK Bio: Authorised 15/02/21 EU nodes: Authorised 16/04/21 CSL, Australia: Authorised 09/07/21 Daiichi Sankyo, Japan: Authorised 09/07/21
Serum Institute of India	Covishield (ChAdOx1_nCoV19)	Adenoviral vector	Final decision made	Authorised 15/02/21
Sinopharm/Beijing Institute of Biological Products (BIBP)	SARS-CoV-2 Vaccine (Vero Cell), Inactivated (InCoV)	Inactivated	In progress	Authorised: 07/05/2021
Sinovac	SARS-CoV-2 Vaccine (Vero Cell), Inactivated	Inactivated	In progress	Authorised 01/06/2021
Moderna	mRNA-1273	mRNA	In progress (to use abridged procedure relying on EMA)	Authorised 30/04/2021
Johnson & Johnson	Ad26.COV2.S	Adenoviral vector	Final decision made	Authorised 12/03/21
Russian Direct Investment Fund	Sputnik V	Adenoviral vector	Process restarted, awaiting completion of rolling submission	Will be determined when all data are submitted
Bharat Biotech	Covaxin; BBV152	Inactivated	Rolling data assessment started 6 July 2021	Authorised 03/11/2021
CanSino Biologics	Ad5-nCoV	Adenoviral vector	Rolling data assessment started 9 August 2021	TBC
Novavax	NVX-CoV2373	Protein subunit	Rolling data assessment started 19 August 2021	Authorised 20/12/2021
CureVac	Zorecimeran	mRNA	Application withdrawn by manufacturer	-
Clover Biopharmaceuticals	SCB-2019 (CpG 1018/Alum)	Protein subunit	Rolling data starting 20 September 2021	TBC

Source: WHO Guidance Document: Status of COVID-19 Vaccines within WHO EUL/PQ evaluation process. Available at: https://www.who.int/teams/regulation-prequalification/eul/covid-19

Pediatric COVID-19 Vaccine Safety Summary

Post-licensure vaccine surveillance is undertaken to monitor vaccine safety and identify signals for rare events. Post-licensure safety data for COVID-19 vaccines in children <18 years, for both primary courses and booster doses, are still emerging.

Relevant dates: The CDC (USA) endorsed Pfizer vaccine for 5–11-year-olds on 2 Nov 2021, Pfizer booster doses for 16–17-year-olds on 9 Dec 21 and Pfizer boosters for 12-15 year olds on 5 Jan 22. The Moderna vaccine has not been licensed in the USA for children under 18 years. [1] ATAGI (Australia) recommended Pfizer or Moderna vaccine for adolescents ≥12 years on 27 Aug 21, Pfizer vaccine for 5-11 year old on 9 Dec 21 (with roll out commencing 10 Jan 22), Moderna vaccine for 6-11 year olds on 23 Feb 22, and Pfizer booster doses for 16-17 year old on 3 Feb 22.

Estimates of frequency of adverse events vary depending on setting, definitions and methodology, as well as vaccine roll-out progress. Original data regarding rare serious adverse events have been converted to per million vaccine doses/people where relevant to enable comparison across settings.

Key messages

Adverse events following immunisation (AEFI) – any untoward medical event following immunisation, whether or not caused by the vaccine. [2]

- Local and systemic side effects are common and tend to be mild-moderate and well-tolerated. They typically occur 1-2 days following vaccine, and resolve within 3 days.
- Children <12 years have tended to report fewer side effects that older age groups. [3] [4]
- In trial data, <12-year-olds receiving Moderna vaccine reported mild side effects more frequently than those receiving Pfizer vaccine (although measured differently). [1] [5]
- Differences in vaccine dose and formulation for children <12 years increase the potential for vaccine administration errors [6] [7], highlighting the importance of preventive actions to avoid vaccine errors, and procedures to appropriately manage errors if they occur. [8] [9] [10]

Adverse events of special interest (AESI) - pre-specified medically significant events that have the potential to be causally associated with vaccines. They can be serious or non-serious, and must be carefully monitored and confirmed by further studies. (2)
Myocarditis/pericarditis and PIMS-TS are AESIs of particular relevance following COVID-19 vaccine administration in children.

Myocarditis and pericarditis are rare AESI that have been reported following mRNA vaccines. Myocarditis in particular has been reported more commonly after the second dose, and in males aged 16-17 years.
The most recent estimates from the largest group of vaccinated children (VAERS USA) reported 70.2 myocarditis cases in males and 7.6 myocarditis cases in females aged 16-17 years per million second doses, with lower rates in 12-15 year olds and much lower rates in 5-11 year olds. [11] Early estimates show myocarditis also occurs following booster doses, but less frequently than following second doses. [7] [12]
Myocarditis and pericarditis can also occur as complications of COVID-19 infection, at a significantly higher rates than following immunisation. [13]

PIMS-TS is a rare inflammatory syndrome occurring in children following COVID-19 infection. There is emerging evidence that vaccination is likely to provide protection against PIMS-TS. (14) (15) There have been very rare reports of PIMS-TS following COVID-19 vaccination - these are being closely monitored. [16] [17]

New updates

Most reported cases of myocarditis following COVID-19 mRNA vaccines have had a mild clinical course and rapid symptom improvement, with normal or rapid normalisation of heart systolic function on echocardiogram. (4) (18) (19) Longer term follow-up of cases is ongoing. A recent report indicated persistence of cardiac MRI changes at 3-8 months in some adolescents, the clinical significance of which is still uncertain. [20]
Primary course

12-17* years (*except where different age bracket specified)

AEFI

Pfizer & Moderna

Most common reported to v-safe (USA – Pfizer) and Ausvaxsafety (Aus – Pfizer & Moderna): Injection site reaction, fatigue, headache, myalgia, fever, gastrointestinal symptoms [21] [22]
Reported missing work, study or routine duties (majority for ≤1 day): 6-8% post dose 1 & 21-28.8% post dose 2 (Pfizer), 9-11% post dose 1 & 31-38% post dose 2 (Moderna) [22] [23] [7]

Most common notified to VAERS (USA – Pfizer) - dizziness, syncope, headache, nausea, fever, vomiting, fatigue (11) – 10,458 reports from 18,707,169 doses given, 92% non-serious, at 19 Dec 21 (12-15 years)
Most common notified to TGA (Aus – Pfizer & Moderna) - chest pain, headache, dizziness, nausea, fever (5) – 4,100 reports from 3.6 million doses given, at 17 Apr 22

AESI

Pfizer

Myocarditis & pericarditis

VAERS (USA) – cases of myocarditis per million second doses (within 7 days):
16-17 years
Both sexes – 37.4 Males – 69.1 Females – 7.9 (24)
Males – 70.2 Females – 7.6 (11)
Males – 105.86 Females – 10.98 (compared with expected: Males – 1.34 Females 0.42) (25)
12-15 years

Both sexes – 21.5 Males – 39.9 Females – 3.91 (24)
Males – 45.7 Females – 3.8 (11)
Males – 70.73 Females – 6.35 (compared with expected: Males – 0.53 Females 0.17) (25)

VSD (USA) – excess myocarditis/pericarditis cases per million second doses (within 21 days) compared with vaccinated comparators, *12-17 years:*
Both sexes – 70.8 (26)

Ontario, Canada – crude reporting rate of myocarditis/pericarditis per million second doses administered, *12-17 years:*
Both sexes – 63.3 Males – 107.5 Females – 17.4 (27)
Both sexes – 54.4 Males – 97.3 Females – 9.7 (28)
Canada – myocarditis/pericarditis cases per million second doses, *12-17 years:*
Males – 86 (29)

Australia – cases of myocarditis per million second doses, *12-17 years:*
Males – 122 Females - 24 (5)
Australia – cases of pericarditis per million doses, *12-17 years:*
Both sexes – 21 (5)
Victoria, Australia – cases of myocarditis per million doses (combined Pfizer and Moderna)
16-17 years
Both sexes – 110 (30)
12-15 years
Both sexes – 72 (30)

Israel – cases of myocarditis after second dose per million vaccinees:
16-19 years
Males – 153 Females – 9 (31)
Males – 150.7 Females – 10.0 (32)
12-15 years
Males – 66 Females – 6 (31)

UK – suspected myocarditis and pericarditis per million second doses, *<18 years:*
Both sexes – 11 (33)

Hong Kong – incidence rate of myocarditis/pericarditis after second dose, per one million people vaccinated (within 14 days), *12-17 years:*
Both sexes – 212.2 Males - 373.2 Females - 47.7 (34)

PIMS-TS

France - PIMS-TS cases per million doses (>95% Pfizer), *12-17 years*:
Both sexes - 1.1 Males – 1.9 Females – 0.3 (17) (compared to post COVID-19 infection PIMS-TS cases per million doses: both sexes – 113, males – 126, females – 100)

VAERS (USA) – PIMS-TS cases per million vaccinated people (one or more doses, 85% of doses Pfizer), *12-20 years:*
Both sexes - 1 (16)

Moderna

Australia – cases of myocarditis per million second doses, *12-17 years:*
Males – 204 Females – 51 (5)
Australia – cases of pericarditis per million doses, *12-17 years:*
Both sexes – 9 (5)

Canada – one case of myocarditis/pericarditis, 12-17 years, at 12 Nov 21 (29)

5-11 years

AEFI

Pfizer (5-11 years)

Most commonly reported to Ausvaxsafety (Aus) and v-safe (USA): injection site pain, fatigue, headache, myalgia, gastrointestinal symptoms, fever [35] [21]
Reported missing work, study or routine duties (majority for ≤1 day): 3-5.1% post dose 1, 7.4-8% after post dose 2 [6] [35]

Most common notified to VAERS (USA): vomiting, fever, headache, syncope (11) – 4,249 reports from 8,674,378 doses given, 98% non-serious, at 19 Dec 21
Most common notified to TGA (Australia): chest pain, vomiting, fever, headache, abdominal pain (5) – 1,300 notifications from 2 million doses given, at 17 Apr 2022

Moderna (6-11 years)

Most common side effects reported in clinical trial: injection site pain, fatigue, headache, fever, nausea and vomiting, myalgia and arthralgia, lymph node swelling [36]

AESI

Pfizer (5-11 years)
VAERS (USA) - cases of myocarditis per million second doses (within 7 days): Males – 4.3 Females 2.0 [11] Australia – 2 cases of likely myocarditis, and 5 possible cases of mild pericarditis, from approx. 2 million doses given, at 17 Apr 22 [5]
Moderna (6-11 years)
No cases of death, PIMS-TS or myocarditis/pericarditis reported in trial data, but trial not powered to detect these events or other rare unanticipated adverse events [36] Awaiting post-licensure data.

Booster doses

12-17 years(*except where different age bracket specified)

AEFI
Pfizer
Most commonly reported to v-safe (USA, 12-17 years) & Ausvaxsafety (Aus, 16-17 years): injection site reaction, fatigue, headache, myalgia, fever, gastrointestinal symptoms [7] [22] Reported missing work, study or routine duties (majority for ≤1 day): 20-25.8% [7] [22] Most common notified to VAERS (USA): product storage error, dizziness, syncope – 914 reports from 2.8 million booster doses given, 91.6% non-serious, at 20 Feb 22 [7]
AESI
Pfizer
VAERS (USA) – cases of myocarditis per million booster doses given (within 7 days) – 5 month interval: *16-17 years* Males – 23.2 (12) *12-15 years* Males – 17.2 (12) Israel – cases of myocarditis per million third doses – 5 month interval: *16-19 years* Males – 65 Females – 16 (from 123,355 3rd doses given to males, 125,088 3rd doses given to females, at 15 Dec 21) [31] *12-15 years* 2 cases myocarditis following 41,610 booster doses given (both male), at 5 Jan 22 [37]

Ausvaxsafety = voluntary smartphone-based safety surveillance system for adverse events after vaccination (Australia)
ATAGI = Australian Technical Advisory Group on Immunisation
PIMS-TS = Paediatric Inflammatory Multisystem Syndrome Temporally associated with SARS-CoV-2
TGA = Therapeutic Goods Administration (Australia), administers a national passive vaccine safety surveillance system
VAERS = Vaccine Adverse Event Reporting System, a passive vaccine safety surveillance system co-managed by CDC and FDA (USA)
VSD RCA = Vaccine Safety Datalink Rapid Cycle Analyses (USA), active surveillance system, a collaboration between CDC's Immunization Safety Office and nine health care organizations
v-safe = voluntary smartphone-based safety surveillance system for adverse events after COVID-19 vaccination (USA)

International comparison tables - Myocarditis

Pfizer - Myocarditis cases per million doses						
16-17 years*				**12-15 years #**		
		Males	Females		Males	Females
Dose 1						
	USA	6.1	0	USA	4.8	1
	Israel	12	0	Israel	5	0
Dose 2						
	USA	70.2	7.6	USA	45.7	3.8
	Israel	153	9	Australia	122	24
				Israel	66	6
Dose 3						
	USA	23.2		USA	17.2	
	Israel	65	16			

NB: * Israeli data for 16-19 years # Australian data for 12-17 years

Graphs comparing international Pfizer-Myocarditis cases





References

1. Corrao G, Franchi M, Cereda D, et al. Persistence of protection against SARS-CoV-2 clinical outcomes up to 9 months since vaccine completion: a retrospective observational analysis in Lombardy, Italy. *Lancet Infect Dis*. 2022;22(5):649-656. doi:10.1016/S1473-3099(21)00813-6
2. Nordström P, Ballin M, Nordström A. Risk of SARS-CoV-2 reinfection and COVID-19 hospitalisation in individuals with natural and hybrid immunity: a retrospective, total population cohort study in Sweden. *Lancet Infect Dis*. Published online April 2022. doi:10.1016/S1473-3099(22)00143-8
3. Chalkias S, Eder F, Essink B, et al. Safety, Immunogenicity and Antibody Persistence of a Bivalent Beta-Containing Booster Vaccine. Published online 2022. doi:10.21203/rs.3.rs-1555201/v1
4. Yousaf AR, Cortese MM, Taylor AW, et al. Reported cases of multisystem inflammatory syndrome in children aged 12–20 years in the USA who received a COVID-19 vaccine, December, 2020, through August, 2021: a surveillance investigation. *Lancet Child Adolesc Heal*. Published online February 2022. doi:10.1016/S2352-4642(22)00028-1
5. Andrews N, Stowe J, Kirsebom F, et al. Effectiveness of COVID-19 vaccines against the Omicron (B.1.1.529) variant of concern. *medRxiv*. Published online 2021. doi:10.1101/2021.12.14.21267615
6. UK Health Security Agency. COVID-19 vaccine weekly surveillance reports. Available at: https://www.gov.uk/government/publications/covid-19-vaccine-weekly-surveillance-reports
7. Ferguson N, Ghani A, Cori A, Hogan A, Hinsley W, Volz E. Growth, population distribution and immune escape of the Omicron in England. *Imp Coll London*.
8. Baum U, Poukka E, Leino T, Kilpi T, Nohynek H, Palmu AA. High vaccine effectiveness against severe Covid-19 in the elderly in Finland before and after the emergence of Omicron. *medRxiv*. Published online January 2022:2022.03.11.22272140. doi:10.1101/2022.03.11.22272140
9. Atmar RL, Lyke KE, Deming ME, et al. Homologous and Heterologous Covid-19 Booster Vaccinations. *N Engl J Med*. Published online January 2022:2021.10.10.21264827. doi:10.1056/NEJMoa2116414
10. Gray GE, Collie S, Garrett N, et al. Vaccine effectiveness against hospital admission in South African health care workers who received a homologous booster of Ad26.COV2 during an Omicron COVID19 wave: Preliminary Results of the Sisonke 2 Study. *medRxiv*. Published online January 2022:2021.12.28.21268436. doi:10.1101/2021.12.28.21268436
11. Hansen CH, Schelde AB, Moustsen-Helm IR, et al. Vaccine effectiveness against SARS-CoV-2 infection with the Omicron or Delta variants following a two-dose or booster BNT162b2 or mRNA-1273 vaccination series: A Danish cohort study. *medRxiv*. Published online 2021. doi:10.1101/2021.12.20.21267966
12. Tseng HF, Ackerson BK, Luo Y, et al. Effectiveness of mRNA-1273 against SARS-CoV-2 omicron and delta variants. *medRxiv*. Published online January 2022:2022.01.07.22268919. doi:10.1101/2022.01.07.22268919
13. Chemaitelly H, Ayoub HH, AlMukdad S, et al. Duration of protection of BNT162b2 and mRNA-1273 COVID-19 vaccines against symptomatic SARS-CoV-2 Omicron infection in Qatar. *medRxiv*. Published online January 2022:2022.02.07.22270568. doi:10.1101/2022.02.07.22270568
14. Altarawneh HN, Chemaitelly H, Ayoub HH, et al. Effect of prior infection, vaccination, and hybrid immunity against symptomatic BA.1 and BA.2 Omicron infections and severe COVID-19 in Qatar. *medRxiv*. Published online January 2022:2022.03.22.22272745. doi:10.1101/2022.03.22.22272745
15. Abu-Raddad LJ, Chemaitelly H, Ayoub HH, et al. Effect of mRNA Vaccine Boosters against SARS-CoV-2 Omicron Infection in Qatar. *N Engl J Med*. Published online March 2022. doi:10.1056/NEJMoa2200797
16. Regev-Yochay G, Gonen T, Gilboa M, et al. 4th Dose COVID mRNA Vaccines' Immunogenicity & Efficacy Against Omicron VOC. *medRxiv*. Published online January 2022:2022.02.15.22270948. doi:10.1101/2022.02.15.22270948
17. Discovery Health, South Africa's largest private health insurance administrator, releases at-scale, real-world analysis of Omicron outbreak based on 211 000 COVID-19 test results in South Africa. Press release 14 December 2021. Available at: https://www.discovery.co.za/corporate/news-room
18. Gram MA, Emborg HD, Schelde AB, et al. Vaccine effectiveness against SARS-CoV-2 infection and COVID-19-related hospitalization with the Alpha, Delta and Omicron SARS-CoV-2 variants: a nationwide Danish cohort study. *medRxiv*. Published online January 1, 2022:2022.04.20.22274061. doi:10.1101/2022.04.20.22274061
19. Tartof SY, Slezak JM, Puzniak L, et al. BNT162b2 (Pfizer–Biontech) mRNA COVID-19 Vaccine Against Omicron-Related Hospital and Emergency Department Admission in a Large US Health System: A Test-Negative Design. *SSRN Electron J*. Published online 2022. doi:10.2139/ssrn.4011905
20. Tartof SY, Slezak JM, Puzniak L, et al. Durability of BNT162b2 vaccine against hospital and emergency department admissions due to the omicron and delta variants in a large health system in the USA: a test-negative case–control study. *Lancet Respir Med*. Published online April 2022. doi:10.1016/S2213-2600(22)00101-1
21. Chemaitelly H, Ayoub HH, AlMukdad S, et al. Duration of protection of BNT162b2 and mRNA-1273 COVID-19 vaccines against symptomatic SARS-CoV-2 Omicron infection in Qatar. *medRxiv*. Published online January 2022:2022.02.07.22270568. doi:10.1101/2022.02.07.22270568
22. Arbel R, Sergienko R, Friger M, et al. Second Booster Vaccine and Covid-19 Mortality in Adults 60 to 100 Years Old. *Res Sq Prepr*. Published online 2022. doi:10.21203/rs.3.rs-1478439/v1
23. Jara A, Undurraga EA, Zubizarreta JR, et al. Effectiveness of homologous and heterologous booster doses for an inactivated SARS-CoV-2 vaccine: a large-scale prospective cohort study. *Lancet Glob Heal*. Published online April 2022. doi:10.1016/S2214-109X(22)00112-7
24. Magen O, Waxman JG, Makov-Assif M, et al. Fourth Dose of BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Setting. *N Engl J Med*. 2022;386(17):1603-1614. doi:10.1056/NEJMoa2201688
25. Grewal R, Kitchen SA, Nguyen L, et al. Effectiveness of a Fourth Dose of COVID-19 Vaccine among Long-Term Care Residents in Ontario, Canada. *medRxiv Prepr*. Published online 2022.
26. AstraZeneca press release. AZD1222 US Phase III primary analysis confirms safety and efficacy 25 March 2021. Available at: https://www.astrazeneca.com/media-centre/press-releases/2021/azd1222-us-phase-iii-primary-analysis-confirms-safety-and-efficacy.html#:$~$:text=Positive
27. Whitaker HJ, Tsang RSM, Byford R, et al. Pfizer-BioNTech and Oxford AstraZeneca COVID-19 vaccine effectiveness and immune response among individuals in clinical risk groups. *Khub Prepr*. Published online 2021. https://khub.net/documents/135939561/430986542/RCGP+VE+riskgroups+paper.pdf/a6b54cd9-419d-9b63-e2bf-5dc796f5a91f
28. McKeigue PM, McAllister DA, Robertson C, et al. Efficacy of two doses of COVID-19 vaccine against severe COVID-19 in those with risk conditions and residual risk to the clinically extremely vulnerable: the REACT-SCOT case-control study. *medRxiv*. Published online January 2021:2021.09.13.21262360. doi:10.1101/2021.09.13.21262360
29. Martínez-Baz I, Miqueleiz A, Casado I, et al. Effectiveness of COVID-19 vaccines in preventing SARS-CoV-2 infection and hospitalisation, Navarre, Spain, January to April 2021. *Eurosurveillance*. 2021;26(21). doi:10.2807/1560-7917.ES.2021.26.21.2100438
30. Hyams C, Marlow R, Maseko Z, et al. Effectiveness of BNT162b2 and ChAdOx1 nCoV-19 COVID-19 vaccination at preventing hospitalisations in people aged at least 80 years: a test-negative, case-control study. *Lancet Infect Dis*. Published online June 2021. doi:10.1016/S1473-3099(21)00330-3
31. Public Health England. COVID-19 vaccine surveillance report: 1 July 2021 (week 26). Available at: https://www.gov.uk/government/publications/covid-19-vaccine-surveillance-report
32. Lopez Bernal J, Andrews N, Gower C, et al. Effectiveness of the Pfizer-BioNTech and Oxford-AstraZeneca vaccines on covid-19 related symptoms, hospital admissions, and mortality in older adults in England: test negative case-control study. *BMJ*. Published online May 2021:n1088. doi:10.1136/bmj.n1088
33. Skowronski DM, Setayeshgar S, Febriani Y, et al. Two-dose SARS-CoV-2 vaccine effectiveness with mixed schedules and extended dosing intervals: test-negative design studies from British Columbia and Quebec, Canada. *medRxiv*. Published online January 2021:2021.10.26.21265397. doi:10.1101/2021.10.26.21265397
34. Andrews N, Tessier E, Stowe J, et al. Vaccine effectiveness and duration of protection of Comirnaty, Vaxzevria and Spikevax against mild and severe COVID-19 in the UK. *medRxiv*. Published online 2021. doi:10.1101/2021.09.15.21263583
35. Cerqueira-Silva T, Oliveira V de A, Pescarini J, et al. Influence of age on the effectiveness and duration of protection in Vaxzevria and CoronaVac vaccines. *medRxiv*. Published online January 2021:2021.08.21.21261501. doi:10.1101/2021.08.21.21261501
36. Andrews N, Tessier E, Stowe J, et al. Duration of Protection against Mild and Severe Disease by Covid-19 Vaccines. *N Engl J Med*. Published online January 2022. doi:10.1056/NEJMoa2115481
37. Ismail SA, Vilaplana TG, Elgohari S, et al. Effectiveness of BNT162b2 mRNA and ChAdOx1 adenovirus vector COVID-19 vaccines on risk of hospitalisation among older adults in England: an observational study using surveillance data. *Khub Prepr https//khub.net/documents/135939561/430986542/Effectiveness%2Bof%2BBNT162b2%2BmRNA%2Band%2BChAdOx1%2Badenovirus%2Bvector%2BCOVID-19%2Bvaccines%2Bon%2Brisk%2Bof%2Bhospitalisation%2Bamong%2Bolder%2Badults%2Bin%2BEngland.pdf/9e18c525-dde6-5ee4*.
38. Sheikh A, Robertson C, Taylor B. BNT162b2 and ChAdOx1 nCoV-19 Vaccine Effectiveness against Death from the Delta Variant. *N Engl J Med*. Published online October 2021. doi:10.1056/NEJMc2113864
39. Ella R, Reddy S, Blackwelder W, et al. Efficacy, safety, and lot-to-lot immunogenicity of an inactivated SARS-CoV-2 vaccine (BBV152): interim results of a randomised, double-blind, controlled, phase 3 trial. *Lancet*. Published online November 2021:2021.06.30.21259439. doi:10.1016/S0140-6736(21)02000-6

40. Logunov DY, Dolzhikova I V, Shcheblyakov D V, et al. Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine. *Lancet*. Published online 2021.
41. US federal Drug Administration (FDA) Briefing Document Janssen Ad26.COV2.S Vaccine for the Prevention of COVID-19. Vaccines and Related Biological Products Advisory Committee Meeting February 26, 2021. Available at: https://www.fda.gov/media/146217/download
42. Baden LR, El Sahly HM, Essink B, et al. Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. *N Engl J Med*. Published online 2021. doi:10.1056/nejmoa2035389
43. de Gier B, Kooijman M, Kemmeren J, et al. COVID-19 vaccine effectiveness against hospitalizations and ICU admissions in the Netherlands, April- August 2021. *medRxiv*. Published online January 2021:2021.09.15.21263613. doi:10.1101/2021.09.15.21263613
44. Bruxvoort KJ, Sy LS, Qian L, et al. Effectiveness of mRNA-1273 against Delta, Mu, and other emerging variants. *medRxiv*. Published online January 2021:2021.09.29.21264199. doi:10.1101/2021.09.29.21264199
45. Bruxvoort K, Sy LS, Qian L, et al. Real-World Effectiveness of the mRNA-1273 Vaccine Against COVID-19: Interim Results from a Prospective Observational Cohort Study. *SSRN Electron J*. Published online 2021. doi:10.2139/ssrn.3916094
46. Dunkle LM, Kotloff KL, Gay CL, et al. Efficacy and Safety of NVX-CoV2373 in Adults in the United States and Mexico. *N Engl J Med*. Published online December 2021:2021.10.05.21264567. doi:10.1056/NEJMoa2116185
47. Chodick G, Tene L, Rotem RS, et al. The effectiveness of the TWO-DOSE BNT162b2 vaccine: analysis of real-world data. *Clin Infect Dis*. Published online May 2021. doi:10.1093/cid/ciab438
48. Saciuk Y, Kertes J, Mandel M, Hemo B, Shamir Stein N, Zohar AE. Pfizer-BioNTech Vaccine Effectiveness Against SARS-CoV-2 Infection: Findings From a Large Observational Study in Israel. *SSRN Electron J*. Published online 2021. doi:10.2139/ssrn.3868853
49. World Health Organisation (WHO). *Background Document on the MRNA Vaccine BNT162b2 (Pfizer-BioNTech) against COVID-19*.; 2021. https://www.who.int/publications/i/item/background-document-on-mrna-vaccine-bnt162b2-(pfizer-biontech)-against-covid-19
50. Emborg HD, Valentiner-Branth P, Schelde AB, et al. Vaccine effectiveness of the BNT162b2 mRNA COVID-19 vaccine against RT-PCR confirmed SARS-CoV-2 infections, hospitalisations and mortality in prioritised risk groups. *medRxiv*. Published online January 2021:2021.05.27.21257583. doi:10.1101/2021.05.27.21257583
51. Thomas SJ, Moreira ED, Kitchin N, et al. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine through 6 Months. *N Engl J Med*. Published online September 2021. doi:10.1056/NEJMoa2110345
52. Chung H, He S, Nasreen S, et al. Effectiveness of BNT162b2 and mRNA-1273 covid-19 vaccines against symptomatic SARS-CoV-2 infection and severe covid-19 outcomes in Ontario, Canada: test negative design study. *BMJ*. Published online August 2021:n1943. doi:10.1136/bmj.n1943
53. Mason T, Whitston M, Hodgson J, et al. Effects of BNT162b2 mRNA vaccine on Covid-19 infection and hospitalisation among older people: matched case control study for England. *medRxiv*. Published online January 2021:2021.04.19.21255461. doi:10.1101/2021.04.19.21255461
54. World Health Organisation Extraordinary meeting of the Strategic Advisory Group of Experts on Immunization (SAGE) – 29 April 2021. Available at: https://www.who.int/news-room/events/detail/2021/04/29/default-calendar/extraordinary-meeting-of-the-strategic-advisory-group-of-experts-on-immunization-(sage)-29-april-2021
55. Moderna press release. Moderna Announces Positive Top Line Data from Phase 2/3 Study of COVID-19 Vaccine in Children 6 to 11 Years of Age. 25 October 2021. Available at: https://investors.modernatx.com/news-releases/news-release-details/moderna-announces-positive-top-line-data-phase-23-study-covid-19
56. Moderna press release. Moderna Announces TeenCOVE Study of its COVID-19 Vaccine in Adolescents Meets Primary Endpoint and Plans to Submit Data to Regulators in Early June 25 May 2021. Available at: https://investors.modernatx.com/news-releases/news-release-details/moderna-announces-teencove-study-its-covid-19-vaccine
57. Walter EB, Talaat KR, Sabharwal C, et al. Evaluation of the BNT162b2 Covid-19 Vaccine in Children 5 to 11 Years of Age. *N Engl J Med*. Published online November 2021. doi:10.1056/NEJMoa2116298
58. United States Food and Drug Administration (FDA). Vaccines and Related Biological Products Advisory Committee October 26, 2021 Meeting Document. Available at: https://www.fda.gov/media/153409/download
59. Pfizer press release. Pfizer and BioNTech provide update on ongoing studies of COVID-19 vaccine December 17 2021. Available at: https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-provide-update-ongoing-studies-covid-19
60. UK JCVI Independent report. JCVI statement on COVID-19 vaccination of children and young people: 22 December 2021. Available at:
61. New York State Department of Health Special Report. Pediatric COVID-19 update. 7 January 2022. Available at: https://www.health.ny.gov/press/releases/2022/docs/pediatric_covid-19_hospitalization_report_summary.pdf
62. Klein NP, Stockwell MS, Demarco M, et al. Effectiveness of COVID-19 Pfizer-BioNTech BNT162b2 mRNA Vaccination in Preventing COVID-19–Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Nonimmunocompromised Children and Adolescents Aged 5–17 Years — VISION Network. *MMWR Morb Mortal Wkly Rep*. 2022;71(9). doi:10.15585/mmwr.mm7109e3
63. Price AM, Olson SM, Newhams MM, et al. BNT162b2 Protection against the Omicron Variant in Children and Adolescents. *N Engl J Med*. Published online March 2022. doi:10.1056/NEJMoa2202826
64. Fleming-Dutra KE, Britton A, Shang N, et al. Association of Prior BNT162b2 COVID-19 Vaccination With Symptomatic SARS-CoV-2 Infection in Children and Adolescents During Omicron Predominance. *JAMA*. Published online May 13, 2022. doi:10.1001/jama.2022.7493
65. Frenck RW, Klein NP, Kitchin N, et al. Safety, Immunogenicity, and Efficacy of the BNT162b2 Covid-19 Vaccine in Adolescents. *N Engl J Med*. 2021;385(3):239-250. doi:10.1056/NEJMoa2107456
66. Pfizer press release. Follow-up data from phase 3 trial of Pfizer-BioNTech COVID-19 vaccine support safety and efficacy in adolescents 12 through 15 years of age. 22 November 2021. Available at: https://www.pfizer.com/news/press-release/press-release-detail/follow-data-phase-3-trial-pfizer-biontech-covid-19-vaccine
67. Miron O, Wilf-Miron R, Davidovitch N. Effectiveness of COVID-19 vaccine BNT162b2 at age 12-15 years with one dose. *OSF Prepr*. Published online 2021. doi:10.31219/osf.io/cnw5t
68. Reis BY, Barda N, Leshchinsky M, et al. Effectiveness of BNT162b2 Vaccine against Delta Variant in Adolescents. *N Engl J Med*. Published online October 2021. doi:10.1056/NEJMc2114290
69. Olson SM, Newhams MM, Halasa NB, et al. Effectiveness of Pfizer-BioNTech mRNA Vaccination Against COVID-19 Hospitalization Among Persons Aged 12–18 Years — United States, June–September 2021. *MMWR Morb Mortal Wkly Rep*. 2021;70(42):1483-1488. doi:10.15585/mmwr.mm7042e1
70. Powell AA, Kirsebom F, Stowe J, et al. Adolescent vaccination with BNT162b2 (Comirnaty, Pfizer-BioNTech) vaccine and effectiveness of the first dose against COVID-19: national test-negative case-control study, England. *medRxiv*. Published online January 2021:2021.12.10.21267408. doi:10.1101/2021.12.10.21267408
71. Zambrano LD, Newhams MM, Olson SM, et al. Effectiveness of BNT162b2 (Pfizer-BioNTech) mRNA Vaccination Against Multisystem Inflammatory Syndrome in Children Among Persons Aged 12–18 Years — United States, July–December 2021. *MMWR Morb Mortal Wkly Rep*. 2022;71(2). doi:10.15585/mmwr.mm7102e1
72. Olson SM, Newhams MM, Halasa NB, et al. Effectiveness of BNT162b2 Vaccine against Critical Covid-19 in Adolescents. *N Engl J Med*. Published online January 2022. doi:10.1056/NEJMoa2117995
73. Powell AA, Kirsebom F, Stowe J, et al. Adolescent vaccination with BNT162b2 (Comirnaty, Pfizer-BioNTech) vaccine and effectiveness against COVID-19: national test-negative case-control study, England. *medRxiv*. Published online January 2022:2021.12.10.21267408. doi:10.1101/2021.12.10.21267408
74. Levy M, Recher M, Hubert H, et al. Multisystem Inflammatory Syndrome in Children by COVID-19 Vaccination Status of Adolescents in France. *JAMA*. 2022;327(3):281. doi:10.1001/jama.2021.23262
75. Veneti L, Berild JD, Watle SV, et al. Vaccine effectiveness with BNT162b2 (Comirnaty, Pfizer-BioNTech) vaccine against reported SARS-CoV-2 Delta and Omicron infection among adolescents, Norway, August 2021 to January 2022. *medRxiv*. Published online January 1, 2022:2022.03.24.22272854. doi:10.1101/2022.03.24.22272854
76. Florentino PTV, Millington T, Cerqueira-Silva T, et al. Vaccine Effectiveness of Two-Dose BNT162b2 Over Time Against COVID-19 Symptomatic Infection and Severe Cases Among Adolescents: Test Negative Design Case Control Studies in Brazil and Scotland. *SSRN Electron J*. Published online 2022. doi:10.2139/ssrn.4074678
77. Han B, Song Y, Li C, et al. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy children and adolescents: a double-blind, randomised, controlled, phase 1/2 clinical trial. *Lancet Infect Dis*. Published online June 2021. doi:10.1016/S1473-3099(21)00319-4
78. Hillson K, Clemens SC, Madhi SA, Voysey M, Pollard AJ, Minassian AM. Fertility rates and birth outcomes after ChAdOx1 nCoV-19 (AZD1222) vaccination. *Lancet*. Published online October 2021. doi:10.1016/S0140-6736(21)02282-0
79. Trostle ME, Aguero-Rosenfeld ME, Roman AS, Lighter JL. High antibody levels in cord blood from pregnant women vaccinated against COVID-19. *Am J Obstet Gynecol MFM*. Published online September 2021:100481. doi:10.1016/j.ajogmf.2021.100481
80. Shimabukuro TT, Kim SY, Myers TR, et al. Preliminary Findings of mRNA Covid-19 Vaccine Safety in Pregnant Persons. *N Engl J Med*. Published online April 2021:NEJMoa2104983. doi:10.1056/NEJMoa2104983
81. Shook LL, Atyeo CG, Yonker LM, et al. Durability of Anti-Spike Antibodies in Infants After Maternal COVID-19 Vaccination or Natural Infection. *JAMA*. Published online February 2022. doi:10.1001/jama.2022.1206
82. Halasa NB, Olson SM, Staat MA, et al. Effectiveness of Maternal Vaccination with mRNA COVID-19 Vaccine During Pregnancy Against COVID-19–Associated Hospitalization in Infants Aged <6 Months — 17 States, July 2021–January 2022. *MMWR Morb Mortal Wkly Rep*. 2022;71(7):264-270. doi:10.15585/mmwr.mm7107e3
83. Dagan N, Barda N, Biron-Shental T, et al. Effectiveness of the BNT162b2 mRNA COVID-19 vaccine in pregnancy. *Nat Med*. 2021;27(10):1693-1695. doi:10.1038/s41591-021-01490-8
84. Goldshtein I, Nevo D, Steinberg DM, et al. Association Between BNT162b2 Vaccination and Incidence of SARS-CoV-2 Infection in Pregnant Women. *JAMA*. 2021;326(8):728. doi:10.1001/jama.2021.11035
85. United States National Institutes of Health (NIH) News release. NIH begins study of COVID-19 vaccination during pregnancy and postpartum. 23 June 2021. Available at: https://www.nih.gov/news-events/news-releases/nih-begins-study-covid-19-vaccination-during-pregnancy-postpartum

86. Goldshtein I, Steinberg DM, Kuint J, et al. Association of BNT162b2 COVID-19 Vaccination During Pregnancy With Neonatal and Early Infant Outcomes. *JAMA Pediatr*. Published online February 2022. doi:10.1001/jamapediatrics.2022.0001
87. Government of Spain Ministry of Health and Innovation. The combined use of AstraZeneca and Pfizer vaccines against SARS-CoV-2 offers a powerful immune response. Press release 18 May 2021. Available at: https://www.isciii.es/Noticias/Noticias/Paginas/Noticias/Presentación-resultados-preliminares-CombivacS.aspx
88. Shaw RH, Stuart A, Greenland M, Liu X, Van-Tam JSN, Snape MD. Heterologous prime-boost COVID-19 vaccination: initial reactogenicity data. *Lancet*. 2021;397(10289):2043-2046. doi:10.1016/S0140-6736(21)01115-6
89. Hillus D. Reactogenicity of homologous and heterologous prime-boost immunisation with BNT162b2 and ChAdOx1-nCoV19: a prospective cohort study. *medRxiv Prepr*. doi:doi.org/10.1101/2021.05.19.21257334
90. Powell AA, Power L, Westrop S, et al. Real-world data shows increased reactogenicity in adults after heterologous compared to homologous prime-boost COVID-19 vaccination, March−June 2021, England. *Eurosurveillance*. 2021;26(28). doi:10.2807/1560-7917.ES.2021.26.28.2100634
91. Borobia AM, Carcas AJ, Pérez-Olmeda M, et al. Immunogenicity and reactogenicity of BNT162b2 booster in ChAdOx1-S-primed participants (CombiVacS): a multicentre, open-label, randomised, controlled, phase 2 trial. *Lancet*. 2021;398(10295):121-130. doi:10.1016/S0140-6736(21)01420-3
92. Liu X, Shaw RH, Stuart AS V, et al. Safety and Immunogenicity Report from the Com-COV Study – a Single-Blind Randomised Non-Inferiority Trial Comparing Heterologous And Homologous Prime-Boost Schedules with An Adenoviral Vectored and mRNA COVID-19 Vaccine. *SSRN Electron J*. Published online 2021. doi:10.2139/ssrn.3874014
93. Schmidt T, Klemis V, Schub D, et al. Immunogenicity and reactogenicity of a heterologous COVID-19 prime-boost vaccination compared with homologous vaccine regimens. *medRxiv*. Published online January 2021:2021.06.13.21258859. doi:10.1101/2021.06.13.21258859
94. Barros-Martins J, Hammerschmidt SI, Cossmann A, et al. Humoral and cellular immune response against SARS-CoV-2 variants following heterologous and homologous ChAdOx1 nCoV-19/BNT162b2 vaccination. *medRxiv*. Published online January 2021:2021.06.01.21258172. doi:10.1101/2021.06.01.21258172
95. Behrens GMN, Cossmann A, Stankov M V, et al. SARS-CoV-2 delta variant neutralisation after heterologous ChAdOx1-S/BNT162b2 vaccination. *Lancet*. Published online August 2021. doi:10.1016/S0140-6736(21)01891-2
96. Public Health Agency of Canada. An Advisory Committee Statement (ACS) National Advisory Committee on Immunization (NACI) Recommendations on the use of COVID-19 Vaccines. 17 June 2021. Available at: https://www.canada.ca/content/dam/phac-aspc/documents/services/immunization/national-advisory-committee-on-immunization-naci/recommendations-use-covid-19-vaccines/recommendations-use-covid-19-vaccines-en.pdf
97. US National Library of Medicine ClinicalTrials.gov. Mix and Match of the Second COVID-19 Vaccine Dose for Safety and Immunogenicity (MOSAIC). Available at: https://clinicaltrials.gov/ct2/show/NCT04894435?term=mixed+schedule%2C+covid19%2C+vaccine&draw=2&rank=1
98. Gram MA, Nielsen J, Schelde AB, et al. Vaccine effectiveness when combining the ChAdOx1 vaccine as the first dose with an mRNA COVID-19 vaccine as the second dose. *medRxiv*. Published online January 2021:2021.07.26.21261130. doi:10.1101/2021.07.26.21261130
99. Jara A, Undurraga EA, Zubizarreta JR, et al. Effectiveness of homologous and heterologous booster shots for an inactivated SARSCoV-2 vaccine: A large-scale observational study. *SSRN Prepr*. Published online 2022.
100. World Health Organisation. *WHO Guideline on Mass Drug Administration of Azithromycin to Children under Five Years of Age to Promote Child Survival*.; 2020. https://apps.who.int/iris/handle/10665/333942
101. Voysey M, Costa Clemens SA, Madhi SA, et al. Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials. *Lancet*. 2021;397(10277):881-891. doi:10.1016/S0140-6736(21)00432-3
102. Bravo L, Smolenov I, Han HH, et al. Efficacy of the adjuvanted subunit protein COVID-19 vaccine, SCB-2019: a phase 2 and 3 multicentre, double-blind, randomised, placebo-controlled trial. *Lancet*. 2022;399(10323):461-472. doi:10.1016/S0140-6736(22)00055-1
103. Russian Direct Investment Fund Press Release 2 June 2021. Sputnik LIght (the first component of Sputnik V vaccine) demonstrates 78.6-83.7% eficacy among the elderly in Argentina. Available at: https://sputnikvaccine.com/newsroom/pressreleases/sputnik-light-vaccine-the-first-component-of-sputnik-v-vaccine-demonstrates-78-6-83-7-efficacy-among/
104. El Sahly HM, Baden LR, Essink B, et al. Efficacy of the mRNA-1273 SARS-CoV-2 Vaccine at Completion of Blinded Phase. *N Engl J Med*. Published online September 2021. doi:10.1056/NEJMoa2113017
105. Sadoff J, Gray G, Vandebosch A, et al. Final Analysis of Efficacy and Safety of Single-Dose Ad26.COV2.S. *N Engl J Med*. Published online February 2022. doi:10.1056/NEJMoa2117608
106. Sadoff J, Gray G, Vandebosch A, et al. Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19. *N Engl J Med*. 2021;384(23):2187-2201. doi:10.1056/NEJMoa2101544
107. Sisonke Phase 3b clinical trial. Available at: http://sisonkestudy.samrc.ac.za/
108. Moderna press release. Moderna Provides Clinical and Supply Updates on COVID-19 Vaccine Program Ahead of 2nd Annual Vaccines Day 13 April 2021. Available at: https://investors.modernatx.com/news-releases/news-release-details/moderna-provides-clinical-and-supply-updates-covid-19-vaccine
109. Ali K, Berman G, Zhou H, et al. Evaluation of mRNA-1273 SARS-CoV-2 Vaccine in Adolescents. *N Engl J Med*. Published online August 2021:NEJMoa2109522. doi:10.1056/NEJMoa2109522
110. Heath PT, Galiza EP, Baxter DN, et al. Safety and Efficacy of NVX-CoV2373 Covid-19 Vaccine. *N Engl J Med*. Published online June 2021:NEJMoa2107659. doi:10.1056/NEJMoa2107659
111. Tanriover MD, Doğanay HL, Akova M, et al. Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomised, placebo-controlled, phase 3 trial in Turkey. *Lancet*. 2021;398(10296):213-222. doi:10.1016/S0140-6736(21)01429-X
112. Palacios R, Batista AP, Albuquerque CSN, al. E. Efficacy and Safety of a COVID-19 Inactivated Vaccine in Healthcare Professionals in Brazil: The PROFISCOV Study. *SSRN Electron J*. Published online 2021.
113. Halperin SA, Ye L, MacKinnon-Cameron D, et al. Final efficacy analysis, interim safety analysis, and immunogenicity of a single dose of recombinant novel coronavirus vaccine (adenovirus type 5 vector) in adults 18 years and older: an international, multicentre, randomised, double-blinded, placebo-cont. *Lancet*. Published online December 2021. doi:10.1016/S0140-6736(21)02753-7
114. Lopez Bernal J, Andrews N, Gower C, et al. Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant. *N Engl J Med*. Published online July 2021:NEJMoa2108891. doi:10.1056/NEJMoa2108891
115. Sheikh A, McMenamin J, Taylor B, Robertson C. SARS-CoV-2 Delta VOC in Scotland: demographics, risk of hospital admission, and vaccine effectiveness. *Lancet*. Published online June 2021. doi:10.1016/S0140-6736(21)01358-1
116. Pouwels KB, Pritchard E, Matthews PC, et al. Effect of Delta variant on viral burden and vaccine effectiveness against new SARS-CoV-2 infections in the UK. *Nat Med*. Published online October 2021. doi:10.1038/s41591-021-01548-7
117. Martínez-Baz I, Trobajo-Sanmartín C, Miqueleiz A, et al. Product-specific COVID-19 vaccine effectiveness against secondary infection in close contacts, Navarre, Spain, April to August 2021. *Eurosurveillance*. 2021;26(39). doi:10.2807/1560-7917.ES.2021.26.39.2100894
118. Chadeau-Hyam M, Wang H, Eales O, et al. REACT-1 study round 14: High and increasing prevalence of SARS-CoV-2 infection among school-aged children during September 2021 and vaccine effectiveness against infection in England. *medRxiv*. Published online January 2021:2021.10.14.21264965. doi:10.1101/2021.10.14.21264965
119. Thiruvengadam R, Awasthi A, Medigeshi G, et al. Effectiveness of ChAdOx1 nCoV-19 vaccine against SARS-CoV-2 infection during the delta (B.1.617.2) variant surge in India: a test-negative, case-control study and a mechanistic study of post-vaccination immune responses. *Lancet Infect Dis*. Published online November 2021. doi:10.1016/S1473-3099(21)00680-0
120. Hall V, Foulkes S, Insalata F, et al. Protection against SARS-CoV-2 after Covid-19 Vaccination and Previous Infection. *N Engl J Med*. Published online February 2022. doi:10.1056/NEJMoa2118691
121. Nasreen S, Chung H, He S, et al. Effectiveness of COVID-19 vaccines against variants of concern in Ontario, Canada. *medRxiv*. Published online January 2021:2021.06.28.21259420. doi:10.1101/2021.06.28.21259420
122. Vacunas contra SARS- CoV-2 utilizadas en Chile mantienen altos niveles de efectividad para evitar hospitalización, ingreso a UCI y muerte. 3 August 2021. Available at: https://www.minsal.cl/vacunas-contra-sars-cov-2-utilizadas-en-chile-mantienen-altos-niveles-de-efectividad-para-evitar-hospitalizacion-ingreso-a-uci-y-muerte/
123. Katikireddi SV, Cerqueira-Silva T, Vasileiou E, et al. Two-dose ChAdOx1 nCoV-19 vaccine protection against COVID-19 hospital admissions and deaths over time: a retrospective, population-based cohort study in Scotland and Brazil. *Lancet*. Published online December 2021. doi:10.1016/S0140-6736(21)02754-9
124. Kissling E, Hooiveld M, Sandonis Martín V, et al. Vaccine effectiveness against symptomatic SARS-CoV-2 infection in adults aged 65 years and older in primary care: I-MOVE-COVID-19 project, Europe, December 2020 to May 2021. *Eurosurveillance*. 2021;26(29). doi:10.2807/1560-7917.ES.2021.26.29.2100670
125. McKeigue PM, McAllister DA, Hutchinson SJ, et al. Efficacy of vaccination against severe COVID-19 in relation to Delta variant and time since second dose: the REACT-SCOT case-control study. *medRxiv*. Published online January 2021:2021.09.12.21263448. doi:10.1101/2021.09.12.21263448
126. Public Health England (PHE) press release. Vaccines highly effective against hospitalisation from Delta variant. Available at: https://www.gov.uk/government/news/vaccines-highly-effective-against-hospitalisation-from-delta-variant.
127. Vasileiou E, Simpson CR, Robertson C, et al. Effectiveness of First Dose of COVID-19 Vaccines Against Hospital Admissions in Scotland: National Prospective Cohort Study of 5.4 Million People. *SSRN Electron J*. Published online 2021. doi:10.2139/ssrn.3789264

128. Desai D, Khan AR, Soneja M, et al. Effectiveness of an inactivated virus-based SARS-CoV-2 vaccine, BBV152, in India: a test-negative, case-control study. *Lancet Infect Dis*. Published online November 2021. doi:10.1016/S1473-3099(21)00674-5
129. Corchado-Garcia J, Puyraimond-Zemmour D, Hughes T, et al. Real-world effectiveness of Ad26.COV2.S adenoviral vector vaccine for COVID-19. *medRxiv*. Published online January 2021:2021.04.27.21256193. doi:10.1101/2021.04.27.21256193
130. Polinski JM, Weckstein AR, Batech M, et al. Effectiveness of the Single-Dose Ad26.COV2.S COVID Vaccine. *medRxiv*. Published online January 2021:2021.09.10.21263385. doi:10.1101/2021.09.10.21263385
131. Cohn BA, Cirillo PM, Murphy CC, Krigbaum NY, Wallace AW. Breakthrough SARS-CoV-2 infections in 620,000 U.S. Veterans, February 1, 2021 to August 13, 2021. *medRxiv*. Published online January 2021:2021.10.13.21264966. doi:10.1101/2021.10.13.21264966
132. Corchado-Garcia J, Zemmour D, Hughes T, et al. Analysis of the Effectiveness of the Ad26.COV2.S Adenoviral Vector Vaccine for Preventing COVID-19. *JAMA Netw Open*. 2021;4(11):e2132540. doi:10.1001/jamanetworkopen.2021.32540
133. Self WH, Tenforde MW, Rhoads JP, et al. Comparative Effectiveness of Moderna, Pfizer-BioNTech, and Janssen (Johnson & Johnson) Vaccines in Preventing COVID-19 Hospitalizations Among Adults Without Immunocompromising Conditions — United States, March–August 2021. *MMWR Morb Mortal Wkly Rep*. 2021;70(38):1337-1343. doi:10.15585/mmwr.mm7038e1
134. Cohn BA, Cirillo PM, Murphy CC, Krigbaum NY, Wallace AW. SARS-CoV-2 vaccine protection and deaths among US veterans during 2021. *Science (80-)*. Published online November 2021. doi:10.1126/science.abm0620
135. Puranik A, Lenehan PJ, Silvert E, et al. Comparison of two highly-effective mRNA vaccines for COVID-19 during periods of Alpha and Delta variant prevalence. *medRxiv*. Published online January 2021:2021.08.06.21261707. doi:10.1101/2021.08.06.21261707
136. Chemaitelly H, Tang P, Hasan MR, et al. Waning of BNT162b2 Vaccine Protection against SARS-CoV-2 Infection in Qatar. *N Engl J Med*. Published online October 2021. doi:10.1056/NEJMoa2114114
137. Lauring AS, Tenforde MW, Chappell JD, et al. Clinical severity of, and effectiveness of mRNA vaccines against, covid-19 from omicron, delta, and alpha SARS-CoV-2 variants in the United States: prospective observational study. *BMJ*. Published online March 2022:e069761. doi:10.1136/bmj-2021-069761
138. Haas EJ, Angulo FJ, McLaughlin JM, et al. Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data. *Lancet*. 2021;397(10287):1819-1829. doi:10.1016/S0140-6736(21)00947-8
139. Moustsen-Helms IR, Emborg HD, Nielsen J, et al. Vaccine effectiveness after 1st and 2nd dose of the BNT162b2 mRNA Covid-19 Vaccine in long-term care facility residents and healthcare workers – a Danish cohort study. *medRxiv*. Published online January 2021:2021.03.08.21252200. doi:10.1101/2021.03.08.21252200
140. Britton A, Jacobs Slifka KM, Edens C, et al. Effectiveness of the Pfizer-BioNTech COVID-19 Vaccine Among Residents of Two Skilled Nursing Facilities Experiencing COVID-19 Outbreaks — Connecticut, December 2020–February 2021. *MMWR Morb Mortal Wkly Rep*. 2021;70(11):396-401. doi:10.15585/mmwr.mm7011e3
141. Cavanaugh AM, Fortier S, Lewis P, et al. COVID-19 Outbreak Associated with a SARS-CoV-2 R.1 Lineage Variant in a Skilled Nursing Facility After Vaccination Program — Kentucky, March 2021. *MMWR Morb Mortal Wkly Rep*. 2021;70(17):639-643. doi:10.15585/mmwr.mm7017e2
142. Israel Ministry of Health press release. Data Compiled by the Vaccine Operation's Supervising Committee Published 22 July 2021. Available at: https://www.gov.il/en/departments/news/22072021-03
143. Tartof SY, Slezak JM, Fischer H, et al. Effectiveness of mRNA BNT162b2 COVID-19 vaccine up to 6 months in a large integrated health system in the USA: a retrospective cohort study. *Lancet*. Published online October 2021. doi:10.1016/S0140-6736(21)02183-8
144. Dagan N, Barda N, Kepten E, et al. BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting. *N Engl J Med*. Published online February 2021:NEJMoa2101765. doi:10.1056/NEJMoa2101765
145. Tang L, Hijano DR, Gaur AH, et al. Asymptomatic and Symptomatic SARS-CoV-2 Infections After BNT162b2 Vaccination in a Routinely Screened Workforce. *JAMA*. Published online May 2021. doi:10.1001/jama.2021.6564
146. Bedston S, Akbari A, Jarvis CI, et al. COVID-19 vaccine uptake, effectiveness, and waning in 82,959 health care workers: A national prospective cohort study in Wales. *Vaccine*. Published online January 2022. doi:10.1016/j.vaccine.2021.11.061
147. Uruguay Ministry of Public Health. Third study of effectiveness of vaccination against SARS-CoV-2 in Uruguay as of June 30, 2021. Press release 3 July 2021. Available at: https://www.gub.uy/ministerio-salud-publica/comunicacion/noticias/segundo-estudio-efectividad-vacunacion-anti-sars-cov-2-uruguay-8-junio-2021
148. de Gier B, Andeweg S, Joosten R, et al. Vaccine effectiveness against SARS-CoV-2 transmission and infections among household and other close contacts of confirmed cases, the Netherlands, February to May 2021. *Eurosurveillance*. 2021;26(31). doi:10.2807/1560-7917.ES.2021.26.31.2100640
149. Australian Government Therapeutic Goods Administration (TGA). Australian Product Information - COVID-19 Vaccine AstraZeneca (ChAdOx1-S) solution for injection. Available at: https://www.ebs.tga.gov.au/ebs/picmi/picmirepository.nsf/pdf?OpenAgent&id=CP-2021-PI-01194-1&d=202105261016933
150. US Federal Drug Administration (FDA). Fact sheet for healthcare providers administering vaccine (vaccination providers) emergency use authorisation (EUA) of the Moderna COVID-19 vaccine to prevent coronavirus disease 2019 (COVID-19). Available at: https://www.modernatx.com/covid19vaccine-eua/eua-fact-sheet-providers.pdf
151. Australian Government Therapeutic Goods Administration (TGA). Australian Product Information - Comirnaty (BNT162b2 [mRNA]) COVID-19 Vaccine. Available at: https://www.tga.gov.au/sites/default/files/covid-19-vaccine-pfizer-australia-comirnaty-bnt162b2-mrna-pi.pdf
152. US Federal Drug Administration (FDA). Fact sheet for healthcare providers administering vaccine (vaccination providers). Emergency use authorisation (EUA) of the Janssen COVID-19 vaccine to prevent coronavirus disease 2019 (COVID-19). Available at: https://www.janssenlabels.com/emergency-use-authorization/Janssen+COVID-19+Vaccine-HCP-fact-sheet.pdf
153. Xia S, Zhang Y, Wang Y, et al. Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomised, double-blind, placebo-controlled, phase 1/2 trial. *Lancet Infect Dis*. 2021;21(1):39-51. doi:10.1016/S1473-3099(20)30831-8
154. Zhang Y, Zeng G, Pan H, et al. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18–59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial. *Lancet Infect Dis*. 2021;21(2):181-192. doi:10.1016/S1473-3099(20)30843-4
155. European Medicines Agency (EMA). Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 3-6 May 2021. Available at: https://www.ema.europa.eu/en/news/meeting-highlights-pharmacovigilance-risk-assessment-committee-prac-3-6-may-2021
156. Australian Government Therapeutic Goods Administation (TGA). COVID-19 vaccine weekly safety report - 08-07-2021. Available at: https://www.tga.gov.au/periodic/covid-19-vaccine-weekly-safety-report-08-07-2021
157. United States Advisory Committee on Immunization Practices (ACIP). ACIP Presentation Slides: October 20-21, 2021 Meeting. Available at: https://www.cdc.gov/vaccines/acip/meetings/slides-2021-10-20-21.html
158. Welsh KJ, Baumblatt J, Chege W, Goud R, Nair N. Thrombocytopenia including immune thrombocytopenia after receipt of mRNA COVID-19 vaccines reported to the Vaccine Adverse Event Reporting System (VAERS). *Vaccine*. 2021;96(5):534-537. doi:10.1016/j.vaccine.2021.04.054
159. United States Advisory Committee on Immunization Practices (ACIP). ACIP Presentation Slides: June 23-25, 2021 Meeting. Available at: https://www.cdc.gov/vaccines/acip/meetings/slides-2021-06.html
160. Vogel G. Israel reports link between rare cases of heart inflammation and COVID-19 vaccination in young men. *Science (80-)*. Published online June 2021. doi:10.1126/science.abj7796
161. Barda N, Dagan N, Ben-Shlomo Y, et al. Safety of the BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Setting. *N Engl J Med*. Published online August 2021:NEJMoa2110475. doi:10.1056/NEJMoa2110475
162. US Food and Drug Administration (FDA) press release. Coronavirus (COVID-19) Update: July 13, 2021. Available at: https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-july-13-2021
163. European Medicines Agency (EMA). AstraZeneca's COVID-19 vaccine: EMA finds possible link to very rare cases of unusual blood clots with low blood platelets 7 April 2021. Available at: https://www.ema.europa.eu/en/news/astrazenecas-covid-19-vaccine-ema-finds-possible-link-very-rare-cases-unusual-blood-clots-low-blood
164. Pavord S, Scully M, Hunt BJ, et al. Clinical Features of Vaccine-Induced Immune Thrombocytopenia and Thrombosis. *N Engl J Med*. Published online August 2021:NEJMoa2109908. doi:10.1056/NEJMoa2109908
165. Australian Government Therapeutic Goods Administation (TGA). COVID-19 vaccine weekly safety report - 12-08-2021. Available at: https://www.tga.gov.au/periodic/covid-19-vaccine-weekly-safety-report-12-08-2021
166. Government of Canada National Advisory Committee on Immunization (NACI) statement. NACI rapid response: Recommended use of AstraZeneca COVID-19 vaccine in younger adults.
167. Australian Technical Advisory Group on Immunisation (ATAGI) ATAGI statement on revised recommendations on the use of COVID-19 Vaccine AstraZeneca, 17 June 2021. Available at: https://www.health.gov.au/news/atagi-statement-on-revised-recommendations-on-the-use-of-covid-19-vaccine-astrazeneca-17-june-2021
168. UK Government press release. JCVI advises on COVID-19 vaccine for people aged under 40. 7 May 2021. Available at: https://www.gov.uk/government/news/jcvi-advises-on-covid-19-vaccine-for-people-aged-under-40
169. European Medicines Agency (EMA). Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 6-9 April 2021. Available at: https://www.ema.europa.eu/en/news/meeting-highlights-pharmacovigilance-risk-assessment-committee-prac-6-9-april-2021
170. Statement of the WHO Global Advisory Committee on Vaccine Safety (GACVS) COVID-19 subcommittee on reports of Guillain-Barré Syndrome (GBS) following adenovirus vector COVID-19 vaccines 26 July 2021. Available at: https://www.who.int/news/item/26-07-2021-statement-of-the-who-gacvs-covid-19-subcommittee-on-gbs
171. Patone M, Handunnetthi L, Saatci D, et al. Neurological complications after first dose of COVID-19 vaccines and SARS-CoV-2 infection. *Nat Med*. Published online October 2021. doi:10.1038/s41591-021-01556-7

172. Gordon SF, Clothier HJ, Morgan H, et al. Immune thrombocytopenia following immunisation with Vaxzevria ChadOx1-S (AstraZeneca) vaccine, Victoria, Australia. *Vaccine*. Published online October 2021. doi:10.1016/j.vaccine.2021.10.030
173. European Medicines Agency (EMA). COVID-19 Vaccine Janssen: EMA finds possible link to very rare cases of unusual blood clots with low blood platelets 20 April 2021. Available at: https://www.ema.europa.eu/en/news/covid-19-vaccine-janssen-ema-finds-possible-link-very-rare-cases-unusual-blood-clots-low-blood
174. Shimabukuro TT, Cole M, Su JR. Reports of Anaphylaxis After Receipt of mRNA COVID-19 Vaccines in the US—December 14, 2020-January 18, 2021. *JAMA*. 2021;325(11):1101. doi:10.1001/jama.2021.1967
175. World Health Organisation (WHO). COVID-19 subcommittee of the WHO Global Advisory Committee on Vaccine Safety (GACVS): updated guidance regarding myocarditis and pericarditis reported with COVID-19 mRNA vaccines. 9 July 2021. Available at: https://www.who.int/news/item/09-07-2021-gacvs-guidance-myocarditis-pericarditis-covid-19-mrna-vaccines
176. Public Health Ontario enhanced epidemiological summary. Myocarditis and Pericarditis Following Vaccination with COVID-19 mRNA Vaccines in Ontario: December 13, 2020 to August 7, 2021. Available at: https://www.publichealthontario.ca/-/media/documents/ncov/epi/covid-19-myocarditis-pericarditis-vaccines-epi.pdf?sc_lang=en
177. UK Medicines & Healthcare products Regulatory Agency. Coronavirus vaccine - weekly summary of Yellow Card reporting. Updated 7 October 2021. Available at: https://www.gov.uk/government/publications/coronavirus-covid-19-vaccine-adverse-reactions/coronavirus-vaccine-summary-of-yellow-card-reporting
178. European Medicines Agency (EMA) Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 29 November - 2 December 2021. Available at: https://www.ema.europa.eu/en/news/meeting-highlights-pharmacovigilance-risk-assessment-committee-prac-29-november-2-december-2021
179. Buchan SA, Seo CY, Johnson C, et al. Epidemiology of myocarditis and pericarditis following mRNA vaccines in Ontario, Canada: by vaccine product, schedule and interval. *medRxiv*. Published online January 2021:2021.12.02.21267156. doi:10.1101/2021.12.02.21267156
180. Patone M, Mei XW, Handunnetthi L, et al. Risks of myocarditis, pericarditis, and cardiac arrhythmias associated with COVID-19 vaccination or SARS-CoV-2 infection. *Nat Med*. Published online December 2021. doi:10.1038/s41591-021-01630-0
181. Australian Government Therapeutic Goods Administration COVID-19 vaccine weekly safety report - 16-12-2021. Available at: https://www.tga.gov.au/periodic/covid-19-vaccine-weekly-safety-report-16-12-2021#section-1326
182. Australian Therapeutic Goods Administration COVID-19 vaccine weekly safety report - 13-01-2022. Available at:
183. Novavax COVID-19 Vaccine Demonstrates 89.3% Efficacy in UK Phase 3 Trial. Novavax press release 28 January 2021. https://ir.novavax.com/news-releases/news-release-details/novavax-covid-19-vaccine-demonstrates-893-efficacy-uk-phase-3
184. Witberg G, Barda N, Hoss S, et al. Myocarditis after Covid-19 Vaccination in a Large Health Care Organization. *N Engl J Med*. Published online October 2021. doi:10.1056/NEJMoa2110737
185. Mevorach D, Anis E, Cedar N, et al. Myocarditis after BNT162b2 mRNA Vaccine against Covid-19 in Israel. *N Engl J Med*. Published online October 2021. doi:10.1056/NEJMoa2109730
186. United States Food and Drug Administration (FDA). Vaccines and Related Biological Products Advisory Committee October 14-15, 2021 Meeting Presentation. Available at: https://www.fda.gov/media/153086/download
187. Chua GT, Kwan MYW, Chui CSL, et al. Epidemiology of Acute Myocarditis/Pericarditis in Hong Kong Adolescents Following Comirnaty Vaccination. *Clin Infect Dis*. Published online November 2021. doi:10.1093/cid/ciab989
188. Hause AM, Baggs J, Marquez P, et al. COVID-19 Vaccine Safety in Children Aged 5–11 Years — United States, November 3–December 19, 2021. *MMWR Morb Mortal Wkly Rep*. 2021;70(5152):1755-1760. doi:10.15585/mmwr.mm705152a1
189. Ouldali N, Bagheri H, Salvo F, et al. Multisystemic inflammatory syndrome following COVID-19 mRNA vaccine in children: a national post-authorization pharmacovigilance study. *medRxiv*. Published online January 2022:2022.01.17.22269263. doi:10.1101/2022.01.17.22269263
190. Friedensohn L, Levin D, Fadlon-Derai M, et al. Myocarditis Following a Third BNT162b2 Vaccination Dose in Military Recruits in Israel. *JAMA*. Published online March 2022. doi:10.1001/jama.2022.4425
191. Chile Institute of Public Health. Informe Estadistico: ESAVI de Vacnus SARS-CoV-2 (CoronaVac) notificados en ninos entre 6 a 11 anos de edad, 13 Septiembre - 7 Octubre 2021. Available at: https://ispch.cl/wp-content/uploads/2021/10/20211021-Informe-estadistico-ESAVI-ninos-6-y-11-anos-VFinal.pdf
192. Bernal JL, Andrews N, Gower C, et al. Effectiveness of BNT162b2 mRNA vaccine and ChAdOx1 adenovirus vector vaccine on mortality following COVID-19. *Prepr medRxiv*. doi:10.1101/2021.05.14.21257218
193. Mateo-Urdiales A, Spila Alegiani S, Fabiani M, et al. Risk of SARS-CoV-2 infection and subsequent hospital admission and death at different time intervals since first dose of COVID-19 vaccine administration, Italy, 27 December 2020 to mid-April 2021. *Eurosurveillance*. 2021;26(25). doi:10.2807/1560-7917.ES.2021.26.25.2100507
194. University College London press release. Covid-19 vaccine: care home residents gain 62% protection from one dose. 29 March 2021.
195. Pritchard E, Matthews PC, Stoesser N, et al. Impact of vaccination on SARS-CoV-2 cases in the community: a population-based study using the UK's COVID-19 Infection Survey. *medRxiv*. Published online January 2021:2021.04.22.21255913. doi:10.1101/2021.04.22.21255913
196. Johnson & Johnson press release. Johnson & Johnson Announces Real-World Evidence and Phase 3 Data Confirming Strong and Long-Lasting Protection of Single-Shot COVID-19 Vaccine in the U.S. 21 September 2021. Available at: https://www.jnj.com/johnson-johnson-announces-real-world-evidence-and-phase-3-data-confirming-strong-and-long-lasting-protection-of-single-shot-covid-19-vaccine-in-the-u-s
197. Tenforde MW, Self WH, Naioti EA, et al. Sustained Effectiveness of Pfizer-BioNTech and Moderna Vaccines Against COVID-19 Associated Hospitalizations Among Adults — United States, March–July 2021. *MMWR Morb Mortal Wkly Rep*. 2021;70(34). doi:10.15585/mmwr.mm7034e2
198. Thompson MG, Natarajan K, Irving SA, et al. Effectiveness of a Third Dose of mRNA Vaccines Against COVID-19–Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Adults During Periods of Delta and Omicron Variant Predominance — VISION Network, 10 States, August 2021–. *MMWR Morb Mortal Wkly Rep*. 2022;71(4). doi:10.15585/mmwr.mm7104e3
199. Ferdinands JM, Rao S, Dixon BE, et al. Waning 2-Dose and 3-Dose Effectiveness of mRNA Vaccines Against COVID-19–Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Adults During Periods of Delta and Omicron Variant Predominance — VISION Network, 10 States, Aug. *MMWR Morb Mortal Wkly Rep*. 2022;71(7). doi:10.15585/mmwr.mm7107e2
200. Daniel W, Nivet M, Warner J, Podolsky DK. Early Evidence of the Effect of SARS-CoV-2 Vaccine at One Medical Center. *N Engl J Med*. Published online March 2021:NEJMc2102153. doi:10.1056/NEJMc2102153
201. Thompson MG, Burgess JL, Naleway AL, et al. Interim Estimates of Vaccine Effectiveness of BNT162b2 and mRNA-1273 COVID-19 Vaccines in Preventing SARS-CoV-2 Infection Among Health Care Personnel, First Responders, and Other Essential and Frontline Workers — Eight U.S. Locations, December 2020–March . *MMWR Morb Mortal Wkly Rep*. 2021;70(13):495-500. doi:10.15585/mmwr.mm7013e3
202. Fowlkes A, Gaglani M, Groover K, Thiese MS, Tyner H, Ellingson K. Effectiveness of COVID-19 Vaccines in Preventing SARS-CoV-2 Infection Among Frontline Workers Before and During B.1.617.2 (Delta) Variant Predominance — Eight U.S. Locations, December 2020–August 2021. *MMWR Morb Mortal Wkly Rep*. 2021;70(34):1167-1169. doi:10.15585/mmwr.mm7034e4
203. Barda N, Dagan N, Cohen C, et al. Effectiveness of a third dose of the BNT162b2 mRNA COVID-19 vaccine for preventing severe outcomes in Israel: an observational study. *Lancet*. Published online October 2021. doi:10.1016/S0140-6736(21)02249-2
204. Bar-On YM, Goldberg Y, Mandel M, et al. Protection by a Fourth Dose of BNT162b2 against Omicron in Israel. *N Engl J Med*. Published online April 5, 2022. doi:10.1056/NEJMoa2201570
205. Benenson S, Oster Y, Cohen MJ, Nir-Paz R. BNT162b2 mRNA Covid-19 Vaccine Effectiveness among Health Care Workers. *N Engl J Med*. Published online March 2021:NEJMc2101951. doi:10.1056/NEJMc2101951
206. Li XN, Huang Y, Wang W, et al. Effectiveness of inactivated SARS-CoV-2 vaccines against the Delta variant infection in Guangzhou: a test-negative case–control real-world study. *Emerg Microbes Infect*. 2021;10(1):1751-1759. doi:10.1080/22221751.2021.1969291
207. Hall VJ, Foulkes S, Saei A, et al. COVID-19 vaccine coverage in health-care workers in England and effectiveness of BNT162b2 mRNA vaccine against infection (SIREN): a prospective, multicentre, cohort study. *Lancet*. 2021;397(10286):1725-1735. doi:10.1016/S0140-6736(21)00790-X
208. Regev-Yochay G, Amit S, Bergwerk M, et al. Decreased Infectivity Following BNT162b2 Vaccination. *SSRN Electron J*. Published online 2021. doi:10.2139/ssrn.3815668
209. Shrotri M, Krutikov M, Palmer T, et al. Vaccine effectiveness of the first dose of ChAdOx1 nCoV-19 and BNT162b2 against SARS-CoV-2 infection in residents of long-term care facilities in England (VIVALDI): a prospective cohort study. *Lancet Infect Dis*. Published online June 2021:2021.03.26.21254391. doi:10.1016/S1473-3099(21)00289-9
210. Harris RJ, Hall JA, Zaidi A, Andrews NJ, Dunbar JK, Dabrera G. Effect of Vaccination on Household Transmission of SARS-CoV-2 in England. *N Engl J Med*. Published online June 2021:NEJMc2107717. doi:10.1056/NEJMc2107717
211. Clifford S, Waight P, Hackman J, et al. Effectiveness of BNT162b2 and ChAdOx1 against SARS-CoV-2 household transmission: a prospective cohort study in England. *medRxiv*. Published online January 2021:2021.11.24.21266401. doi:10.1101/2021.11.24.21266401
212. Pritchard E, Matthews PC, Stoesser N, et al. Impact of vaccination on new SARS-CoV-2 infections in the United Kingdom. *Nat Med*. Published online June 2021. doi:10.1038/s41591-021-01410-w
213. Menni C, Klaser K, May A, et al. Vaccine side-effects and SARS-CoV-2 infection after vaccination in users of the COVID Symptom Study app in the UK: a prospective observational study. *Lancet Infect Dis*. 2021;21(7):939-949. doi:10.1016/S1473-3099(21)00224-3
214. V Shah AS, Gribben C, Bishop J, et al. Effect of vaccination on transmission of COVID-19: an observational study in healthcare workers and their households. *medRxiv*. Published online January 2021:2021.03.11.21253275. doi:10.1101/2021.03.11.21253275
215. Singanayagam A, Hakki S, Dunning J, et al. Community transmission and viral load kinetics of the SARS-CoV-2 delta (B.1.617.2) variant in vaccinated and unvaccinated individuals in the UK: a prospective, longitudinal, cohort study. *Lancet Infect Dis*. Published

online October 2021. doi:10.1016/S1473-3099(21)00648-4
216. Baker JM, Nakayama JY, O'Hegarty M, et al. SARS-CoV-2 B.1.1.529 (Omicron) Variant Transmission Within Households — Four U.S. Jurisdictions, November 2021–February 2022. *MMWR Morb Mortal Wkly Rep*. 2022;71(9). doi:10.15585/mmwr.mm7109e1
217. Cavanaugh AM, Spicer KB, Thoroughman D, Glick C, Winter K. Reduced Risk of Reinfection with SARS-CoV-2 After COVID-19 Vaccination — Kentucky, May–June 2021. *MMWR Morb Mortal Wkly Rep*. 2021;70(32):1081-1083. doi:10.15585/mmwr.mm7032e1
218. Pawlowski C, Lenehan P, Puranik A, et al. FDA-authorized COVID-19 vaccines are effective per real-world evidence synthesized across a multi-state health system. *medRxiv*. Published online January 2021:2021.02.15.21251623. doi:10.1101/2021.02.15.21251623
219. Thompson MG, Burgess JL, Naleway AL, et al. Interim Estimates of Vaccine Effectiveness of BNT162b2 and mRNA-1273 COVID-19 Vaccines in Preventing SARS-CoV-2 Infection Among Health Care Personnel, First Responders, and Other Essential and Frontline Workers .
220. Tande AJ, Pollock BD, Shah ND, et al. Impact of the COVID-19 Vaccine on Asymptomatic Infection Among Patients Undergoing Pre-Procedural COVID-19 Molecular Screening. *Clin Infect Dis*. Published online March 2021. doi:10.1093/cid/ciab229
221. White EM, Yang X, Blackman C, Feifer RA, Gravenstein S, Mor V. Incident SARS-CoV-2 Infection among mRNA-Vaccinated and Unvaccinated Nursing Home Residents. *N Engl J Med*. Published online May 2021:NEJMc2104849. doi:10.1056/NEJMc2104849
222. Lipsitch M, Kahn R. Interpreting vaccine efficacy trial results for infection and transmission. *Vaccine*. Published online June 2021. doi:10.1016/j.vaccine.2021.06.011
223. Amit S, Regev-Yochay G, Afek A, Kreiss Y, Leshem E. Early rate reductions of SARS-CoV-2 infection and COVID-19 in BNT162b2 vaccine recipients. *Lancet*. 2021;397(10277):875-877. doi:10.1016/S0140-6736(21)00448-7
224. Prunas O, Warren JL, Crawford FW, et al. Vaccination with BNT162b2 reduces transmission of SARS-CoV-2 to household contacts in Israel. *medRxiv*. Published online January 2021:2021.07.13.21260393. doi:10.1101/2021.07.13.21260393
225. Layan M, Gilboa M, Gonen T, et al. Impact of BNT162b2 vaccination and isolation on SARS-CoV-2 transmission in Israeli households: an observational study. *medRxiv*. Published online January 2021:2021.07.12.21260377. doi:10.1101/2021.07.12.21260377
226. Michael Weekes, Nick K Jones, Lucy Rivett, et al. Single-dose BNT162b2 vaccine protects against asymptomatic SARS-CoV-2 infection. Authorea. February 24, 2021. doi:10.22541/au.161420511
227. Salo J, Hägg M, Kortelainen M, et al. The indirect effect of mRNA-based Covid-19 vaccination on unvaccinated household members. *medRxiv*. Published online January 2021:2021.05.27.21257896. doi:10.1101/2021.05.27.21257896
228. Levine-Tiefenbrun M, Yelin I, Katz R, et al. Initial report of decreased SARS-CoV-2 viral load after inoculation with the BNT162b2 vaccine. *Nat Med*. 2021;27(5):790-792. doi:10.1038/s41591-021-01316-7
229. Milman O, Yelin I, Aharony N, et al. SARS-CoV-2 infection risk among unvaccinated is negatively associated with community-level vaccination rates. *medRxiv*. Published online January 2021:2021.03.26.21254394. doi:10.1101/2021.03.26.21254394
230. De Salazar PM, Link N, Lamarca K, Santillana M. High coverage COVID-19 mRNA vaccination rapidly controls SARS-CoV-2 transmission in Long-Term Care Facilities. *medRxiv*. Published online January 2021:2021.04.08.21255108. doi:10.1101/2021.04.08.21255108
231. World Health Organisation (WHO). Weekly epidemiological update on COVID-19 - 11 May 2021. Available at: https://www.who.int/publications/m/item/weekly-epidemiological-update-on-covid-19---11-may-2021
232. World Health Organisation (WHO). Tracking SARS-CoV-2 variants. Available at: https://www.who.int/en/activities/tracking-SARS-CoV-2-variants/
233. Emary KRW, Golubchik T, Aley PK, et al. Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B.1.1.7): an exploratory analysis of a randomised controlled trial. *Lancet*. Published online March 2021. doi:10.1016/S0140-6736(21)00628-0
234. Madhi SA, Baillie V, Cutland CL, et al. Safety and efficacy of the ChAdOx1 nCoV-19 (AZD1222) Covid-19 vaccine against the B.1.351 variant in South Africa. *Alex Sigal*. Published online 2021.
235. Shinde V, Bhikha S, Hoosain Z, et al. Efficacy of NVX-CoV2373 Covid-19 Vaccine against the B.1.351 Variant. *N Engl J Med*. Published online May 2021:NEJMoa2103055. doi:10.1056/NEJMoa2103055
236. Kustin T, Harel N, Finkel U, et al. Evidence for increased breakthrough rates of SARS-CoV-2 variants of concern in BNT162b2 mRNA vaccinated individuals. *medRxiv*. Published online January 2021:2021.04.06.21254882. doi:10.1101/2021.04.06.21254882
237. Abu-Raddad LJ, Chemaitelly H, Butt AA. Effectiveness of the BNT162b2 Covid-19 Vaccine against the B.1.1.7 and B.1.351 Variants. *N Engl J Med*. Published online May 2021:NEJMc2104974. doi:10.1056/NEJMc2104974
238. Hitchings MDT, Ranzani OT, Torres MSS, et al. Effectiveness of CoronaVac among healthcare workers in the setting of high SARS-CoV-2 Gamma variant transmission in Manaus, Brazil: A test-negative case-control study. *Lancet Reg Heal - Am*. Published online July 2021:100025. doi:10.1016/j.lana.2021.100025
239. Ranzani OT, Hitchings M, Nieto MD, et al. Effectiveness of the CoronaVac vaccine in the elderly population during a P.1 variant-associated epidemic of COVID-19 in Brazil: A test-negative case-control study. *medRxiv*. Published online January 2021:2021.05.19.21257472. doi:10.1101/2021.05.19.21257472
240. Ferguson N, Ghani A, Hinsley W, Volz E. Hospitalisation risk for Omicron cases in England. *Imp Coll London*. https://www.imperial.ac.uk/media/imperial-college/medicine/mrc-gida/2021-12-22-COVID19-Report-50.pdf
241. Israel Ministry of Health press release. Decline in Vaccine Effectiveness Against Infection and Symptomatic Illness. 5 July 2021. Available at: https://www.gov.il/en/departments/news/05072021-03
242. Li X ning, Huang Y, Wang W, et al. Efficacy of inactivated SARS-CoV-2 vaccines against the Delta variant infection in Guangzhou: A test-negative case-control real-world study. *Emerg Microbes Infect*. Published online August 2021:1-32. doi:10.1080/22221751.2021.1969291
243. Andrews N, Stowe J, Kirsebom F, et al. Effectiveness of COVID-19 booster vaccines against covid-19 related symptoms, hospitalisation and death in England. *Nat Med*. Published online January 2022. doi:10.1038/s41591-022-01699-1
244. United States Advisory Committee on Immunization Practices (ACIP). ACIP Presentation Slides: November 19, 2021 Meeting. Available at: https://www.cdc.gov/vaccines/acip/meetings/slides-2021-11-19.html
245. Andrews N, Stowe J, Kirsebom F, Gower C, Ramsay M, Bernal JL. Effectiveness of BNT162b2 (Comirnaty, Pfizer-BioNTech) COVID-19 booster vaccine against covid-19 related symptoms in England: test negative case-control study. *medRxiv*. Published online 2021. doi:10.1101/2021.11.15.21266341
246. Bar-On YM, Goldberg Y, Mandel M, et al. Protection against Covid-19 by BNT162b2 Booster across Age Groups. *N Engl J Med*. Published online December 2021. doi:10.1056/NEJMoa2115926
247. AlKaabi N, Yang YK, Zhang J, et al. Safety and immunogenicity of a heterologous boost with a recombinant vaccine, NVSI-06-07, in the inactivated vaccine recipients from UAE: a phase 2 randomised, double-blinded, controlled clinical trial. *medRxiv*. Published online January 2022:2021.12.29.21268499. doi:10.1101/2021.12.29.21268499
248. Pan H, Wu Q, Zeng G, et al. Immunogenicity and safety of a third dose, and immune persistence of CoronaVac vaccine in healthy adults aged 18-59 years: interim results from a double-blind, randomized, placebo-controlled phase 2 clinical trial. *medRxiv*. Published online 2021. doi:10.1101/2021.07.23.21261026
249. Arbel R, Hammerman A, Sergienko R, et al. BNT162b2 Vaccine Booster and Mortality Due to Covid-19. *N Engl J Med*. Published online December 2021. doi:10.1056/NEJMoa2115624
250. Tenforde MW, Olson SM, Self WH, et al. Effectiveness of Pfizer-BioNTech and Moderna Vaccines Against COVID-19 Among Hospitalized Adults Aged ≥65 Years — United States, January–March 2021. *MMWR Morb Mortal Wkly Rep*. 2021;70(18). doi:10.15585/mmwr.mm7018e1
251. Nunes B, Rodrigues AP, Kislaya I, et al. mRNA vaccine effectiveness against COVID-19-related hospitalisations and deaths in older adults: a cohort study based on data linkage of national health registries in Portugal, February to August 2021. *Eurosurveillance*. 2021;26(38). doi:10.2807/1560-7917.ES.2021.26.38.2100833
252. Rossman H, Shilo S, Meir T, Gorfine M, Shalit U, Segal E. COVID-19 dynamics after a national immunization program in Israel. *Nat Med*. Published online April 2021. doi:10.1038/s41591-021-01337-2
253. United Nations Children's Fund (UNICEF), Pacific Office. Situation Analysis of Children in the Pacific Island Countries. December 2017.
254. European Medicines Agency (EMA) press release. AstraZeneca's COVID-19 vaccine: benefits and risks in context 23 April 2021. Available at:
255. Centers for Disease Control and Prevention (CDC). Selected Adverse Events Reported after COVID-19 Vaccination. Updated 27 May 2021. Available at: https://www.cdc.gov/coronavirus/2019-ncov/vaccines/safety/adverse-events.html
256. Hu Z, Tao B, Li Z, et al. Effectiveness of inactivated COVID-19 vaccines against severe illness in B.1.617.2 (Delta) variant–infected patients in Jiangsu, China. *Int J Infect Dis*. 2022;116:204-209. doi:10.1016/j.ijid.2022.01.030
257. Amir O, Goldberg Y, Mandel M, et al. Protection against omicron severe disease 0-7 months after BNT162b2 booster. *medRxiv*. Published online January 1, 2022:2022.05.04.22274647. doi:10.1101/2022.05.04.22274647
258. Carazo S, Skowronski DM, Brisson M, et al. Protection against Omicron re-infection conferred by prior heterologous SARS-CoV-2 infection, with and without mRNA vaccination. *medRxiv*. Published online January 1, 2022:2022.04.29.22274455. doi:10.1101/2022.04.29.22274455

Acknowledgements

This document was compiled by Oashe Bhattacharya, Dr John Hart and Dr Ingrid Laemmle-Ruff

Technical leads: Professor Fiona Russell, Professor Kim Mulholland and Associate Professor Nigel Crawford

Quality checks: Professor Julie Bines and Associate Professor Margie Danchin

Other resources on COVID-19 vaccines:

WHO COVID-19 vaccines website: https://www.who.int/emergencies/diseases/novel-coronavirus-2019/covid-19-vaccines
EMA COVID-19 vaccines website: https://www.ema.europa.eu/en/human-regulatory/overview/public-health-threats/coronavirus-disease-covid-19/treatments-vaccines/covid-19-vaccines

To subscribe to receive the weekly updates, please email kase.anderson@unimelb.edu.au

Murdoch Children's Research Institute
50 Flemington Rd, Parkville
Victoria 3052 Australia
ABN 21 006 566 972
https://www.mcri.edu.au/research/themes/infection-and-immunity/asia-pacific-health

Appendix 1: COVID-19 Vaccine Effectiveness

VACCINE	SEVERE / HOSPITALISATION / DEATH	INFECTION AND OTHER OUTCOMES
AstraZeneca	Single dose in Scotland: 94% (73-99)[127] Risk of death in vaccine failures compared to unvaccinated cases in England reduced by: 55% (41-66)[192] (not peer reviewed) Single dose against hospitalisation in Spain: 92% (46-99)[29] Pooled analysis of AstraZeneca, Pfizer/BioNTech and Moderna vaccines in Italy: Hospitalisation: 89% (85-91); Death: 93% (89-96)[193] Chile: Hospitalisation: 100%; ICU admission: 100%; Death: 100%[122] Scotland: Hospitalisation: 94% (90-99)[28] Netherlands: Hospitalisation: 94% (92-95)[43] Spain: Hospitalisation: 95% (79-99)[117] Scotland: Death: 91% (86-94)[36] British Colombia and Quebec, Canada: Hospitalisation: 94% (90-96); 94% (89-97)[33] Scotland and Brazil, *respectively* (delta variant dominant in Scotland; gamma variant common in Brazil): Hospitalisation or death: Single dose: 49.3% (43.3-54.6); 57.9% (56.9-58.9). 2 doses: 2-3 weeks: 83.7% (79.7-87.0); 86.4% (85.4-87.3). 2 doses 18-19 weeks: 63.7% (59.6-67.4); 42.2% (32.4-50.6)[123] England: Hospitalisation: 2-9 weeks: 95.2% (94.7-95.7); ≥20 weeks: 80.0% (76.8-82.7) Death: 2-9 weeks: 95.0% (93.1-96.4); ≥20 weeks: 84.8% (76.2-90.3)[35] Effectiveness of third doses following Sinovac primary series: Hospitalisation with Omicron: 97.7% (97.3- 98). Death: 98.1% (97.3-98.6)[99,100]	Pooled analysis of Pfizer/BioNTech and AstraZeneca vaccines in elderly care home residents in UK: Reduction in risk of infection 4 weeks after-single dose: 56% Reduction in risk of infection 5 weeks after single dose: 62%[194] Pooled analysis of Pfizer/BioNTech and AstraZeneca vaccines: reduced odds of infection post-second dose: 70% (62-77)[195] Single dose in Spain: Any infection: 44% (31-54); Symptomatic infection: 50% (37-61)[29] Pooled analysis of AstraZeneca, Pfizer/BioNTech and Moderna vaccines in Italy: Infection: 78% (76-79)[193] Single dose against symptomatic infection in multiple European countries: 68% (39-83)[124] Symptomatic infection in 16-64 years in UK: single dose: 50.2% (40.8-58.2); 2 doses: 78.0% (69.7-84.0)[27] Symptomatic infection in Chile: 68.7% (39.8-83.7)[122] Spain: Any infection: 54% (48-60); Symptomatic infection: 56% (48-63)[117] British Colombia and Quebec, Canada: Symptomatic infection: 71% (69-74); 73% (69-77)[33] England REACT-1 study: Any infection: 44.8% (22.5-60.7)[118] India: Any infection: 2 doses: 63·1% (51·5-72·1); Single dose: 46·2% (31·6-57·7). Moderate-severe disease: 2 doses: 81·5% (9·9-99·0); Single dose: 79·2% (46·1-94·0)[119] UK: Symptomatic infection: 2-9 weeks: 76.2% (63.7-84.4); 15-19 weeks: 48.5% (44.7-52.0) 20-24 weeks: 45.4% (43.0-47.6); ≥25 weeks: 41.8% (39.4-44.1)[5] Brazil: Infection: 72.9% (71.9-73.8); Hospitalisation: 88.0% (86.8-89.2); Death: 90.2% (88.5-91.5)[35] England: Omicron: Symptomatic infection: -39% (-50--30); Delta: 25.0% (24.3-25.7)[7] Scotland and Brazil, *respectively* (delta variant dominant in Scotland; gamma variant common in Brazil): Symptomatic infection: Single dose: 37.6% (34.6-40.5); 37.6% (37.3-37.9). 2 doses 2-3 weeks: 67.9% (65.9-69.8); 69.8% (69.3-70.4); 2 doses 18-19 weeks: 44.6% (41.5-47.6); 57.7% (55.4-60.0)[123] England: Symptomatic infection: 2-9 weeks: 67.6% (67.3-67.9); ≥20 weeks: 44.3% (43.2-45.4)[36] UK: Any infection Dec 2020 - Sep 2021: 14-73 days: 58% (23-77); 134-220 days: 72% (39-87)[120] Finland: Effectiveness: Hospitalisation with Omicron: 2 doses: 14-90 days: 83% (53-94); 91-180 days: 76% (62-84); ≥181 days: 39% (-1-63)[8] Effectiveness of third doses following Sinovac primary series: Symptomatic infection with Omicron: 93.2 (92.9-93.6)[99,100]
Johnson & Johnson	USA: Hospitalisation: 81% (79-84)[130] USA: 71% (56-81)[133] Netherlands: Hospitalisation: 91% (88-94)[43] Spain: Hospitalisation: 74% (43-88)[117] Death in veterans in USA: <65 years: 73.0% (52.0-84.8); ≥65 years: 52.2% (37.2-63.6)[134] South Africa: Booster against hospitalisation during Omicron wave: 85% (54-95)[10]	USA: Any infection: 76.7% (30.3-95.3)[129] USA: Infection: 79% (77-80)[130] Efficacy following booster 2 months after first dose: Moderate-Severe infection in USA: 94% (58-100); worldwide: 75% (55-87)[196] Spain: Any infection: 50% (42-57); Symptomatic infection: 54% (45-62)[117] Symptomatic infection in veterans in USA: 88% (87-89)[131] Any infection in USA: 73.6% (65.9-79.9)[132] Infection in veterans in USA: March: 86.4% (85.2-87.6); September: 13.1% (9.2-16.8)[134]
Moderna	Pooled analysis of AstraZeneca, Pfizer/BioNTech and Moderna in Italy: Hospitalisation: 89% (85-91); Death: 93% (89-96)[193] Pooled analysis of Pfizer/BioNTech and Moderna against hospitalisation: 2-12 weeks after second dose: 86% (82%-90%) 13-24 weeks after second dose: 84% (77%-90%)[197] USA: Hospitalisation: 95.8% (90.7-98.1); Death: 97.9% (66.9-99.9)[45] Scotland: Pooled Pfizer/BioNTech and Moderna against hospitalisation: 92% (85-99)[28] USA: 93% (91-95)[133] Spain: Hospitalisation: 98% (82-100)[117] Qatar: Decline in effectiveness accelerated beyond the fourth month after the second dose; First month after second dose: 96.0% (93.9-97.4); ≥7 months: 55.6% (−44.3-86.3)[136] USA: Hospitalisation: 97.6% (92.8-99.2)[44] Moderna and Pfizer/BioNTech in British Colombia and Quebec, Canada: Hospitalisation:98% (97-98); 97% (96-97)[33] Death in veterans in USA: <65 years: 81.5% (70.7-88.4); ≥65 years:75.5% (71.8-78.7)[134] USA: Hospitalisation with Delta: Single dose: 68.9% (0.0-99.4); 2 doses Delta: 98.0% (87.2-99.7)[12] USA: Moderna and Pfizer: Hospitalisation: Delta: 2 doses: <6 months: 90% (89-90); ≥6 months: 81% (80-82); 3 doses: 94% (93-95); Omicron: 2 doses: <6 months: 81% (65-90); ≥6 months: 57% (39-70); 3 doses: 90% (80-94)[198] USA: Pooled Pfizer/BioNTech and Moderna against hospitalisation: Delta: 2 doses: <2 months: 94 (92–96); ≥5 months: 82 (82–83); 3 doses: <2 months: 96 (95–97); ≥4 months: 76 (14–93); Omicron: 2 doses: <2 months: 71 (51–83); ≥5 months: 54 (48–59); 3 doses: <2 months: 91 (88–93); ≥4 months: 78 (67–85)[199] Qatar (Omicron): Hospitalisation: 2 doses: 1-3 months: 76.9% (19.2-93.4); ≥7 months: 64.0% (39.1-78.7)[13] USA: Effectiveness against hospitalisation with Omicron: 90% (85-93)[137] USA: Pooled effectiveness of Moderna and Pfizer against hospitalisation: 2 doses: Delta: Overall: 85% (83-87); ≤150 days: 88% (86-90); >150 days: 81% (78-84); Omicron: 65% (51-75); 3 doses: Delta: 94% (92-95); Omicron: 86% (77-91)[137] Qatar: Effectiveness against Omicron BA.1 and BA.2 (median time since second dose −9 months): Hospitalisation and death: 2 doses: 86.3% (78.5-93.6); 3 doses: 82.7% (60.2-98.3)[14]	Pooled analysis of Moderna and Pfizer/BioNTech vaccines in USA: Infections in nonvaccinated: 234 of 8969; 2.61% (2.29-2.96) Fully vaccinated: 4/8121; 0.05% (0.01-0.13)[200] Pooled analysis of Moderna and Pfizer/BioNTech vaccines against infection in USA: Fully vaccinated: 90% (68–97) Two weeks after first dose: 80% (59–90)[201] Pooled analysis of AstraZeneca, Pfizer/BioNTech and Moderna vaccines in Italy: Infection: 78% (76-79)[193] Single dose against symptomatic disease in the UK: Age 15-39 years: 72% (46-86)[31] Minnesota, USA: January to July 2021 (Delta variant <0.7% in May): Infection: 86% (81-91); Hospitalisation: 92% (81-97) July (Delta variant >70%): Infection: 76% (58-87); Hospitalisation: 81% (33-96)[135] Infection in USA (98% vaccines used Pfizer/BioNTech and Moderna): Pre-Delta variant predominant: 91% (81–96); Delta variant predominant: 66% (26–84)[202] Infection in Canada: 1 dose: 72% (63-80); 2 doses: 94% (86-97)[52] USA: Any infection: 87.4% (84.8-89.6); Symptomatic infection: 88.3% (86.1-90.2)[45] Spain: Any infection: 82% (78-86); Symptomatic infection: 85% (80-89)[117] Qatar: First month after second dose: 77.5% (76.4-78.6); ≥7 months: 22.3% (−1.7-40.7)[136] USA: Any infection: 86.7% (84.3-88.7)[44] Moderna and Pfizer/BioNTech in British Colombia and Quebec, Canada: Symptomatic infection: 90% (89-90); 88% (88-89)[33] Infection in veterans in USA: March: 89.2% (88.8-89.6); September: 58.0% (56.9-59.1)[134] Denmark: Effectiveness against infection: Omicron: First month: 36.7% (-69.9-76.4); Third month: 4.2% (-30.8-29.8); Delta: First month: 88.2% (83.1-91.8); Third month: 72.2% (70.4-74.0); Booster first month: 82.8% (58.8-92.9)[11] USA: Any infection: Single dose: Delta: 60.2% (42.6-72.3); Omicron: 20.3% (0.0-39.8); 2 doses: Delta 14-90 days: 82.8% (69.6-90.3); 181-270 days: 61.4% (56.8-65.5); Omicron 14-90 days: 30.4% (5.0-49.0); 181-270 days: 0.0% (0.0-1.2); 3 doses: Delta ≤2 months: 95.7% (94.2-96.9); >2 months: 90.7% (81.4-95.3); Omicron ≤2 months: 63.6% (57.4-68.9); >2 months: 39.1% (3.8-61.5)[12] Qatar (Omicron): Symptomatic infection: Single dose: -1.6% (-56.8-34.1); 2 doses: 1-3 months: 44.8% (16.0-63.8); ≥7 months: -9.3% (-16.3--2.8); 3 doses: 4-5 weeks: 54.6% (41.1-65.0); ≥6 weeks: 38.6% (19.4-53.1)[13]

		Qatar: Effectiveness of third dose compared to primary series: Symptomatic infection: Omicron: 47.3% (40.7-53.3)[15] Finland: Effectiveness: Hospitalisation with Omicron: 2 doses: 14-90 days: 97% (88-99); 91-180 days: 85% (78-90); ≥181 days: 81% (67-89); 3 doses: 14-60 days: 98% (95-99); ≥61 days: 93% (82-98)[8] Qatar: Effectiveness against Omicron BA.1 and BA.2 (median time since second dose ~9 months): Symptomatic infection: 2 doses: 2.2% (-4.6-8.5); 3 doses: 61.3% (53.3-67.9)[14]
Pfizer/BioNTech	Severe in Israel: 92% (75-100)[144] Severe/critical in Israel: 97.5% (97.1-97.8)[138] Single dose against hospitalisation in Scotland: 85% (76-91)[127] Risk of death in vaccine failures compared to unvaccinated cases in England reduced by: Single dose: 44% (32-53) Fully vaccinated: 69% (31-86)[192] (not peer reviewed) Israel: Hospitalisation: 97.2% (96.8-97.5); Death: 96.7% (96.0-97.3)[138] Hospitalisation in Spain: 94% (60-99)[29] Priority groups in Denmark: Hospitalisation: 93% (89-96); Death: 94% (90-96)[50] Pooled analysis of AstraZeneca, Pfizer/BioNTech and Moderna vaccines in Italy: Hospitalisation: 89% (85-91); Death: 93% (89-96)[193] USA care facility: Hospitalisation: 94.4 (73.9-98.8); Death 94.4 (44.6–99.4)[141] Uruguay: Hospitalisation: 97.8% (96.0-98.8); Death: 96.2 (95.4-96.8)[147] Israel: Hospitalisation: 93·4% (91·9-94·7); Death: 91·1% (86·5-94·1)[48] Chile: Hospitalisation: 97.2% (96.6-97.6); ICU admission: 98.3% (97.6-98.8); Death: 100%[122] Pooled analysis of Pfizer/BioNTech and Moderna against hospitalisation: 2-12 weeks after second dose: 86% (82%-90%) 13-24 weeks after second dose: 84% (77%-90%)[197] Pooled analysis of Moderna and Pfizer/BioNTech against hospitalisation or death: 98% (83-100)[52] Pooled Pfizer/BioNTech and Moderna against hospitalisation in Scotland: 92% (85-99)[28] USA: 88% (85-91)[133] Netherlands: Hospitalisation: 96% (95-96)[43] USA: Hospitalisation: 93% (84–96)[143] Spain: Hospitalisation: 93% (88-96)[117] Scotland: Death: 90% (83-94)[28] Moderna and Pfizer/BioNTech in British Colombia and Quebec, Canada: Hospitalisation:98% (97-98); 97% (96-97)[33] Death in veterans in USA: <65 years: 84.3% (76.3-89.7); ≥65 years: 70.1% (66.1-73.6)[134] Israel: Booster ≥5 months after the primary series: Hospitalisation: 93%; Death 81%[203] USA: Hospitalisation: Delta: 2 doses <3 months: 88% (71-95); ≥6 months: 74% (65-80); 3 doses <3 months: 95% (91-97); ≥3 months: 65% (16-85) Omicron: 2 doses: <3 months: 70% (41-84); ≥6 months: 68% (56-76); 3 doses: <3 months: 89% (83-92); ≥3 months: 90% (57-98)[19] USA: Moderna and Pfizer: Hospitalisation: Delta: 2 doses: <6 months: 90% (89-90); ≥6 months: 81% (80-82); 3 doses: 94% (93-95); Omicron: 2 doses: <6 months: 81% (65-90); ≥6 months: 57% (39-70); 3 doses: 90% (80-94)[198] England: Hospitalisation: 2-9 weeks: 98.7% (98.3-99.0); ≥20 weeks: 91.7% (90.2-93.0); Death: 2-9 weeks: 98.5% (96.5-99.3); ≥20 weeks: 91.9% (88.5-94.3)[36] Pfizer/BioNTech and Moderna against hospitalisation: Delta: 2 doses: <2 months: 94 (92–96); ≥5 months: 82 (82–83); 3 doses: <2 months: 96 (95–97); ≥4 months: 76 (14–93); Omicron: 2 doses: <2 months: 71 (51–83); ≥5 months: 54 (48–59); 3 doses: <2 months: 91 (88–93); ≥4 months: 78 (67–85)[199] Qatar (Omicron): Hospitalisation: 2 doses: 1-6 months: 73.7% (46.8-87.0); ≥7 months: 80.7% (71.3-87.0); 3 doses: 1-6 weeks: 90.6% (77.8-96.0); (≥7 months: 90.8% (81.5-95.5)[13] Qatar: Effectiveness of third dose compared to primary series: Hospitalisation or death: Omicron: 76.5% (55.9-87.5)[15] USA: Effectiveness against hospitalisation with Omicron: 82% (80-84)[137] USA: Pooled effectiveness of Moderna and Pfizer against hospitalisation: 2 doses: Delta: Overall: 85% (83-87); ≤150 days: 88% (86-90); >150 days: 81% (78-84); Omicron: 65% (51-75); 3 doses: Delta: 94% (92-95); Omicron: 86% (77-91)[137] Qatar: Effectiveness against Omicron BA.1 and BA.2 (median time since second dose ~9 months): Hospitalisation and death: 2 doses: 73.5% (60.5-83.2); 3 doses: 92.5 (84.4-96.3)[14] Israel: Effectiveness of second booster compared to single booster against death ≥60 years: 78% (72-83)[22] Hospitalisation: Fourth dose compared to third dose: 68%(59 -74)[24] Death: Fourth dose compared to third dose: 74%% (50 -90)[24] Hospitalisation and death: Fourth dose compared to third dose among long-term care residents:Severe infection: 54%(31-70)[25] Fourth dose compared to third doses: Severe illness: Week 4: 3.5 (2.7-4.6)[204] Third doses following Sinovac primary series: Hospitalisation with Omicron:: 86.3% (83.7-88.5); Death:: 86.7% (80.5-91.0) [99,100]	Pooled analysis of Moderna and Pfizer/BioNTech vaccines in USA: Infections in nonvaccinated: 234 of 8969; 2.61% (2.29-2.96) Fully vaccinated: 4/8121; 0.05% (0.01-0.13)[200] Pooled analysis of Moderna and Pfizer/BioNTech vaccines in USA: Fully vaccinated: 90% (68–97); Two weeks after first dose: 80% (59–90)[201] Symptomatic infection in Israel: 94% (87-98)[144] Any infection in Israel: 90% (79-95)[47] Israel: Any infection: 95.3% (94.9-95.7); Symptomatic infection: 97.0% (96.7-97.2)[138] Pooled analysis of Pfizer/BioNTech and AstraZeneca vaccines in elderly care home residents in UK: 4 weeks after first dose: 56%; 5 weeks after first dose: 62%[194] Documented infection in Israel: incidence decreased from 9.4 infections per 1,000 HCWs in the week following first dose to <1.0 infection per 1,000 HCWs per week from 1 week after the second dose[205] Pooled analysis of Pfizer/BioNTech and AstraZeneca vaccines: reduced odds of infection post-second dose: 70% (62-77)[195] Spain: Any infection: 65% (56-73); Symptomatic infection: 82% (73-88)[29] Infection in priority groups in Denmark: 82% (79-84)[50] USA: Symptomatic infection: 84% (75-90)[145] Denmark: Infection in care facility residents: >14 days after first dose:17% (4-28); >7 days after second dose: 64% (14-84)[139] USA: Single dose against infection in 2 care facilities: 63% (33-79)[140] A care facility in USA: Infection 66% (41-81); Symptomatic illness 87% (66-95)[141] Pooled analysis of AstraZeneca, Pfizer/BioNTech and Moderna vaccines in Italy: Infection: 78% (76-79)[193] Uruguay: Infection: 78.1% (77.0-79,1)[147] Israel: Infection: 93·0% (92·6-93·4)[48] Single dose against symptomatic disease in the UK: Age 15-39 years: 61% (56-66)[31] Symptomatic infection in multiple European countries: single dose: 61% (39-75); 2 doses: 87% (74-93)[124] Symptomatic infection in 16-64 years in UK: single dose: 48.6% (27.9-63.3); 2 doses: 93.3% (85.8-96.8)[27] Symptomatic infection in Chile: 87.7% (87.3-88.1)[122] Minnesota, USA: January to July 2021 (Delta variant <0.7% in May): Infection: 76% (69-81); Hospitalisation: 85% (73-93) July (Delta variant >70%): Infection: 42% (13-62); Hospitalisation: 75% (24-94)[135] Infection in USA (98% vaccines used Pfizer/BioNTech and Moderna): Pre-Delta variant predominant: 91% (81–96); Delta variant predominant: 66% (26–84)[202] Infection in Canada: 1 dose: 59% (55-62); 2 doses: 91% (88-93)[52] Any infection with Delta in USA: 1 month after vaccination: 93% (85–97); 4 months: 53% (39-65)[143] Spain: Any infection: 69% (66-72); Symptomatic infection: 72% (69-75)[117] Moderna and Pfizer/BioNTech in British Colombia and Quebec, Canada: Symptomatic infection: 90% (89-90); 88% (88-89)[33] Symptomatic infection in veterans in USA: 91% (91-92) England REACT-1 study: Any infection: 71.3% (56.6-81.0)[118] Infection in veterans in USA: March: 86.9% (86.5-87.3); September:43.3% (41.9-44.6)[134] UK: Symptomatic infection: 2-9 weeks: 88.2% (86.7-89.5); 15-19 weeks: 72.2% (71-73.4); 20-24 weeks: 64.8% (62.6-66.9); ≥25 weeks: 63.5% (61.4-65.5)[5] England: Omicron: Symptomatic infection: Single dose: 2% (-7-11); 2 doses: -18% (-26--11); Delta: Single dose: 33.1% (32.7-33.6); 2 doses: 55.9% (55.5-56.3)[7] Denmark: Effectiveness against infection: Omicron: First month: 55.2% (23.5-73.7); Third month: 9.8% (-10.0-26.1); Booster first month: 54.6% (30.4-70.4); Delta: First month: 86.7% (84.6-88.6); Third month: 72.8% (71.7-73.8); Booster first month: 81.2% (79.2-82.9)[11] England: Symptomatic infection: 2-9 weeks: 89.7% (89.5-89.8); ≥20 weeks: 66.3% (65.7-66.9)[36] Wales: Any infection: Single dose: 52% (45-58); 2 doses: 2-5 weeks: 86% (79-91); ≥26 weeks: 45% (39-51)[146] Qatar (Omicron): Symptomatic infection: Single dose: 26.1% (5.8-42.0); 2 doses: First month: 61.9% (49.9-71.1); Seventh month): 9.6% (2.4-16.3); 3 doses: 4-5 weeks: 56.6% (50.8-61.7); ≥12 weeks: 37.6% (28.8-45.4)[13] UK: Any infection Dec 2020 - Sep 2021: ≥6 week dose interval: 14-73 days: 85% (72-92); 194-239 days: 51% (22-69); <6 week dose interval: 14-73 days: 89% (78-94); 194-265 days: 53% (28-69)[120] Qatar: Effectiveness of third dose compared to primary series: Symptomatic infection: Omicron: 49.4% (47.1-51.6); Delta: 86.1% (67.3-94.1)[15] Finland: Effectiveness: Hospitalisation with Omicron: 2 doses: 14-90 days: 93% (90-95); 91-180 days: 87% (84-89); ≥181 days: 72% (66-77); 3 doses: 14-60 days: 96% (95-97); ≥61 days: 92% (89-94)[8] Qatar: Effectiveness against Omicron BA.1 and BA.2 (median time since second dose ~9 months): Symptomatic infection: 2 doses: -0.2% (-5.5-4.9); 3 doses: 54.0% (50.4-57.3)[14] Canada: Fourth dose compared to third dose among long-term care residents: Symptomatic infection: 63%(51-71)[25] Third doses following Sinovac primary series: Symptomatic infection with Omicron: 96.5% (96.2-96.7)[99,100] Third dose of vaccine against Omicron after 14-30 days: 55.2 (54.7-55.6)[18]
Sinovac	Uruguay: Hospitalisation: 90.9% (88.6-92.7); Death: 94.7% (93.4-95.7)[147]	Uruguay: Infection: 59.9% (59.1-60.7)[147] Symptomatic infection in Chile: 58.5% (58.0-59.0)[122]

	Chile: Hospitalisation: 86.0% (85.6-86.5); ICU admission: 89.7% (89.1-90.2); Death: 86.4% (85.6-87.2)[122] Brazil: Infection: 52.7% (52.1-53.4); Hospitalisation: 72.8% (71.8-73.7); Death: 73.7% (72.3-75.0)[35] Third dose: Hospitalisation: 86.3% (83.7-88.5); Death: 86.7% (80.5-91.0)[23] Three doses: Hospitalisation with Omicron: 86.3% (83.7-88.5); Death: 86.7% (80.5-91.0)[99,100]	Third dose:Symptomatic infection: 78.8% (76.8-80.6)[23] Two doses against Delta variant in China: 59% (16-81.6)[206] Three doses: Symptomatic infection with Omicron: 78.8% (76.8-80.6) [99,100]
Sinopharm	-	Symptomatic infection in Bahrain: 90% (88-91)[54]
Bharat Biotech	-	India: Symptomatic infection: 50% (33-62)[128]

Appendix 2: Vaccine Efficacy/Effectiveness Against Asymptomatic Infection at-a-glance

Some of these studies assessed multiple variants, including Delta but none analyzed the Delta variant alone.
Detailed summary of vaccine efficacy/effectiveness against transmission available in Appendix 7.

VACCINE	VACCINE EFFECTIVENESS UNLESS OTHERWISE STATED
AstraZeneca	Efficacy: 54%[101]
Bharat Biotech	Efficacy: 64[39]
Johnson & Johnson	Efficacy: 60%[41]
Moderna	73%[45]
Pfizer/BioNTech	65-92%[136,138,144,145,207,208]

Appendix 3: Vaccine Efficacy/Effectiveness Against Transmission

There are limitations related to the analysis and comparison of transmission data between studies and vaccines. Criteria for testing vary between studies and may include, for example, random testing, testing at defined intervals, or retrospective serology.

VACCINE	EFFICACY/EFFECTIVENESS AGAINST ASYMPTOMATIC INFECTION	OTHER OUTCOMES
AstraZeneca	EFFICACY (UK only): 22·2% (−9·9-45·0); Symptomatic and asymptomatic combined (UK, SOUTH AFRICA & BRAZIL): 54.1% (44.7-61.9)[101] ENGLAND: Hazard ratio for single dose in vaccinated vs. unvaccinated care facility residents: 0.32 (0.15-0.66)[209]; Odds ratio for household contacts of vaccinated vs non-vaccinated health workers testing positive: 0.52 (0.43-0.62)[210] Effectiveness against household transmission of Delta: 42% (14-69); Vaccination of household contacts against infection from a symptomatic household index case: 14% (−5-46)[211] UK: Regular testing of randomly selected households: 79% (65-88)[212]; Single dose against symptomatic and asymptomatic infection: 60% (49–68)[213] NETHERLANDS: Effectiveness against transmission (secondary attack rate among household contacts): 58% (−12-84)[148]	SCOTLAND: POOLED ANALYSIS OF PFIZER/BIONTECH AND ASTRAZENECA: Hazard ratio for household contacts of vaccinated vs non-vaccinated health workers testing positive: 0.70 (0.63-0.78)[214] PF and AZ: Secondary attack rates in household contacts in the UK: Vaccinated contacts: 25% (18-33); Unvaccinated contacts: 38% (24-53); Unvaccinated index cases: 23% (15-31); Vaccinated index cases: 25% (15-35)[215]
Bharat Biotech	EFFICACY IN INDIA: Asymptomatic: 63.6% (29.0-82.4); Symptomatic and asymptomatic combined: 68.8% (46.7-82.5)[39]	-
Johnson & Johnson	EFFICACY (multiple countries): Asymptomatic infection: 59.7% (32.8-76.6)[41] UK: Single dose against symptomatic and asymptomatic infection: 60% (49–68)[213] Netherlands: Effectiveness against transmission (secondary attack rate among household contacts): 77% (6-94)[148] USA: POOLED ANALYSIS OF PFIZER/BIONTECH, MODERNA AND JOHNSON & JOHNSON: Omicron: Attack rate: Overall: 52.7% (227 of 431); Household contacts who had received: Booster: 47.8% (54 of 113); Primary series <5 months before the index date: 50.0% (14 of 28); Primary series ≥5 months before the index date: 70% (60-80); Unvaccinated: 53% (45-61)[216]	USA (Kentucky): OR for reinfection in unvaccinated vs vaccinated with Johnson & Johnson, Moderna or Pfizer/BioNTech): 2.34 (1.58–3.47)[217]
Moderna	USA: Asymptomatic infection: 72.7% (53.4-84.0)[45] USA: POOLED ANALYSIS OF PFIZER/BIONTECH AND MODERNA: 88.7% (68.4-97.1)[218]; 90% (68%-97)[219]; single dose: 80% (59-90)[219]; Relative risk of infection in asymptomatic pre-surgical patients >10 days after first dose compared to unvaccinated residents: 0.21 (0.12-0.37)[220]; Incident cases in unvaccinated nursing home residents decreased from 4.3% within 14 days of the first vaccination clinic to 0.3% after 42 days[221] MODELLING: Reduced potential for transmission: at least 61%[222] UK: Single dose against symptomatic and asymptomatic infection: 60% (49–68)[213] Netherlands: Effectiveness against transmission (secondary attack rate among household contacts): 88% (50-97)[148] USA: 63.0% (56.6-68.5)[104] Qatar: First month after second dose: 73.1% (70.3-75.5); declining to no evidence of any effect by 4 months post-vaccination[136] USA: POOLED ANALYSIS OF PFIZER/BIONTECH, MODERNA AND JOHNSON & JOHNSON: Omicron: Attack rate: Overall: 52.7% (227 of 431); Household contacts who had received: Booster: 47.8% (54 of 113); Primary series <5 months before the index date: 50.0% (14 of 28); Primary series ≥5 months before the index date: 70% (60-80); Unvaccinated: 53% (45-61)[216]	USA (Kentucky): OR for reinfection in unvaccinated vs vaccinated with Johnson & Johnson, Moderna or Pfizer/BioNTech): 2.34 (1.58–3.47)[217]
Pfizer/BioNTech	ENGLAND: 86% (76-97) 7 days after 2 doses; 72% (58-86) 21 days after 1 dose[207] Effectiveness against household transmission of Delta: 31% (−3-61); Vaccination of household contacts against infection from a symptomatic household index case: 24% (−2-64)[211] ISRAEL: 92% (88-95)[144]; 91.5% (90.7-92.2)[138]; 65% (45-79%)[208]; single dose: 75% (72-84)[223]; Effectiveness against transmission: 88.5% (82.3-94.8)[224]; Effectiveness against infection in the household: 78% (30-94)[225] USA: Asymptomatic screening: 90% (78-96)[145] USA: POOLED ANALYSIS OF PFIZER/BIONTECH AND MODERNA: 88.7% (68.4-97.1)[218]; 90% (68%-97)[219]; single dose: 80% (59-90)[219]; Relative risk of infection in asymptomatic pre-surgical patients >10 days after first dose compared to unvaccinated residents: 0.21 (0.12-0.37)[220]; Incident cases in unvaccinated nursing home residents decreased from 4.3% within 14 days of the first vaccination clinic to 0.3% after 42 days[221] UK: single dose: 4-fold decrease in risk amongst HCWs ≥12 days post-vaccination[226]; Regular testing of randomly selected households: 80% (73-85)[212]; Single dose against symptomatic and asymptomatic infection: 72% (63–79)[213]; 60% (49–68)[213] FINLAND: Effectiveness against transmission to unvaccinated household contacts: 2 weeks after first dose: 8.7% (-28.9-35.4); 10 weeks after first dose: 42.9% (22.3-58.1)[227] Netherlands: Effectiveness against transmission (secondary attack rate among household contacts): 70% (61-77)[148] Finland: Effectiveness against transmission to unvaccinated household contacts of vaccinated cases: 42.9% (22.3-58.1)[227] USA: POOLED ANALYSIS OF PFIZER/BIONTECH, MODERNA AND JOHNSON & JOHNSON: Omicron: Attack rate: Overall: 52.7% (227 of 431); Household contacts who had received: Booster: 47.8% (54 of 113); Primary series <5 months before the index date: 50.0% (14 of 28); Primary series ≥5 months before the index date: 70% (60-80); Unvaccinated: 53% (45-61)[216]	ISRAEL: Lower viral load in vaccine failure cases 12-37 days after the first dose of vaccine compared to within the first 11 days, indicating potentially lower infectiousness[228]; Data from 223 communities: strong correlation between community vaccination rate and a later decline in infection among children under 16 years of age who were unvaccinated[229]; Substantially decreased viral load for infections occurring 12-37 days after the first dose of vaccine, indicating likely lower infectiousness[228] Detectable transmission in long-term care facilities in Spain reduced by 90% (76-93)[230] ENGLAND: Odds ratio for household contacts of vaccinated health workers vs non-vaccinated health workers testing positive: 0.54 (0.47-0.62)[210] SCOTLAND: POOLED ANALYSIS OF PFIZER/BIONTECH AND ASTRAZENECA: Hazard ratio for single dose in vaccinated vs. unvaccinated care facility residents: 0.35 (0.17-0.71)[209] USA (Kentucky): OR for reinfection in unvaccinated vs vaccinated with Johnson & Johnson, Moderna or Pfizer/BioNTech): 2.34 (1.58–3.47)[217] PF and AZ: Secondary attack rates in household contacts in the UK: Vaccinated contacts: 25% (18-33); Unvaccinated contacts: 38% (24-53); Unvaccinated index cases: 23% (15-31); Vaccinated index cases: 25% (15-35)[215]

Appendix 4: Vaccine Efficacy/Effectiveness Against Variants

Refer to Appendix 1 for vaccine effectiveness results for the Pfizer/BioNTech vaccine in Scotland, England and Israel, where all locations had predominant B.1.1.7 circulation. There are four Variants of Concern listed by WHO.[231] The WHO recommends labelling SARS-CoV-2 variants with letters of the Greek alphabet, as in the tables below.[232]

VACCINE	VACCINE EFFICACY/EFFECTIVENESS (EFFECTIVENESS AGAINST INFECTION UNLESS SPECIFIED)		
	B.1.1.7 (ALPHA) VARIANT	B.1.351 (BETA) VARIANT	P.1 (GAMMA) VARIANT
AstraZeneca	UK: 70·4% (43·6-84·5) (vs. 81·5% (67·9-89·4) against wild variant)[233] England: ≥21 days after one dose: 48.7% (45.2-51.9). ≥14 days after two doses: 74.5% (68.4-79.4)[114] Scotland: 73% (66-78)[115] Canada: Single dose: 64% (60-68)[121] UK: Single dose: 63% (55-69); 2 doses: 79% (56-90)[116] Severe disease in Canada: Single dose: 85% (81-88)[121]	South Africa: 10.4% (−76.8 to 54.8)[234] Study against severe disease underway[41]	Brazil: Symptomatic infection: Single dose: 37.6% (37.3-37.9); 2 doses 2-3 weeks: 69.8% (69.3-70.4); 2 doses 18-19 weeks: 57.7% (55.4-60.0); Hospitalisation or death: Single dose: 57.9% (56.9-58.9); 2 doses 2-3 weeks: 86.4% (85.4-87.3); 2 doses 18-19 weeks: 42.2% (32.4-50.6)[123]
Johnson & Johnson	-	Moderate to severe/critical: 64.0% (41.2-78.7) Severe/critical: 81.7% (46.2-95.4)[41] Efficacy against hospitalisation in South Africa: 67%[107]	Moderate to severe/critical: 68.1% (48.8-80.7); Severe/critical: 87.6% (7.8-99.7)[41]
Moderna	Canada: Single dose: 83% (80-86); 2 doses: 92% (86-96)[121] Severe disease in Canada: Single dose: 79% (74-83); 2 doses: 94% (89-97)[121]	-	-
Novavax	UK: 86.3% (71.3-93.5) (vs. 96.4% (73.8-99.5) against wild variant)[110]	South Africa: 51.0% (−0.6 to 76.2)[235]	-
Pfizer/BioNTech	Case-control study in Israel: After one dose, vaccinees were disproportionally infected with B.1.1.7 (OR: 26:10) [236] Qatar: 89.5% (85.9-92.3)[237] England: ≥21 days after one dose: 47.5% (41.6 to 52.8) ≥14 days after second dose: 93.7% (91.6-95.3)[114] Scotland: 92% (90-93)[115] Canada: Single dose: 66% (64-68); 2 doses: 89% (86-91)[121] UK: Single dose: 59% (52-65); 2 doses: 78% (68-84)[116] Severe disease in Qatar: 100% (81.7-100)[237] Severe disease in Canada: Single dose: 80% (78-82); 2 doses: 95% (92-97)[121]	Israel case-control study: Vaccinees infected at least 1 week after the second dose were disproportionally infected with B.1.351 (odds ratio: 8:1)[236] Qatar: 75.0% (70.5-78.9)[237] South Africa: 100% (53.5-100)[51] Severe disease in Qatar: 100% (73.7-100)[237]	-
Sinovac	Chile: 67% (65-69)*[54]	-	Brazil: 1 or 2 doses: 37.9% (−46.4-73.6)[238] Chile: 67% (65-69)*[54] Brazil: ≥70 years: 41.6% (26.9-53.3); 70-74 years: 61.8% (34.8-77.7); 75-79 years: 48.9% (23.3-66.0); ≥80 years: 28.0% (0.6-47.9)[239]

* While it is known P.1. and B.1.1.7 were circulating at the time of the study, the extent is unknown based on available surveillance

VACCINE	VACCINE EFFICACY/EFFECTIVENESS (EFFECTIVENESS AGAINST INFECTION UNLESS SPECIFIED)	
	B.1.617.2 (DELTA) VARIANT	OMICRON VARIANT
AstraZeneca	England: ≥21 days after one dose: 30.0% (24.3-35.3); ≥14 days after second dose: 67.0% (61.3-71.8)[114] Scotland: 60% (53-66)[115] Canada: Single dose: 67% (44-80)[121] UK: Single dose: 46% (35-55); 2 doses: 67% (62-71)[116] Symptomatic infection in England: 66.7% (66.3-67.0)[34] Hospitalisation in England: 1 dose: 71% (51-83); 2 doses: 92% (75-97)[126]; 93.9% (91.3-95.7)[34] Death in England: 94.1% (91.8-95.8)[34] Severe disease in Canada: Single dose: 88% (60-96)[121] Hospitalisation and death in Scotland: 88% (85-90)[125] Scotland: Death: 91% (86-94)[38] India: Any infection: 2 doses: 63·1% (51·5-72·1); Single dose: 46·2% (31·6-57·7); Moderate-severe: 2 doses: 81·5% (9·9-99·0); Single dose: 79·2% (46·1-94·0)[119] UK: Symptomatic infection: 2-9 weeks: 76.2% (63.7-84.4); 15-19 weeks: 48.5% (44.7-52.0) 20-24 weeks: 45.4% (43.0-47.6); ≥25 weeks: 41.8% (39.4-44.1)[5] England: Symptomatic infection: 25% (24.3-25.7)[7] Scotland: Symptomatic infection: Single dose: 37.6% (34.6-40.5); 2 doses 2-3 weeks: 67.9% (65.9-69.8); 2 doses 18-19 weeks: 44.6% (41.5-47.6); Hospitalisation or death: Single dose: 49.3% (43.3-54.6); 2 doses: 2-3 weeks: 83.7% (79.7-87.0); 2 doses 18-19 weeks: 63.7% (59.6-67.4)[123] England: Symptomatic infection: 2-9 weeks: 67.6% (67.3-67.9); ≥20 weeks: 44.3% (43.2-45.4); Hospitalisation: 2-9 weeks: 95.2% (94.7-95.7); ≥20 weeks: 80.0% (76.8-82.7); Death: 2-9 weeks: 95.0% (93.1-96.4); ≥20 weeks: 84.8% (76.2-90.3)[36]	UK: No protective effect beyond 15 weeks[5] England: Symptomatic infection: -39% (-50--30)[7] England: Hazard ratio for hospitalisation with Omicron relative to primary Delta infection in unvaccinated: Single dose: 0.42; 2 doses: 0.37; 2 doses plus Pfizer booster: 0.21[240] Finland: Effectiveness: Hospitalisation: 2 doses: 14-90 days: 83% (53-94); 91-180 days: 76% (62-84); ≥181 days: 39% (-1-63)[8]
Johnson & Johnson	Efficacy against hospitalisation in South Africa: 71%[107] USA: Infection: 78% (73-82); Hospitalisation: 85% (73-91)[130]	South Africa: Booster against hospitalisation: 85% (54-95)[10]
Moderna	Canada: Single dose: 72% (57-82)[121] Minnesota, USA: 76% (58-87)[135] England: 95.2% (94.4-95.9)[34] Severe disease in Canada: Single dose: 96% (72-99)[121] Severe disease in Minnesota: 81% (33-96)[135] Hospitalisation in England: 97.5% (82.3-99.7)[34] Pooled Pfizer/BioNTech and Moderna against hospitalisation and death in Scotland: 91% (88-93)[125] USA: Infection: 86.7% (84.3-88.7); Hospitalisation: 97.6% (92.8-99.2)[44] Denmark: First month: 88.2% (83.1-91.8); Third month: 72.2% (70.4-74.0); Booster first month: 82.8% (58.8-92.9)[11] USA: Infection: Single dose: 60.2% (42.6-72.3); 2 doses: 14-90 days: 82.8% (69.6-90.3); 181-270 days: 61.4% (56.8-65.5); 3 doses: ≤2 months: 95.7% (94.2-96.9); >2 months: 90.7% (81.4-95.3); Hospitalisation: Single dose: 68.9% (0.0-99.4); 2 doses: 98.0% (87.2-99.7)[12] Moderna and Pfizer in USA: Hospitalisation: 2 doses: <6 months: 90% (89-90); ≥6 months: 81% (80-82); 3 doses: 94% (93-95)[198]	Denmark: First month: 36.7% (-69.9-76.4); Third month: 4.2% (-30.8-29.8)[11] USA: Infection: Single dose: 20.3% (0.0-39.8); 2 doses: 14-90 days: 30.4% (5.0-49.0); 181-270 days: 0.0% (0.0-1.2); 3 doses: ≤2 months: 63.6% (57.4-68.9); >2 months: 39.1% (3.8-61.5)[12] Moderna and Pfizer in USA: Hospitalisation: 2 doses: <6 months: 81% (65-90); ≥6 months: 57% (39-70); 3 doses: 90% (80-94)[198] Qatar: Symptomatic infection: Single dose: -1.6% (-56.8-34.1); 2 doses: 1-3 months: 44.8% (16.0-63.8); ≥7 months: -9.3% (-16.3--2.8); 3 doses: 4-5 weeks: 54.6% (41.1-65.0); ≥6 weeks: 38.6% (19.4-53.1); Hospitalisation: 2 doses: 1-3 months: 76.9% (19.2-93.4); ≥7 months: 64.0% (39.1-78.7)[13] Efficacy: Fourth dose compared to three doses: Any infection: 11% (-43-44); Symptomatic infection: 31% (-18-60)[16] USA: Effectiveness against hospitalisation: 90% (85-93) Finland: Effectiveness: Hospitalisation: 2 doses: 14-90 days: 97% (88-99); 91-180 days: 85% (78-90); ≥181 days: 81% (67-89); 3 doses: 14-60 days: 98% (95-99); ≥61 days: 93% (82-98)[8] Qatar: Effectiveness against Omicron BA.1 and BA.2 (median time since second dose ~9 months): Symptomatic infection: 2 doses: 2.2% (-4.6-8.5); 3 doses: 61.3% (53.3-67.9); Hospitalisation and death: 2 doses: 86.3% (78.5-93.6); 3 doses: 82.7% (60.2-98.3)[14]
Pfizer/BioNTech	England: ≥21 days after one dose: 35.6% (22.7-46.4); ≥14 days after second dose: 88.0% (85.3-90.1)[114] Scotland: 79% (75-82)[115] Canada: Single dose: 56% (45-64); 2 doses: 87% (64-95)[121] Effectiveness in Israel: Infection: 64%; Symptomatic illness: 64%[241] Israel 6m after roll out: 39.0% (9.0-59.0)[142] Minnesota, USA: 42% (13-62)[135] UK: Single dose: 57% (50-63); 2 doses: 80% (77-83)[116] England: 89.8% (89.6-90.0)[34] Hospitalisation in England: 1 dose: 94% (46-99); 2 doses: 96% (86-99)[126]; 99.7% (97.6-100.0)[34] Death in England: 98.2% (95.9-99.2)[34] Severe disease in Canada: Single dose: 78% (65-86)[121] Hospitalisation in Israel: 93%[241]	UK: Symptomatic infection: Single dose: 34.2% (-3.5-58.1); 2 doses: 2-9 weeks: 88.0% (65.9-95.8); 15-19 weeks: 34.1% (9.7-52.0); Booster after PF primary series: 75.5% (56.1-86.3); Booster after AZ primary series: 71.4% (41.8-86.0)[5] South Africa: Symptomatic infection: 33%; Hospitalisation: 70% (risk of hospital admission 29% lower for Omicron compared to first wave in mid-2020, adjusted for vaccination status)[17] England: Hazard ratio for hospitalisation with Omicron relative to primary Delta infection in unvaccinated: Single dose: 0.66; 2 doses: 0.26; 3 doses: 0.37[240] Denmark: First month: 55.2% (23.5-73.7); Third month: 9.8% (-10.0-26.1); Booster first month: 54.6% (30.4-70.4)[11] USA: Effectiveness against hospitalisation: 2 doses: <3 months: 70% (41-84); ≥6 months: 68 (56-76); 3 doses: <3 months: 89% (83-92); ≥3 months: 90% (57-98)[19]

	Severe disease in Israel: 91.4% (82.5-95.7)[142] Severe disease in Minnesota: 75% (24-94)[135] Pooled Pfizer/BioNTech and Moderna against hospitalisation and death in Scotland: 91% (88-93)[125] Scotland: Death: 90% (83-94)[38] UK: Symptomatic infection: 2-9 weeks: 88.2% (86.7-89.5); 15-19 weeks: 72.2% (71-73.4); 20-24 weeks: 64.8% (62.6-66.9); ≥25 weeks: 63.5% (61.4-65.5)[5] Denmark: First month: 86.7% (84.6-88.6); Third month: 72.8% (71.7-73.8); Booster first month: 81.2% (79.2-82.9)[11] USA: Hospitalisation: 2 doses: <3 months: 88% (71-95); ≥6 months: 74% (65-80); 3 doses: <3 months: 95% (91-97); ≥3 months: 65% (16-85)[19] Moderna and Pfizer in USA: Hospitalisation: Delta: 2 doses: <6 months: 90% (89-90); ≥6 months: 81% (80-82); 3 doses: 94% (93-95)[198] England: Symptomatic infection: 2-9 weeks: 89.7% (89.5-89.8); ≥20 weeks: 66.3% (65.7-66.9); Hospitalisation: 2-9 weeks: 98.7% (98.3-99.0); ≥20 weeks: 91.7% (90.2-93.0); Death: 2-9 weeks: 98.5% (96.5-99.3); ≥20 weeks: 91.9% (88.5-94.3)[36] Qatar: Effectiveness of third dose compared to primary series: Symptomatic infection: 86.1% (67.3-94.1)[15]	Moderna and Pfizer in USA: Hospitalisation: Omicron: 2 doses: <6 months: 81% (65-90); ≥6 months: 57% (39-70); 3 doses: 90% (80-94)[198] Qatar: Symptomatic infection: Single dose: 26.1% (5.8-42.0); 2 doses: First month: 61.9% (49.9-71.1); Seventh month): 9.6% (2.4-16.3); 3 doses: 4-5 weeks: 56.6% (50.8-61.7); ≥12 weeks: 37.6% (28.8-45.4); Hospitalisation: 2 doses: 1-6 months: 73.7% (46.8-87.0); ≥7 months: 80.7% (71.3-87.0); 3 doses: 1-6 weeks: 90.6% (77.8-96.0); (≥7 months: 90.8% (81.5-95.5)[13] Efficacy: Fourth dose compared to three doses: Any infection: 30% (-9-55); Symptomatic infection: 43% (7-65)[16] Qatar: Effectiveness of third dose compared to primary series: Symptomatic infection: 49.4% (47.1-51.6); Hospitalisation or death: 76.5% (55.9-87.5)[15] USA: Effectiveness against hospitalisation: 82% (80-84)[137] Finland: Effectiveness: Hospitalisation: 2 doses: 14-90 days: 93% (90-95); 91-180 days: 87% (84-89); ≥181 days: 72% (66-77); 3 doses: 14-60 days: 96% (95-97); ≥61 days: 92% (89-94)[8] Qatar: Effectiveness against Omicron BA.1 and BA.2 (median time since second dose ~9 months): Symptomatic infection: 2 doses: -0.2% (-5.5-4.9); 3 doses: 54.0% (50.4-57.3); Hospitalisation and death: 2 doses: 73.5% (60.5-83.2); 3 doses: 92.5 (84.4-96.3)[14] Israel: Effectiveness of second booster compared to single booster against death ≥60 years: 78% (72-83)[22] Hospitalisation: Fourth dose compared to third dose: 68%(59 -74); Death: Fourth dose compared to third dose: 74%% (50 -90)[24] Hospitalisation and death: Fourth dose compared to third dose among long-term care residents: Severe infection: 54%(31-70)[25]
Sinovac	China (combined Sinovac and Sinopharm): Single dose: 13.8% (-60.2-54.8);; 2 doses: 59.0% (16.0-81.6) Severe disease: 100%[242]	Third dose: Symptomatic infection: 78.8% (76.8-80.6)[23] Third dose: Hospitalisation: 86.3% (83.7-88.5); Death: 86.7% (80.5-91.0)[23]
Sinopharm	China (combined Sinovac and Sinopharm): Single dose: 13.8% (-60.2-54.8); 2 doses: 59.0% (16.0-81.6) Severe disease: 100%[242]	-
Bharat Biotech	Efficacy against infection in India: 65.2% (33.1-83.0)[39] India: Symptomatic infection: 50% (33-62)[128]	-
Clover	Efficacy in Philippines, Colombia, Brazil, South Africa and Belgium: Symptomatic infection: 78.7% (57.3-90.4); Mod-Severe: 81.7% (35.9-96.6)[102]	-

Appendix 5: Vaccine Efficacy/Effectiveness of Primary Series Against Delta at-a-glance

VACCINE	VACCINE EFFECTIVENESS UNLESS OTHERWISE STATED				
	ANY INFECTION	SYMPTOMATIC INFECTION	HOSPITALISATION AND DEATH	EFFECTIVENESS 4 to <6 MONTHS	EFFECTIVENESS ≥6 MONTHS
AstraZeneca	60-67%[114–116,119] Single dose 30-67%[114,116,119,121]	25-76%[5,7,33,34,36,123] Moderate-Severe: 82%; Single dose: 38-79%[119,123]	84-95%[33,34,36,38,123,125,126] Single dose: 49-88%[121,123,126]	Infection: 44-45%[5,36,123] Hospitalisation: 64-80%[36,123] Death: 82%[36]	Infection: 42%[5]
Bharat Biotech	Efficacy: 65%[39]	50%[128]	-	-	-
Clover	-	Efficacy: 79% [102]	Efficacy (moderate-severe): Delta: 82%[102]	-	-
Johnson & Johnson	78%[130]	-	71-85%[107,130]	-	Infection: 13%[134] Death: <65 years: 73%; ≥65 years: 52%[134]
Moderna	76-88%[11,44,135] Single dose: 60-72%[12,121]	95%[34]	81-98%[12,34,44,135,137] Single dose: 69-96%[12,121]	-	Infection: 22-58%[134,136] Death: <65 years: 82%; ≥65 years: 76%[134] 56%[136]
Pfizer/BioNTech	39-93%[11,114,115,135,142,143] Single dose: 36-57%[114,116,121]	56-90%[5,7,34,36] Single dose: 33%[7]	75-100%[19,34,36,38,126,135,137,142,143] Single dose: 78-94%[121,126]	Infection: 53-66%[5,36,143] Hospitalisation: 92%[36] Death: 92%[36]	Infection: 43-64%[5,34,134] Death: <65 years: 84%; ≥65 years: 70%[134] Hospitalisation: 74%[19]

Appendix 6: Vaccine Efficacy/Effectiveness and Immunogenicity of Boosters Against Delta at-a-glance

Booster refers to an additional dose administered at least 5 months after completion of the primary series.
Booster efficacy/effectiveness reported relative to primary series (not unvaccinated) unless otherwise specified.
Detailed summary available in Appendix 3.

VACCINE	IMMUNOGENICITY	BOOSTER VACCINE EFFECTIVENESS (UNLESS OTHERWISE STATED)			
		ANY INFECTION	SYMPTOMATIC INFECTION	HOSPITALISATION	DEATH
Johnson & Johnson	Strong antibody response[9]	-	-	-	-
Moderna	Strong antibody response[9]	83-96%*[11,12]	87%[243] 95%*[243]	-	-
Pfizer/BioNTech	Strong antibody response[9]	81%*[11]	Efficacy: 84-95%[244,245] 86%[15,243] 89-94%*[5,7,243] After AZ primary series: 90-94%*[5,7,243]	93-99%[19,203,243] ≥3 months: 65%[19]	81-99%[203,243,246]
Sinopharm	Strong antibody response but stronger with a Sinopharm recombinant protein vaccine booster[247]	90%[54]	-	-	-
Sinovac	Strong antibody response[248]	-	79%[99]	86%[99]	87%[99]

*Relative to unvaccinated

Appendix 7: Vaccine Efficacy/Effectiveness and Immunogenicity of Boosters Against Delta

Booster refers to an additional dose administered at least 5 months after completion of the primary series.
Booster efficacy/effectiveness reported relative to primary series (not unvaccinated) unless otherwise specified.

VACCINE	IMMUNOGENICITY	VACCINE EFFECTIVENESS UNLESS OTHERWISE STATED			
		ANY INFECTION	SYMPTOMATIC INFECTION	HOSPITALISATION	DEATH
Johnson & Johnson	Strong antibody response[9]	-	-	-	-
Moderna	Strong antibody response[9]	USA (relative to unvaccinated): Delta: ≤2 months: 95.7% (94.2-96.9); >2 months: 90.7% (81.4-95.3)[12]	England (after Pfizer primary series): Relative to primary series at least 6 months earlier: 86.8% (81.5-90.5); relative to unvaccinated: 94.8% (92.7-96.3)[243]	Moderna and Pfizer in USA: 94% (93-95)[198]	-
Pfizer/BioNTech	Strong antibody response[9]	Israel; Infection ~10 times lower in boosted group (range across five age groups, 9.0 to 17.2)[246] Denmark (relative to unvaccinated): First month: 54.6% (30.4-70.4)[11]	Efficacy: ≥6 months (median 10.8 months) in USA, South Africa, Brazil: 95.3 (89.5-98.3)[244] UK: Relative to primary series at least 4.6 months earlier: PF primary: 84.4% (82.8-85.8); AZ primary: 87.4% (84.9-89.4); Relative to unvaccinated: PF primary: 94.0% (93.4-94.6); AZ primary: 93.1% (91.7-94.3)[245] UK: relative to unvaccinated: PF primary: 92.6% (92.0-93.1); AZ primary: 93.8% (93.2-94.3)[5] England: PF primary: 88.6% (88.1-89.1) AZ primary: 89.7% (88.9-90.4)[7] England: Relative to primary series at least 6 months earlier: 85.6% (84.9-86.3); relative to unvaccinated: 94.4% (94.1-94.7)[243] Qatar: Symptomatic infection: 86.1% (67.3-94.1)[15]	Israel ≥5 months: 93% (88-97)[203] Israel: Severe disease: ≥60 years: 17.9 times lower in boosted group (15.1-21.2); 40-59 years: 21.7 times lower (10.6-44.2)[246] USA: <3 months: 95% (91-97); ≥3 months: 65% (16-85)[19] Moderna and Pfizer in USA: 94% (93-95)[198] England: Relative to unvaccinated: 98.6 (98.0 to 99.0)[243]	Israel ≥5 months: 81% (59-97)[203] Israel ≥5 months: 90% (86-93)[249] Israel ≥60 years: mortality 14.7 times lower in boosted group: (10.0-21.4)[246] England: Relative to unvaccinated: 98.7% (97.4-99.4)[243]
Sinovac	Strong antibody response[248]	-	Chile: 78·8% (76·8-80·6)[99]	Chile: 86·3% (83·7-88·5)[99]	Chile: 86·7% (80·591·0)[99]

Appendix 8: Vaccine Efficacy/Effectiveness in High-Risk Groups

VACCINE	VACCINE EFFICACY UNLESS OTHERWISE STATED			
	DIABETES	OBESITY	AT RISK FOR SEVERE COVID-19	ELDERLY
AstraZeneca	-	-	76% against symptomatic infection in a sample where 60% had comorbidities, including diabetes, severe obesity or cardiac disease[26] (not peer-reviewed) Effectiveness against symptomatic infection in the UK in those with comorbidities and ≥65 years: Single dose: 60.0% (46.5-70.1); 2 doses: 79.7% (61.6-89.3)[27] Hospitalisation in Scotland: 63% (46-75)[28]	In ≥65 years: 85%[26] (not peer-reviewed) Effectiveness against hospitalisation at 28-34 days after a single dose (pooled analysis of AstraZeneca and Pfizer vacines): 18-64 years: 85% (68-93); 65-79 years: 79% (17-95); ≥80 years: 81% (65-90)[127] Effectiveness of single dose against hospitalisation in England: ≥80 years: 73% (60-81)[37] Effectiveness in England: Symptomatic infection ≥70 years: 73% (27-90); Hospitalisation ≥80 years: 37% (3-59)[32] Hospitalisation following single dose in the UK: ≥80 years: 80.4% (36.4-94.5)[30] Single dose in Spain: ≥60 years: 53% (19-72) vs. 18-59 years: 50% (34-62)[29] Effectiveness against death in the UK: ≥65 years: Single dose: 83% (78-86); Two doses: 94% (80-98)[31] Effectiveness against symptomatic infection in the UK, ≥65 years: single dose: 60.9% (49.0-70.0); 2 doses: 76.4% (58.8-86.5)[27] Effectiveness against death in Scotland ≥60 years: 90% (84-94)[38] British Colombia and Quebec, Canada: Symptomatic infection ≥70 years: 73% (42-88); 81% (74-86)[33] Brazil: Infection: 80-89 years: 73.1% (71.2-74.9); ≥90 years: 39.0% (23.5-51.4); Hospitalisation: 80-89 years: 85.1% (83.0-86.9); ≥90 years: 50.9% (31.3-64.9); Death: 80-89 years: 89.9% (87.7-91.7); ≥90 years: 65.4% (46.1-77.8)[35] England: ≥65 years: Symptomatic infection: 2-9 weeks: 59.1% (55.4-62.6); ≥25 weeks: 27.8% (16.3-37.8); Hospitalisation: 2-9 weeks: 91.7% (88.8-93.9); ≥20 weeks: 81.8% (76.6-85.9); Death: 2-9 weeks: 94.1% (89.6-96.7); ≥20 weeks: 82.1% (70.1-89.3)[36] Finland: Effectiveness: Hospitalisation with Omicron ≥70 years: 2 doses: 14-90 days: 83% (53-94); 91-180 days: 76% (62-84); ≥181 days: 39% (-1-63)[8]
Gamaleya	-	-	-	Symptomatic infection >60 years: 91.8% (67.1–98.3)[40]
Johnson & Johnson	Moderate to severe/critical: 23.0% (-90.1-69.8)[41]	Moderate to severe/critical: 65.9% (47.8-78.3)[41]	Moderate to severe/critical: With any comorbidity: 58.6% (40.6-71.6)[41] No comorbidity: 68.8% (59.0-76.6)[41]	Moderate-severe/critical disease ≥28 post vaccination: 18-59 years: 66.1% (53.3-75.8) 60+ years: 66.2% (36.7-83.0)[41]
Moderna	-	-	Symptomatic infection, comorbidities, including diabetes and obesity: In low risk: 95.1% (89.6-97.7) In high risk: 90.9% (74.7-96.7)[42] Pooled Pfizer/BioNTech and Moderna against hospitalisation in Scotland: 72% (51-84)[28] Netherlands: Hospitalisation in a population at high risk for severe COVID-19: 84% (80-87)[43] USA: Pooled effectiveness of Moderna and Pfizer against hospitalisation: 2 doses: Delta: At least one chronic comorbidity: 80% (78-82); No chronic comorbidities: 96% (95-98)[137]	Symptomatic infection: 18-64 years: 95.6% (90.6-97.9) ≥65 years: 86.4% (61.4-95.2)[42] Pooled Moderna and Pfizer vaccines against hospitalisation ≥65 years: 94% (49-99)[250] Infection in Canada: 1 dose ≥70 years: 54% (31-69); 2 doses ≥70 years: 95% (83-98)[52] Pooled Moderna and Pfizer vaccines in Portugal: Hospitalisation 65-79 years: 94% (88-97); ≥80 years: 82% (72-89); Death 65-79 years: 96% (92-98); Death ≥80 years: 81% (74-87)[251] USA: Hospitalisation: ≥65 years: 75.2% (59.6-84.8) vs 18-64 years: 87.9% (85.5-89.9)[44] USA: Effectiveness against infection: Delta ≥65 years: 97.2% (94.1-98.7); Omicron ≥65 years: 57.1% (14.2-78.6)[12] USA: Pooled effectiveness of Moderna and Pfizer against hospitalisation: 2 doses: Delta: ≥65 years: 81% (77-84); 18-64 years 88% (86-89)[137] Finland: Effectiveness: Hospitalisation with Omicron ≥70 years: 2 doses: 14-90 days: 97% (88-99); 91-180 days: 85% (78-90); ≥181 days: 81% (67-89); 3 doses: 14-60 days: 98% (95-99); ≥61 days: 93% (82-98)[8]
Pfizer/BioNTech	Effectiveness in Israel: Diabetes or cardoiovascular disease: 82% (62-92)[47] Effectiveness against infection in Israel: (88·9% (87·3-90·2)[48]	Effectiveness against infection in Israel: (89·7% (88·6-90·7)[48]	Symptomatic infection: With any comorbidity or obesity: 95.3% With no comorbidity: 94.7%[49] Denmark: Infection: 71% (58-80); Hospitalisation: 81% (49-93)[50] Effectiveness against infection in Israel: Hypertension: (89·7% (88.6-91.7)[48] Effectiveness against symptomatic infection in the UK in those with comorbidities and ≥65 years: Single dose: 56.4% (46.2-64.6) 2 doses: 88.5% (81.5-92.9)[27] Pooled Pfizer/BioNTech and Moderna against hospitalisation in Scotland: 72% (51-84)[28] USA: Pooled effectiveness of Moderna and Pfizer against hospitalisation: 2 doses: Delta: At least one chronic comorbidity: 80% (78-82); No chronic comorbidities: 96% (95-98)[137]	Efficacy against infection ≥75 years: 96.2% (76.9-99.9)[51] Mymptomatic infection: >55 years: 93.7% (80.6-98.8); >65 years: 94.7% (66.7-99.9); >75 years: 100% (-13.1-100)[49] Effectiveness against hospitalisation 28-34 days after a single dose (pooled analysis of AstraZeneca and Pfizer vacines): 18-64 years: 85% (68-93); 65-79 years: 79% (17-95); ≥80 years: 81% (65-90)[127] England 80-83 years: Documented infection: 70.1% (55.1-80.1) Hospital attendance: 78.9% (60.0-89.9); Hospital admission: 75.6% (52.8-87.6)[53] Reduction in incidence of infection in vaccinated people aged >60 years and unvaccinated people aged 20-39 years, respectively: Documented infection: 45% versus 28%; Hospitalisation: 68% versus 22%[252] Pooled Moderna and Pfizer vaccines against hospitalisation ≥65 years: 94% (49-99)[250] Effectiveness in England: Symptomatic infection ≥70 years: 61% (51-69); Hospitalisation ≥80 years: 43% (33-52); Death ≥80 years (vaccine failure vs non-vaccinated): 51% (37-62)[32] Effectiveness against hospitalisation in England ≥80 years: Single dose: 81% (76-85) Fully vaccinated: 93% (89-95)[37] (not peer reviewed) Effectiveness in Israel: 65-74 years: 82% (63-92); ≥75 years: 82% (61-91)[47] Hospitalisation following single dose in the UK: ≥80 years: 71.4% (43.1-86.2)[30] Single dose in Spain: ≥60 years: 76% (55-87) vs. 18-59 years: 85% (74-91)[29] Effectiveness against infection in Denmark: ≥80 years: 77% (50-89)[50] Effectiveness against infection in Israel: ≥70 years: 89·1% (83-93)[48] Effectiveness against death in the UK: ≥65 years: Single dose: 77% (72-81); Two doses: 98% (94-99)[31] Effectiveness against symptomatic infection in the UK, ≥65 years: single dose: 56.6% (47.6-64.1); 2 doses: 86.7% (80.1-91.1)[27] Infection in Canada: 1 dose ≥70 years: 40% (29-50); 2 doses ≥70 years: 93% (82-98)[52]

				Pooled Moderna and Pfizer vaccines in Portugal: Hospitalisation 65-79 years: 94% (88-97); ≥80 years: 82% (72-89); Death 65-79 years: 96% (92-98); Death ≥80 years: 81% (74-87)[251] Effectiveness against death in Scotland ≥60 years: 87% (77-93)[38] England: ≥65 years: Symptomatic infection: 2-9 weeks: 79.6% (77.0-81.8); ≥25 weeks: 51.8% (45.4-57.4); Hospitalisation: 2-9 weeks: 98.0% (95.9-99.1); ≥20 weeks: 90.5% (87.6-92.7); Death 2-9 weeks: 97.1% (91.7-99.0); ≥65 years, ≥20 weeks: 90.2% (85.3-93.5)[36] USA: Pooled effectiveness of Moderna and Pfizer against hospitalisation: 2 doses: Delta: ≥65 years: 81% (77-84); 18-64 years 88% (86-89)[137] Finland: Effectiveness: Hospitalisation with Omicron ≥70 years: 2 doses: 14-90 days: 93% (90-95); 91-180 days: 87% (84-89); ≥181 days: 72% (66-77); 3 doses: 14-60 days: 96% (95-97); ≥61 days: 92% (89-94)[8] Israel: Effectiveness of a second booster compared to a single booster against death ≥60 years: 78% (72-83)[22]
Novavax			Any infection with comorbidity, age ≥65 years or frequent COVID-19 exposure in USA and Mexico: 91.0% (83.6-95.0)[46]	
Sinovac	-	74.9% (53.7-86.4)[54]	Any comorbidity: 48.9% (26.6-64.5)[54]	Brazil: Infection: 80-89 years: 55.6% (53.3-57.8); ≥90 years: 27.6% (20.5-34.0); Hospitalisation: 80-89 years: 63.5% (60.4-66.3); ≥90 years: 31.8% (21.9-40.5); Death: 80-89 years: 67.2% (63.6-70.5); ≥90 years: 33.6% (21.9-43.5)[35]
Sinopharm	-	80.7% (56.7-91.4)[54]	-	Effectiveness against symptomatic infection in Bahrain: ≥60 years: 91% (87-94)[54]
Bharat Biotech	-	-	Any infection with comorbidity: 66.2% (33.8-84.0)[39]	Symptomatic infection in India: ≥60 years: 67.8% (8.0-90.0) vs 18-59 years: 79.4% (66.0-88.2)[39]

Appendix 9: Risk of Rare Unusual Blood Clotting with Low Platelets (Thrombosis with Thrombocytopaenia Syndrome – TTS)

Estimated number of TTS that potentially might occur in Pacific Island Countries if all adults received the AstraZeneca or Johnson & Johnson vaccines, based on most recent official estimate of the adult population in each country and the incidence of these events in Europe and Australia.

COUNTRY	TOTAL POPULATION	ESTIMATED POPULATION AGED 18 YEARS AND OVER*	POTENTIAL NUMBER OF TTS CASES IF ALL ADULTS IN EACH COUNTRY RECEIVED ASTRAZENECA VACCINE**	POTENTIAL NUMBER OF TTS CASES IF ALL ADULTS IN EACH COUNTRY RECEIVED JOHNSON & JOHNSON VACCINE***
American Samoa	55,519	33,311	<1	<1
Cook Islands	15,300	9,180	<1	<1
Federated States of Micronesia	102,300	61,380	0.6-1.2	<1
Fiji	867,000	520,200	5.2-10.4	1.6
French Polynesia	275,918	165,551	1.7-3.3	<1
Guam	159,358	95,615	1.0-1.9	<1
Kiribati	113,400	68,040	0.7-1.4	<1
Marshall Islands	54,900	32,940	<1	<1
Nauru	10,900	6,540	<1	<1
New Caledonia	271,407	162,844	1.6-3.3	<1
Niue	1,611	967	<1	<1
Northern Mariana Islands	53,883	32,330	<1	<1
Palau	18,000	10,800	<1	<1
Papua New Guinea	7,744,700	4,646,820	46.5-92.9	14.6
Samoa	195,979	117,587	1.2-2.4	<1
Solomon Islands	642,000	385,200	3.9-7.7	1.2
Tokelau	1,160	696	<1	<1
Tonga	99,419	59,651	0.6-1.2	<1
Tuvalu	10,507	6,304	<1	<1
Vanuatu	272,173	163,304	1.6-3.3	<1
Wallis and Futuna	11,558	6,935	<1	<1
All Pacific Island Countries	10,976,992	6,586,195	65.9-131.7	20.8

* Based on estimate of 60% of population aged ≥18 years[253]
** Based on estimates of TTS occurring in ~1 in 100,000 vaccinated adults by the European Medicines Agency and ~1 in 50,000 in Australia[165,254]
*** Based on estimates of TTS occurring in ~1 in 319,000 vaccinated adults in USA (may be an underestimate as only cerebral venous sinus thrombosis are reported)[255]